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1. A DEFINITION OF CANCER
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 n n n  n n  an  a   n n   d d   n  
and an n ad  n a     a d a a nan   n  n n a  a an  a   
a  n  a n  a d d a  n   an a  a  an  n  an d  
an   an a  ad   a    d    d and   n a 
 a d a a  
1.1. LUNG CANCER
  n  an  n a   a  n a   a  
n a  a n     a  n   a an  d d  9  nd  a nan  
a    a n a   an a  n n a  a    n  a n a  
n n  a n a  n n   n  an   n  an   d  
  an  a nan   na d n  n n   and a     n a   
a  11
1.1.1. Epidemiology
 an  a  n  an  a  n   n  d a n d  n d d n  
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 a  n d  d  n  a  a  d  n a  ad an  n d a n  
and a n  n   et al.  1
d n   a  an a d 1 8 n n  n  an  a  d n 1  a n n  
 a  13   a  an  d a n  d d  n   n d n  n  n and n  
 nd  d a n d   an  a  a  and a  an   n  an  
a n a n    a  a  a d   n   n a  1  n d a  n 
1   an    ad n  an  n d a  a  and a  an  
a n n   a a    a  an  d a   1  a  et al.  1  
3
n a n n  an  a    a  nd  n  a n    n d a n d n 
1   1  n  a  and  1 118 a d d a  an n a  n n d n   d 
  n  n  a  and  an      d a  n 3   
1
Fi ure 1. Bar c art s o in  incidence and mortality o  t e most commonly dia nosed cancers in 2012. Data 
ac uired rom (Ferlay et al.  2015).
1.1.2. Lung cancer risk factors
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n  a n  n an an  a   and n  1  na n   n n 
 a  a  d nd  n    an  d n   d a  d  n a  9   a  
n  an  a  a  n a  and n d  d  a  n  a   n a n  a 
   a  n d n    d n d a  a n n    a a  
d a n   a  n a n  and  a  n a n  n n a  n n
d d n a n n  a    n  a n n   a a  n a   
and a  n d a   a n  nd n    a    ad   a n  and 
n  n a   a na  a   d n  1   1
n a d 1   n  an  d d  a  n  a a   n   da  
d a  d  a  d n d a  a  a a d  n  an  n n   
 a  a d n  
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n d d a an a n n  n   n n n a  a n   an nd   ad n  
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an   a    d nd n  n    and n  a  n  n 
 n  n   and a da  
 a  n d n  a    n  an    n   na  d a  
 n n  a  a  n a a d  n  an      a   n  an n 
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 and  a d et al.  1
nd d  a a n  n n   n   d n a    n n n a  a  
 n an      1 1 n  n d n a n n  a   
d n  n  a  a a  a  a  an an   n n  a n n  a an an 
and ndan   
1.1.3. Diagnosis
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d a   a ad  a  an ad an d a   a  d a   d a n   a  a n   d 
n  an   a  a   a a  d a n  and a a  a n   d     
a n      n  
Fi ure 2  Es mated causes o  lun  cancer. a  ada d  nd  1
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a na  a a n  n   an  11
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a a n a n   
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a n  a  an  d d   a n  an an   1 a  
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Small cell lung cancer (SCLC)
  n  a  1   a  n  an      n   a  n  n 
a  d n d   a  d  a   d a  n nd n  a  and  d 
 d   n nd n    n nd n  n  n  n    n a  
a d n  n a  a a   n  and n a   a ad n   na n   n a  
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nd n d  d  n  an a  n a  a n  and a n   n n  n   
a  a a d    a n  and a d  d      nd  nn 
et al.  1  
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• Adenocarcinoma: na d n a  n       n  
n n    n  a n a  and  a  a a   n  d n   
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1      a n    nd n a d a nan  n a   a n  
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d n a n
1.1.5. Staging
n  n  an  a  n d a n d  a d n    a  a   and a n  
 n a  and a a  a  an  d n d  a n   an a a n   d   
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n  an
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n   a a   and a a an   an   n  n d  a d n  n   
    d   n
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   d an  a a    d  d a  et al.  1
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a d a  n  d  n  d nd a  an   d  n  n  n  
nd a  an  a  ad nd  n  n
1.1.6. Clinical management
  n  a n  a   a  and ad a  a    an  d 
a n     a n  d d d nd  n   and a   n  an   a n 
   and n a  a    a n
Surgery
 a    and a   n n a   n  an  a  a d      
 nd n  n  n a d  n    n n   d n 
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Fi ure 4  Non-small cell lun  cancer treatment pa erns ( ) y sta e   nd a  a  n d  
n a  and a d a   ad a n a   et al.  1  
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    d  a nd n  d   a n  a  n   and  
n a   n d  n       ad   an  an an   
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Radiation 
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a   a n   ad a n a  na  a  ad a n a  a  n  ad a n  
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ad a n d n n a   a n a n     n     a   
a n   a n   a  n d   na  a  a n n  a a   an  an 
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 a   d a  a a n  n   and  n  a  ann  a  an 
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an n  d  n  d nd n  n  a  a n  a a n a  n d  
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nd n  n  nd d a  and  d  d     a  a  a a d  d  
 n  a   n n d d d n    a  da a  a   a  n d 
a a n    a    d   a  a     a  a  na a 
and n  n a d an   n n  and a  n   d n  a n   an  
a   1
Targeted therapies
 a    d   a n d n a  d n  n  a d  
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 n  an  a n  a   EGFR and ALK n
  a an an   a    n  na   a   n 
 d n   a   nd n    and  nd   d a n and a   
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 n a d a n  an n  a a  and d a d a  da n a an  
d and a  11
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n  na  n  n  a a n and n  a  d     a a n   
an       
    a n  a   an ALK n  a n a  a   ALK and EML4 n d  
a a d n   n  a an n   n n n d   an a n a  
n na  n  a n   d n a  na n  a a   n n n d a  
a n and a  a  and n an  13   a n  a  n   a  
 na  n   a n  n  and a n   nd   n
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a  d    a a  nd a   a  a n n d d   d n  
    an an   1  
Immunotherapy
n  d a  a n  a n  n    d n d    n   n d  
 n  and d  an    
  n  a n  a a n  an   a   d a n  n  n  
a  1 a d  d a  n 1  a a  1  a  d n  a  
 a a d    and 1  n  n  a    an n n n    
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n a a n    a  ad an a    a  and  1  ad  d n 
and n   n  n
  a n n a  a n a a  a d    n a  a n na  an d  
a    1 and nd  a n d  n a d  1  
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a n    an  a n   n        a  a  
 n   an   d  an   an   a   a a  
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a n n  n   d  a  et al  11  
a  a   an a a    and d a  d n  an a   
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   a n a  an   a d n  a n  a and  a  a d n 
 a n a  
• a     an  a  a  n  ad and a  a d a    an  a  n n 
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  nd n  a a
• a   nd       n  and  n   a  n  
ad  
• a   n d   a  an  n   a  n  ad    n d   
an   a   a  a  a  nd d    n d
• a     d d d n  3 a    and   a  n a  an   
   n d  and d an  a a
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Fi ure 5. Sta es in t e tumor de elopment. Adapted rom Ho  Cancer Arises (Wein er  1996).
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1.3.3. Metabolic adaptations of  cancer cells
a     a   d  d   n a d n   a  a n  
n d n a n n   a n and a     a n  a  a d   
n  and a  a d  na n  a a  a  nd   a  n d  n a a  
  a   a   a  n d   a   n  and n  d and  
a a d  a  a    and d n a n  a  and a  11
n  a d   d n  a a   an  a  a  n  n d  a a 
and n  n a   d  a  an  a  a a n  a  n n  and   
a  n  n n  an n a d a   a   n a  n n   a n  
n n  n n n  n   and  a  d n  n  an  n  a  
n n  a  d n  a  a a   a n an   d and  n n  n  
 n  a  a  a  n d n  a a n  n n  a n d n  d  a  
and a a n  n  n n n   a  a   an   a  and 
na n      and d na n a a and n  1
 a n a n a   and a d  d n  a n    n d  n a  
n    d nan      n a n    a   
a    a  an   d  n   n n     d 
 a  a d n a n n   a  an   d  da n  a  
n  nd a  a   n a   d    n a     n    
n d an   an    n a       a n  
n a d n  n  and d  n d  a n  a  and a  11     
a  a  n  d   d   a  an  and d   ad an a   
an    a  a n nan    a a  a an     d n  a  
n d a   a a  n  and a d a n  a a  n n n  
d   a a  n  and a a  1  
 a  a n     d   a a n  n  na n  
a a   a a n  3  a d n  3 na   a   
n n  a   and a nd  a  1    n n a n  n 
  3 and  na  1 1  n     n  a n  
a  and a  11
1.3.4. Dysregulated pH in cancer cells
 a  and  a  n a  a  a n   + n d n  a  and a n  
a d   a  nd d   a  a a   a     n a a  
a d a n and a a  a a n   a d a d a n  n a a     a  
an d  n and  a   a a an  n  and an  a  a a  
a d  a a   and  a  a a n  n a a   i  i and an  11  
 and a i  1  a  et al  13  
8
Fi ure 8. Ma or pH re ulators in a cancer cell a a i  ia  and i i  13
 ain a id a   i i a d in   a n  an   in  a+
+ an   a ni  an d a   and  3  an  n a a  
an  1 1  and  a  n n a  a a +  and in a a  +  
a a i  ia  and i i  13  a   a  13  n     i an  and 
 di d n an  i  a+ + an  i  1  1   a d a i  in an  
i  n id d    a  a  in n   a a  a idi  and n i n   
a i nan  a  an a n and  d n  a  et al.  1
 a   i n and in a d a i    an  a i n   
n a   adi n    a  an   a  a i ni an  a idi a n   a a  
i n i n n  d a in   a     1  i   ain ain an a a in  i   
in a i n i  n a  a     et al.  11
Fi ure 9. Reversed pH radient supports cancer pro ression  et al.  11  
ain ainin  an a a in  in a a  i i  i  a i i  i na    i a n a  i  
in a   a  a  i   n  in a  and     a  and a  
n   ada  ad an a   a in    in   et al.  11   
9
INTRODUCTION
 ain d i  i i  n a   an  i a  in  in a a  a idi a n i  a d 
 a i  a adi ann   and   i  i an  a i i a  a a i  
ada a n n  i  a   a i    n  a a  d d na   
and ina  1 1  i  a  i   in a  a  a a in   i  
i i  and a  1  ina  in a d i  a n d in  and a  ad i n 
n  n a   i n   i a n  n   and  a idi a n   a a  
i n i n n  id   a  ndi n   a i  a ina  and a idi  a  
ina  a in n a a  a in   and   d ad  a a  a i  n  
an  in a i n and a a i   and a  9  i  i i  and a  1
1.3.5. Dysregulated pathways in cancer
 a in n i   a   a   i  ain     a a n  in di n  
in    i na in  a a  a  n    a  i a  i a n  di n a n  
n  a  i na in  a a        a d in  a  a i   an   
a  3  ani  a   a a in  and  n   and  a a n  in 
i  a  ad   d a n  a  a i  in  a   ind     
a in n i
1.3.5.1. PI3K/AKT pathway
in  i  id n a n a  a n n   in nin  ina   a  n n a  in 
ina    a  a n a   in  3  a a  a n  a id  an   i i a  
n n  in din  a i  i a n  i a   an i n i  i a n and in a i n 
 and a i i  1   n     a i   in ina  and i  a   
i  in a a  1  and   d in    and 3  
d in  and ain   i  a   n d n na  d ain  an a in
ina  in   d ain a  a  in a a  a in    in  a 
n a  a a  d ain  and a a ina  a  d ain a i  11  
a n   i  i  d nd n  n 3  a n i   indin    a  
n  and in     in  ina   in      in
d  a   a a an  i  indin   in a n  in a   3 
3 a d a d in i  a  i    i   d ain    an  
n    i  a a d  a d a  a n ani  1 a  d d na  
ina  i  1  i  a   a  d ain a  a i i a  i  indin    a a an  
a   i in i  a a n  a  nin  3 8   a i i   a a d n a n  
 a nd a n a  in  3 i in  a  in  i  a  i d and i  a i d 
   a a ian a   a a in   a i  11
n  a   a a    a a  i i   di n  i  n a  d a  ani  
 i id a a   a a  and n in  i  a   a  a a  
 d a n  3 a n  a  a n a  a        n n i  
a d i  an  an an  an  and  1   a i  i  a  n a  a d  
a a   1   a  d a   i  a i  11
a d  a  a a i   a     a n  i  
d n a  a    i  a  i a d in  1
Fi ure 10  AKT si nalin  pat ay annin  and  1
    and in n i   a a n    i na in  a a  
di   indi  in  i  in i i  in   i    in i i  
a n  3 n n a  ina  3    a  n  a i  in a in  
 n a  and a  a n    i n   n   i a  ia  n a  
a n   a   a i    a    and  and    
 a  ad a i   an i n a   in n  and a a  11  
 a    n a     in a  i i a   a an  i na in   i  in 
i  nd in di n  a i   an an   a  dia   a di a a  di a   
in n  and a a  11
1.3.5.2. MAPK pathways
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4. Ion-selective electrode transport assays
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and  a   d in n  i n  i a n i a d i  d a  i  
n  a  d a  n n a n  an in   3   3  μ      d a  
n a  n  a  a n n a n  1    in  a   9  d an  i
i dia in a n    d a a   a  ni d in d  in a 
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10.1. Synthetic tambjamine analogues emission spectra
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o ound as i  is s o n in e u e 3  Ma i u  e i a on o  o  o ounds as a  88 n
Fi ure 23. Compound 2 and 7 emission spectra. 
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Fi ure 24. Emission spectra e ore and a er p oto leac in .
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11. Dextran uptake
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12. mCherry-Mito7 stable cell transfection
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eas  e a  in d  on ainin  e se e e an io  ana in  μ  a  3   o  1   i  
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ans e on  e u u e ediu  as an ed o  e  o  o e e ediu  i ou   o  
an io s  o  ea  ans e on sa e  e   i o e a ine  n i o en  a s ad    
o e es e e e a ed  o  as id  8  and i o e a ine     e e di u ed in 
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o e  e an ou e  Mia i    en a s a e e Mi o  o e e essin  9 e  ine 
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13. MitotrackerTM staining
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14. ATP depletion measurement
e i e o  u ines en  assa  as used o de e ine e a oun  o   esen  in e  u u e 
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e  a es a  a on en a on o  1  1  e s  in 9  μ  e  e  e s e e a o ed o a a  o   
 en  e s e e ea ed in e ou se o  3   1   and 8  i  e  a ue o  e o ound 
2  on o  e s e e ea ed i  1   o  M  n e e ea en  nis ed  e  a es e e 
e ui i a ed a   o  a o i a e  3  in  e a ds  e e i e o  ea en  as added in an 
a oun  e ua  o e o u e o  e  u u e ediu  esen  in ea  e  e on en  o  e a e as 
i ed o   in on an o i a  s a e  o indu e e  sis  e a es e e in u a ed a   o  1  in 
o s a i i e e si na  u ines en e si na  as easu ed on a s a  Mi o a e eade  M  
 en e  e an  o  ea  ondi on  a  eas  ee inde enden  e e i en s e e 
e o ed in du i a e  oun  o   as e essed as a e en a e o  on o  e s  and da a a e 
s o n as e ean a ue ±  
15. Transmission electron microscopy (TEM)
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o ounds an s o i s o e u  a ni a on and eso u on
9 e s e e seeded in 1   a es a  a on en a on o    1  e s  en ou  ou s 
a e  a n  e e s e e in u a ed i  e  o  e o ound 2 and 7 o    M  1   
as used as a on o  en e ea en  ended  u u e ediu  as e o ed and e e s e e 
ed in a so u on on ainin   a a o a de de and  u a a de de in 1 M os a e 
u e  i  a  o   is o edu e as a ied ou  o  one ou  a   en e e s e e s a ed 
e  en  a es ed a on  i  e a e and en i u ed a    o o ain e  e e s
e o ained e e s e e as ed i  os a e u e  1 M 3 es o  1  in a    
u se uen  a e so u on as e o ed and e e s e e e  in a os ed so u on on ainin  
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Acetone percentage Time Temperature
1  1  in  
1  1  in  
1  1  in  
9 3  1  in  
9 3  1  in  
1 3  1  in  
Ta le 5. De ydra on steps in raded acetone
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Mixture Time
e one s u  3 1 3  
e one s u  3  
e one s u  1 3 3   o  o e ni
u o e ni
u  
Ta le 6. Steps o  sample inclusion in t e resin
a  d o s o  ea  sa e esin i u e e e a ed a  e o o  o  a o d  e o ds e e en 
ed i  esin and u ed a    o  8 ou s  e a ds  se i in se ons 1 μ  e e u  i  a 
ass ni e  oun ed on s ides  s ained i  1  e ene ue and ie ed usin  a i  i os o e o 
se e  e e ion o  in e es  a in se ons  n  e e u  usin  a dia ond ni e  oun ed 
on  es  o e  ids and dou e s ained i   a ueous u an  a e a e o  3  in and e no d s 
ead i a e o  1  in  e i ens e e e a ined in a ans ission e e on i os o e eo  1 1  eo  
o o  a an  and di i a  i a es e e a ui ed usin  a a an ius 1   i i a  a e a a an  
n  easan on  a i o nia   o inde enden  e e i en s e e e o ed and o o a s e e 
a en o  a  eas  ee di e en  se i in se ons o  ea  e e i en
16. Immunoblot analysis
is ana a  e ni ue as e o ed o de e  e e ession o  s e i  o eins in di e en  e  
e a s ea ed i  s n e  a a ine ana o ues  e o edu e is di ided in o ee s e s a  
a e de ai ed e o
 16.1. Protein extract preparation
9 e s e e seeded a  on en a on o  1  1  e s  and a o ed o o  o    e ea e  
e  e e e osed o   and  a ues o  o ound 2 o  7 o   o  8  1   M  as used 
o ea  on o  e s  e  ea en  io  o o ein e a on  e u u e ediu  as o e ed 
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and e s e e as ed i  1   i e  e s e e o e ed  s a in  and e e s o  a es e e 
as ed a ain i  1   o a ui e e a i u  nu e  o  e s  e e  sus ension i  e edia 
as en i u ed a  3   and  o   in  e su e na an  as dis a ded and e e  e e  as 
as ed i  1   and en i u ed a ain in e sa e ondi ons  e su e na an  as dis a ded and 
e e  e e  as in u a ed  o  1  in in sis u e  1   1    sodiu  deo o a e  
 M a   M e o os a e   μM sodiu  o o anada e  1 M en e su on  
uo ide  se ine and s eine o ease in i i o  o ai  o e Mann ei  e an  in 1   a   
u se uen  e sa es e e soni a ed o de ade  o ein on en a on as de e ined   
o ein assa  ie e  o o d    o o in  anu a u e s ins u ons usin   o ine se u  
a u in  o ea e a s anda d u e a  as a en as e e en e o a u a e e o ein on en a on in 
ou  sa es ased on ei  a so an e  is o edu e as e o ed in 9  e  a es in du i a e and 
a so an e as ead on a Mu s an u e  a e eade  e o is e  a   n
16.2. Gel electrophoresis and protein transfer
ae i u e  is   M  8  1    e o  1  o o eno  ue  
e a oe ano  as added o e sa es and ese e e oi ed a  9   o   in  e  a  
3  μ  o  o ein e a s e e oaded in o a a ide e  e e o o esis i  di e en  
a a ide e en a es 8 1  a o din  o e si e o  e o eins a  an ed o e s udied  e 
e s e e un a  1   o  a o i a e  9  in in unnin  u e   M is  19  M ine  
1   n e e o eins e e se a a ed  si e  e  e e ans e ed o o i on M   
e anes Me  Mi i o e  usin  Mini ans o e  io ad i ond    e an  s s e  
in ans e  u e   M is  19  M ine   Me ano  o  9  in a  1   
16.3. Detection of  proteins 
e e anes e e o ed i  o in  so u on   non a  d  i  o    o  di u ed 
in 1  een  M is    1  M a  1  een  a   o  1  and en 
in u a ed i  s a in  o e ni  i  i a  an odies a e  a o din  o e anu a u e s 
ins u ons
Antibody Dilution Produced in Brand Catalog number
n a n 1 oa an a u  io e no o 19  s 1 1
n 1 1 a i e  i na in  e no o  e e  M  9
n as ase 3 1 1 a i e  i na in  e no o 9
n as ase 8 1 1 Mouse e  i na in  e no o 9
n as ase 9 1 1 a i e  i na in  e no o 9
n 3 1 1 a i M  n e na ona  o o a on M 3
n 38 M 1 1 a i e  i na in  e no o 8 9
n 1 1 a i M  n e na ona  o o a on M
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n 1 1 a i e  i na in  e no o 9
n os o 
 3 8 1 1 a i e  i na in  e no o 9
n os o 
M  e 3 8 1 1 a i a a 18 91
n os o 
38 M  
18
18
1 1 a i e  i na in  e no o 11
n 1 1 Mouse  ios ien e 1 9
n in u in 1 Mouse i a d i
Ta le 7. List o  primary an odies used in t is t esis
e da  a e  e e anes e e as ed 3 es o   in ea  i  een and en 
in u a ed i  o se adis  e o idase  on u a ed se onda  an odies di u ed 1 1  in 
o in  so u on o  1  a   i  s a in  e se onda  an odies used e e  oa  an ouse 
 a s  oa  an a i   a s  and don e  an oa   
a s  a  o  an a u  io e no o  e  3 as es in een o  1  in ea  
e e anes e e de e o ed i  e en an ed e i u ines en e de e on i   ea en  
e s a  u in a s i e   and i  e a e uan   s s e   ea a e  
e an  n o  in u in e e used as e  oadin  on o s  ensi o e i  ana sis s o s e o d
in ease o e  on o  un ea ed e s  in ee di e en  e e i en s ean+ M
17. miRNA expression analysis
a ua on o  i  e ession o es ou  i oa a  ana sis as e o ed o iden  a 
s e i  su se  o  i s e essed di e en  a e  ea en  i  s n e  a a ine ana o ues 
e sus un ea ed e s  
17.1. miRNA extraction 
9 e s e e seeded in 1   a es a  a on en a on o  1  1  e s  and a o ed o o  
o    u se uen  e s e e in u a ed i  e  o  o ound 2 o  1  and   M  1  
 as added in on o  e s  
e  ea en  io  o i  e a on i  e i eas  Mini i  ia en  i den  e an  
u u e edia as o e ed and e s e e as ed i  1   i e  en  e s e e o e ed 
usin  a e  s a e  and a es e e as ed a ain i  1   o e o e  e a i u  nu e  o  
e s  e s e e en i u ed a  3   o   in  e su e na an  dis a ded and e e ed e s e e 
o o eni ed in  μ  o  o  sis ea en  usin  a s in e and a  need e  e u e i  e 
e  o o ena e as a ed on e en o  a   o   in  e  a  1  μ  o  o o o  as 
added and e u e as s a en i o ous  o  1  s  n o de  o se a a e e o o ena e in o a ueous 
and o ani  ases  sa es e e en i u ed o  1  in a  1   a    e  en i u a on  e 
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sa es e e se a a ed in o 3 ases   a ons e ained in e u e  a ueous ase   
a ons in e in e ase and o eins in e o e  o ani  ase o  e in e ase  e u e  
a ueous ase as a e u  ans e ed o a ne  o e on u e and 1  o u es o  1  e ano  
as added and i ed  i e n  o o ide a o ia e indin  ondi ons o  a   o e u es 
o  18 nu eo des n  u a ds  a es e e su se uen  a ied o eas  Mini s in o u ns 
and en i u ed a  8   o  1  s a   e  a  on o u n ase di es on i  e ase ee 
ase e  as e o ed o e o e esidua   i s  3  μ  o  u e   as added in o e 
eas  Mini in o u n and en i u ed o  1  s a  8   e o ou  as dis a ded  and 8  
μ  o  e ase  in u a on i  e e di e  a ed on o e eas  Mini in o u n e ane 
and a o ed o in u a e a   o  1  in  ain u e   3  μ  as added in o e o u n and 
en i u ed o  1  s a  8   e o a   as a a ed o e e ane and on a inan s e e 
as ed a a  usin   μ  o  u e   and en i u ed a  8   o   in i e  ina  i  ua i  
 as e u ed in 3  μ  o  ase ee a e
 e e o ed a e ia  as ase ee  o a   on en a on and u i  as e ed   
s e o o o e  in a nano s e o o o e e  en  M n en  e an  and ua i a e 
on o  as ana ed usin  an i en  1  ioana e  i en  e no o ies  an a a a    
i uo s o  ea  i  sa e e e un on e i en  ioana e  usin  an   ano 
a i   sa es ad  n e i  u e   ea e  an 9
17.2. Gene expression analysis
o  e e e se ans i on o  e a u e i s   n  o  o a   as used o   
s n esis usin  e i i i e  u e  and o o in  e i i    i  o o o  ia en  n 
ie  e a u e i s a e o aden a ed usin  a o  o e ase and en e e se ans i ed 
in o  usin  o i o d  i e s  is o ina on ensu es a  i i  i   a s do no  
de e  eno i   Mo eo e  e e is a i s ui in on o   a  i  e de e ed in e a a  
usin  e i i    i  and i  e used o a ess e e e se ans i on e o an e
us  ea  sa e as en  i ed i  e e e se ans i on ea on i  e a ed on i e 
a o din  o a e 8
Component Control IC50 12 h IC50 24 h
 i i i e  u e  μ  μ  μ
1  i i u ei s Mi  μ  μ  μ
ase ee a e 11 8 μ 11 11μ 1 1 μ
i i  e e se ans i ase Mi  μ  μ  μ
e a e  μ 89 μ 1 9 μ
o a  o u e  μ  μ  μ
Ta le 8. Reverse-transcrip on reac on components
i s  sa es e e in u a ed o   in a  3   su se uen  o   in a  9   o ina a e 
i i  e e se ans i ase Mi  and a ed on i e  e  a  e  as di u ed i   μ  
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o  ase ee a e  and sa es e e s o ed a    o e ni  e o e e innin  i  e ea e 
 o o o   
o  ene e ession ana sis  s o  on o  and ea ed e s e e o ined i   uan e  
 een  Mas e  Mi  1  i i  ni e sa  i e and ase ee a e  a   ia en  
a o din  o a e 9 and ans e ed in o a oadin  ese oi
Component Volume
 uan e   een  Mas e  Mi  
1  i i  ni e sa  i e 11  
ase ee a e 3  
e a e 1  
o a  o u e 11  
Ta le 9.Reac on mix or Pat ay-Focused miScript miRNA PCR Arrays
 o onen s i  e e dis ensed 1  e  in e  o e   a  o  u an an e  
a a inde  38  M 31  o a   ia en  is a a  o es e e ession o  3  i s 
di e en a  e essed in u o s e sus no a  ssue (the list of all cancer-related miRNAs included 
in the array can be found in supplementary data, table S1  e a a  a e as  sea ed i  an 
o a  ad esi e  and en i u ed a  3   o   in a   o e o e u es  u se uen  e 
a  as a ed in an  M 9 ea e  s s e  ied ios s e s  e o is e  
ien  n  and e ana sis as a ied ou  a o din  o a e 1
Step Duration Temperature Comments
PCR ini al ac va on step 1  in 9 o a   Taq o e ase as a a ed  e e a u e
3-step cyclin : 
ena u a on 1  s 9  
nnea in 3  s  
ension 3  s  e o s uo es en e da a o e on
enu e  es
e nu e  de ends on e 
a oun  o  e a e  and 
a undan e o  e a e
Ta le 10. Cyclin  condi ons or Applied Biosystems cycler
17.3. Data analysis
e a e a e es o d e  a ues o ained e e ana ed in ia en a a na sis en e  
ia en  o e ie e e o d e u a on a ues o  ea  i  ene   se e on o  i  as ade 
a o din  o e o o in  es o ds  o e an o d e u a on e een on o  and o  ea ed 
ondi ons 1   o    o  o e an o d e u a on e een on o  and one ou  ondi on  
ese i s i  on  e se e ed i  a  eas  one ea ed ondi on as an a e a e es o d e 
e o  3  en e on o  ondi on as an a e a e es o d e e o  3  n a  se e ed i s  
e u a on in o  ondi ons s ou d a ee and e e n  u es and a i a on o s s ou d e 
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e  de ned  isso ia on e n  u es and a i a on o s e e a e u  ana ed usin   
so a e 3 and  Mana e  1  o  o  ied ios s e s  e o is e  ien  n  
e i en a  a ida ed i ene in e a ons da a ases as a ase  
i o na a ase  i a ase  i a ase n u edu  e i e o ds  
i e o ds u n edu i e o ds  and i Ma  i Ma n u edu  
e e e o ed o e a  a e  enes o  e se e ed i  the ima es of the modi ed miRNAs 
a er treatment alon  ith their tar et enes can be found in the supplementary data, ures S1-
S16  ina  e o en sou e so a e  os a e os a e onso u  an ie o    as 
used o ui d a io o e u a  in e a on ne o  i  e os  a e ed i s a e  e o ound 
ea en  
18. Computational methods
o u a ona  e ods su  as o e u a  do in  a e ide  used o edi  ossi e d u  a e s 
o  i e e sa  is s s e  uses di e en  so a e o  indin  si u a on o edi  e os  o a e 
union e een o o e u es  n o a o a on i  o  ua a s esea  ou  o  a e ona 
u e o u n  en e  and usin  do in  si u a ons o  ou  o ounds i  o e an 1  an e
e a ed o eins  e  en e as iden ed as one o  e o eins o i  e o ound a  
ind i  ea e  a ni
18.1. System preparation
oo dina es o  e  ode  e e a en o  e o ein a a an  en  3 M u an  
o ein  d o en a o s and side ains e e o i ed i  e o ein e a a on i a d oo  
o  odin e  a  sio o i a   and issin  a en  esidues  as e o e ed and 
ed i  i e  o ound 2 i and as ui  i  e Maes o a i a  in e a e and o i ed 
i  i e  
ndu ed  do in  si u a ons e e e o ed i   so a e a  o ines a Mon e 
a o s o as  a oa  i  o ein s u u e edi on a o i s o e i et al.,   is 
a a e o  a u a e  e odu in  on  es a e o esses ossins  osseini and ua a  1  and 
on o a ona  an es o  o ein i and e o ni on o e i  en a in and ua a  1  e ne  
et al., 1  o e  o i a and o o  1   sa in  a o i  is a onse u e i e a on o  ee 
ain s e s  1  i and and o ein a ons  e u a ons   o ein side ains sa in  and 3  
ini i a on  
e ini a   s u u es e e ons u ed  ui din   ode s e e e o ound 2 ligand 
s u u e on igu e 3   as a ed a ound  a  dis an es a ing o  1  o 3   o i s a o i a e 
en e  de ned  sn 9  e igand as a o ed o e o e a  e s a e i in 33  o  is en e  
igand ans a on as s i ed e een a a ge  s e  o  1   and a s a  one o    ide ain sa ing 
9
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as e e u ed o  a  esidues i in   o  e igand and is as o o ed  e ini i a on o  
e u  s s e  e en  a si i a  o o o  o  g o a   e o a on as a ied su ess u  o  
in o e  i  ano e  de i a es o  e a a ine a i  o e  et al.  1   si u a ons 
e e a ied ou  using  o es o  8 ou s on e Ma enos u  su e o u e  ea  o o  and 
s a e in igu e 3  e esen s a sing e  a e o  unning on a o u ng o e o e de ai s a ou  
 so a e and si u a ons an e ound a  s e e s es
u e  es o ing o  e  oses as done i  ide using e e a e ision  s o ing un on
19. Surface Plasmon Resonance assays
u a e as on esonan e  assa s e e e o ed using e ia o e  s s e  is 
e no og  a es ossi e o oni o  and easu e io o e u a  in e a ons in ea e i  ig  
sensi i  n is ega d  i  a o s de e ining s e i i  a ni  and ine  a a e e s du ing 
e inding o  di e en  ai  o  o e u es in uding o ein o ein  en e su s a e o  in i i o  
e e o d ug o  o ein s a  o e u es  a ong o e s  e a oa  in o es e i o i i a on 
o  one in e a ng a ne  igand  o e su a e o  a senso  i  and e in e on o  e sa e 
in a on nuous o  on aining e o e  in e a on a ne  ana e  o e  e su a e  is i  is 
o osed o  a g ass su a e o e ed i  a in go d a e  and o e  is a e  a oa ng i  ena es 
e a a en  o  e igand  
e go d a e  is a ondu ng  o a ed a  an in e a e e een edia o  di e en  e a e 
inde  e g ass o  e senso  i  and e sa e so u on   is a eno enon a  o u s en 
a o a i ed in iden  ig  i s e e a  su a e i  e ain in iden e ang e and a e eng  e 
e e ons a  e su a e o  e io i  a so  e ene g  o  in iden  ig  o ons and o e gene a ng 
as on a es due o e e i a on  e ig  is e e ed i  a s e i  ang e  anges in o e u a  
eig  and so u e on en a on a  e su a e o  e senso  i  su  as io o e u a  in e a ons 
e een igand and ana e  ause anges in e e a e inde  o  e so u on gu e  i  
in u n a  e e e ed ang e  us  e esonan e ang e s i s an e easu ed and a e di e  
o o ona  o e on en a on o  io o e u es on e su a e  e es onse o  signa  ange is 
easu ed in esonan e uni s  e e 1  is e ui a en  o a i a  ang e s i  o  1  deg ee 
gu en et al.  1  e s s e  ia o e  a s e anges in  agains  e  s o ing e 
og ess o  e in e a on in a o  no n as senso g a  gu e 
 assa s e e designed in o de  o oni o  e in e a ons e een igand  318  
e o is e  and o ound 2 ana e   igand as i o i i ed o o ing ia o e  
o o o  in a senso  i  M   ea a e io ien es  sa a  eden  is is oa ed i  
a a o e a ed de an a i  a  a o s a o a en  o ein a a en   a ine ou ing  
io  o i o i i a on  in o de  o de e ine e o a   o  e on en a ng e igand o e  
e a i  a  s ou ng as e o ed  e igand as di u ed o 1 μM in 1  M a e a e u e s 
i  di e en   anging o   o  and in e ed du ing 18  s i  a o  o   μ in o e  an 
un odi ed senso  i  en  e su a e as egene a ed i   M a  o ensu e no igand 
e ains ound o e su a e  n e  e o u   as se e ed  e su a e o  e senso  i  
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as a a ed i  a i u e 1 1 o  1 e 3 3 di e a ino o a odii ide  and 
d o su ini ide  in o de  o o  ea e es e  g ou s on e su a e  u se uen   
o ein as di u ed o  μM in 1  M a e a e u e  i    and i o i i ed in o e  
 u  o   e i o i i ed igand e e  as e ious  a u a ed a o ding o e e a e 
o e u a  eig s o  e igand and e ana e and e a i u  inding a a i  o  e su a e i  
a eo e a  a  a i a  es onse  o     
e o e  1 as a a ed and assigned as e e en e anne  n e e i o i i a on as 
e o ed  e ano a ine so u on as in e ed in o de  o dea a e e e aining ea e g ou s 
o  e su a e gu e 
Fi ure 26. AKT2 immo iliza on
Fi ure 25. P in i e o   o  Madei a et al.  9  and s e a  senso g a
99
MATERIAL AND METHODS
o ounds e e s o ed as s o  so u ons in 1  M  a    e o ound as di u ed 
i  unning u e  1    M  a  on en a ons anging o  1  μM o 1  μM  e 
un as s a ed i   s a u  es i  unning u e  e  a  sa es e e in e ed i  a 
3  μ in o  o   s  e o on en a on sa es e e used as an s  e  e e  in e on  e 
og a ed disso ia on ase as 1  s  e o e es e e egene a ed using  M a  io  
o e e  e se ies  Mo eo e  e een sa e se ies  a so en  o e on i  a e u  e a ed 
M  e e en e so u ons anging o   o 8  as un  o en  o e on as e o ed o 
ad us  easu ed sa e es onses due o so en  e e s on e u  e a e inde  a ia ons
e i en s e e e o ed i  e ins u en  e e a u e o  e  senso  i  and sa e 
o a en  e e a u e  se  o   o  ine  and a ni  e a ua ons  ia o e  e a ua on 
so a e as used o  su a on o  e e en e and an  da a  a ong i  so en  o e on as e  
as o  u e ng  using e 1 1 ang ui  ode  o inde enden  e e i en s e e e o ed and 
ons an  a ues a e e essed as e ean ± 
20. In vivo evaluation of  tambjamine-analogues therapeutic effect 
o u ine ode s a e een de e o ed  e e o i  su u aneous  and e o o o i  ode  
s s e s o e a ua e e an u o  a i  o  e s n e  a a ine ana ogues 2 and 7
 ani a  s udies e e a o ed  e o a  i s o i ee ene a i a  de a a un a  unde  
e o o o  9111  o gene a e e su u aneous enog a  ode  i e e e su u aneous  
i an ed i    1  9 e s sus ended in a 1 1 so u on o  M M Ma ige   ios ien e  
o  e o o o i  ode  su u aneous enog a s o  9 in e onen a  g o  o  ee 
di e en  ani a s e e ase a  iso a ed and a ed a   in M M su e en ed i  1   
us   eni i in and  g  s e o in and e su gi a  ese on u o s e e i an ed 
in o n1nu i e o o ing e ious  e o ed o edu es ogio et al.  1  1  
ie  i e e e anes e ed i  a on nuous o  o  1  o 3  iso u ane o gen i u e  
inu es  and su e ed o ig  o a o o  Mi e e e si ua ed in e  a e a  de u i us osi on 
and a s a  ans e se s in in ision a ound 8  as ade in e ig  es  a  es  us es 
e e se a a ed  a s a  disse on and os a  and in e os a  us es e e e osed  n in e os a  
in ision o    on e i d o  ou  i  on e es  a  as ade and a s a  u o  ie e o  
 o  3 as in odu ed in o e es  a i  e u o  s e i en as de osi ed e een e 
se ond and e i d ung o u e  e  e es  a  in ision as osed i  su ge  s a es  and 
na  es  us es and s in e e osed  Mi e e e ins e ed i e a ee  and oni o ed o  e 
esen e o  ea ing o e s
Mi e ea ing o ogeneous su u aneous u o s a o i a e  1  3  e e ando  
a o a ed o e ea en  g ou s n  ea en  o  9 o o o i de i ed ode  i e e e 
ando  a o a ed o ee g ou s n  ea en  and e ea en  s a ed 3  da s a e  u o  
i an a on  o ounds 2 and 7 e e di u ed in  M 8  een 8   ea en s e e 
in a e i onea  ad inis a ed a  a dose o   g g in a e na ng da s du ing  da s  n e ase 
o  e su u aneous ode  e an ed o o a e e e e  o  ou  o ounds i  e s ine 
1
e o e a eu  agen   Mi e e e ad inis a ed i   a  a dose o   g g da s   
and 1  and sa i ed da  1   
Mi e e e eig ed on e s  da  o de e ine e e e s o  o ounds ad inis a on on ei  
gene a  ea  s a us  Mi e eig s o  a  g ou s e e oni o ed o e  a  e e e i en a  e iod  
u o  g o  as e o ded o o ee es e  ee  s a ng o  e s  da  o  ea en  da  
 and u o  o u e in 3  es a ed a o ding o e o u a   a  e e a  is e eng  
o  igges  dia e e  and  is e id  o  s a es  dia e e  e  e na  dose o  e ea en  
ani a s e e sa i ed and u o s e e disse ed ou  and eig ed  i e  and idne  sa es e e 
ed in o a in o e nig  e edded in a a n  and u  in o se ons   a a n e edded 
se ons e e de a a ni ed in ene and g adua  e d a ed o  e a o in and eosin s aining  
ained i e  and idne  se ons e e g adua  de d a ed and oun ed o  e a o o i i  and 
ne o o i i  e a ina on  es e e
21. Statistical analysis
esu s a e e essed as e ean ±  o  ean ± M o  a  eas  ee inde enden  e e i en s  
ne a  s e e a ied ou  i  e a g a i s en u ion s a s a  a age and os  
o  u e  ana ses e e e o ed  a s a  signi an  di e en es     and   1  a e 





1. Anion transport screening
n e sea  o  ne  o e u es i  aniono o i  a i  e esea  g ou  ed   o e o 
uesada as designed and s n esised di e en  a es o  s a  o e u es a a e o  a i i a ng 
e ans e ane ans o  o  ions  n e s n esi ed  i s a a i  as anion a ie s as es ed in 
1 a i o o eo sn g e o 3 os o o ine  i oso es oaded i  a  and dis e sed 
in di e en  u e s on aining a 3 o  a  e e o e  ans e ane anion ans o  a i  o  
e a o e en oned s n e  a a ine ana ogues o e u es as e o ed see ure , material 
and methods sec on  e o ide e u  o  o ide oaded esi es as oni o ed o e  e and 
e  a ues e e e on en a on o  o ound ne essa  o a ie e  anion e u  a  a 
a u a  e  e e a u a ed a e 11  ese es s e ea ed a  s n e  a a ines ana ogues 
a e e  e ien  anion ans o e s sin e ei   a ues a e in e nano o a  ange  
Compound EC50 (nM) NO3 /Cl
a EC50 (nM) HCO3 /Cl
b
 ± 8  ± 
3 1  ± 89  ± 8
 ±  ± 
8  ± 1 3  ± 
 ± 3 88  ± 3
8  ± 119  ± 1
9  ± 3 3  ± 1
1  ± 1  ± 
2. Anticancer effect evaluation 
2.1. Assessment of  anionophores cytotoxicity in oral and lung cancer cell lines
 as e en  een des i ed a  e ans o  o  ions auses  a ong o e  ings  anges in e 
in a e u a   i  an indu e e  dea  Mo eo e  in e en  ea s e e as een onside a e 
in e es  in na u a  a a ines and ei  io ogi a  o e es  n e i e a u e e e a e se e a  
e a es a  a a e i e e  as an i o ia  o o i  o  an u o  agen s a one et al.  1  
Ta le 11. Transport ac vi es expressed as EC50 (nM) o  synt e c tam amine analo ue compounds modi ed 
rom e nando et al.  1 . a  esi es oaded i  88 M a  dis e sed in 88 M a 3  M 
os a e u e     esi es oaded i  1 M a  dis e sed in 1  M a   M os a e 
u e    u on addi on o  a a 3 u se o a e e e a esi u a  i a ona e on en a on  M
1
in e on et al.  1  e e o e  e s  de ided o assess e e e  o  a s n e  a a ine 
ana ogues a  on e  ia i i  is a  o  s n e  a a ines ana ogues onsis ed o  eig  
o ounds de i ed o  e a ead  no n na u a  a a oids a a ines
ese o e u es e e a a e i ed  e esen e o  a o a  g ou s as a ine su s uen  
and ei e  a e o  o  a en o  g ou  in e en a  e e o e  n one and  e  ia i i  as 
e a ua ed a e  e ea en  i  s n e  a a ine ana ogues in di e en  ung an e  e  ines 
e esen a e o  e ou  a o  is o ogi a  su es 9  adeno a ino a  9  s ua ous 
e  a ino a   a ge e  a ino a  M 3  s a e  a ino a  e s e e ea ed i  a  
e es ed o ounds in a sing e dose o  1  μM o    and e M  assa  as e o ed o assess 
e  ia i i  n a e age  e ound a  a e  ea en  e  ia i i  as edu ed o e   i  e 
a o i  o  o ounds gu e 
ong a  o ounds su e ed o s eening  e se e ed e os  o en  s n e  a a ine 
ana ogues  o ound 2  a ong i  i s a en  o ound 7  o  o ounds ea  e sa e a o a  
su s uen  e u en  in e ena ine oie  and o ound 7 esen s a en o  g ou  
e a ing e e o  g ou  a a e is  o  e na u a  a a ine de i a es  
n o de  o o a e e o o i  o en a  o  o  o e u es and o e a ua e e sensi i  o  ung 
an e  e s o ese o ounds  9 e s  e esen a e o  ung adeno a ino a  e e ea ed 
a  di e en  on en a ons a ange e een 8 and 1  μM  o    Mo eo e  dose es onse 
e e i en s e e a so e o ed i  is a n  a e o e a eu  u en  used in ung an e  
ea en  gu e  on o u a ed is a n as es ed i  a ange o  on en a ons e een 
3  and 3  μM  and o e ia  o u a ed is a in   as es ed in a ange o  on en a ions 
o  1  o  μM  
e in i i o  on en a ons  a ues o ained a e s o n in a e 1  n e es ng   a ues o  
ou  o ound ai  e e ound e o   μM   o ound 7 s e e o e  an 2  a ing i  e os  
o en  o  o  o  9 e  ine  Mean i e e a e age a ues o ained i  non o u a ed is a n 
and  e eed  μM  e a ues o  e u en  d ug e e e  ig  o a ed i  s n e  
a a ine o ounds s  ese ndings end su o  o e idea a  s n e  a a ines 
ana ogues a  a e o en a  as u u e an an e  d ugs  
A549
o ound Compound 7 Cispla n CDDP
99± IC25 ± 18 IC25 ± 9 IC25 9 9±9 1
3 38± 98 IC50 1 ± 9 IC50 1 IC50
88±1 9 IC75 3 ± 9 IC75 IC75
Ta le 12. In i itory concentra ons (IC) values o  compound 2 and 7  and t e posi ve control  cispla n (non-
ormulated) and CDDP ( ormulated)  in A549 cell line.  e a ues a e e essed as e ean ±  in μM
n e o e  and  s n e  a a ine ana ogues e e es ed in e  ines e esen a e o  
s ua ous o a  an e   and  s in e e ious ase  s  e d ugs e e es ed in a sing e 
dose o  1 μM gu e 8   M  assa  is es  e ea ed a  e e u a  ia i i  d as a  d o ed 
i  e a o i  o  o ounds
1
RESULTS
Fi ure 27. Synt e c tam amine analo ues si ni cantly decrease cell via ility.  M  e  ia i i  assa  
as e o ed a e    o  ea en  i  s n e  a a ine ana ogues a  1  μM in 9  M 3   
and 9  e  ines   on en a ons anging o  8 o 1  μM o  o ounds 2 and 7 e e used in dose
es onse u e e e i en s in 9 e  ine  is a n non o u a ed  and  o u a ed  e e used as 
a osi e on o  a  on en a ons anging o  3  o 3  μM o  1  o  μM  es e e  esu s s o  
e ean a ue ±  o  a  eas  ee inde enden  e e i en s
1
Fi ure 28. In i i on o  oral cancer cell lines proli era on y synt e c tam amine analo ues   anges in e  ia i i  
e e easu ed  M  assa  a e    o  in u a on i  s n e  a a ine ana ogues a  1  μM in  and  e  
ines   o ounds  and  e e es ed i  on en a ons anging o  8 o 1  μM dose es onse  o a u a e s 
a ue in  e  ine  is a n non o u a ed  as used as osi e on o  i  on en a ons anging o  3  o 
3  μM  esu s s o  e ean a ue ±  o  a  eas  ee inde enden  e e i en s
o ound 2 and 7 e e se e ed a ong e os  o en  ones and s e e a u a ed  M  
assa  using di e en  on en a ons o  8 o 1  μM gu e 8  s a osi e on o  non
o u a ed is a n as es ed o  3  o 3  μM  e  a ues a e is ed in e a e 13  e e 
i  an e seen a  o ound 2 as s ig  o e o en  an 7  u  o  s e e u  o e  an 
is a n  a ues  
CAL27
o ound Compound 7 Cispla n
9± 9 IC25 1 1 ± IC25 3 ± 1
1 ± IC50 1 9 ± IC50 1 ± 13
3 ± 9 IC75 3 1 ± IC75 3± 3
Ta le 13. In i itory concentra ons (IC) values o  compound 2 and 7  and t e posi ve control  cispla n  in CAL27 
cell line expressed in μM and s o n as mean  SD.
1
RESULTS
2.2. Compound effects on cancer stem cells derived from cell lines and patients tumor samples
oug  ou  o ounds o ed o d as a  edu e e ia i i  in an e  e  ines  e an ed 
o e  e e  ese o ounds e e a e agains  an e  s e  e s  i  a e usua  
an i o an  esis an e e anis  o on en ona  ea en s  us  o ound 2 and 7 e e a so 
es ed on s de i ed o  a en s o  iso a ed o  ung an e  e  ines
e i ed u o  s e es e e dee  a a e i ed  s o ing en i en  in s e  e  su a e 
a e s as e  as g ea  u o igeni  o e es in  i e ans an a on e e i en s  n one 
and  s e es de i ed o  a en s 3  and 3 3 and o  9 e  ines  e e disso ia ed in o 
sing e e s and u u ed in sus ension on non ad e en  a es s o ing  o e es  e e ession 
e e  o  an e  s e  e  su a e a e s en et al.  1   in e u o  s e es as ana ed  o  
o e  and is s o ed in e o o ing a e  
Cells Marker expression %
EpCAM CD44 CD166 CD90 CD133
9 1 9 1
3 1 1
3 3 1
Ta le 14. Expression o  stem cell sur ace markers in tumor sp eres rom NSCLC cell lines and primary NSCLC tumors
n e o e  and  i a  ung u o  s e es de i ed o  a en s e e disso ia ed in o sing e 
e s and ans an ed su u aneous  in o  i e o   o 1  e s  see gu e 9  
o  e  o u a ons e e a e o o  u o s in i e  sugges ng a  e  a e ig  en i ed in 
ung s  
e  ia i i  as easu ed a e    o  ea en  i  e e a ua ed o ounds a  1  μM  
o ound 2 s o ed a e a a e de ease in e  ia i i  ei e  in  de i ed o  e  ines o  
de i ed o  e u o  a en  sa es 3  and 3 3  e eas o ound 7 edu ed e  
ia i i  o  in os  sa es gu e 3  ese esu s indi a e a  anion ans o e s a e good 
Fi ure 29. Tumor ro t  curves o  FIS302 and FIS303 tumor sp eres xeno ra s.  u o  s e es a e u o
ini a ng o e es in vivo  u o  g o  u es o  1s  gene a on enog a s de i ed o    o  1  
e s o  3  and 3 3 u o  s e es  
1 8
in i i o s o  an e  e  ia i i  e en  in  is a i i  gi es e  an ad an age o e o ising 
e a eu  andida es in o a ison i  o e  d ugs  es e ia  o  ea ng a en s i  esis an e 
o on en ona  ea en s  
Fi ure 30  Synt e c tam amine analo ues decrease ad erent (Ad ) and cancer stem cells (CSC) via ility. e  
ia i i  as es ed in ad e en  and an e  s e  e s de i ed o  ung an e  a en s 3  3 3  o  an e  
e  ines 9  9  a e  1  μM o  o ound 2 and 7 o   
2.3. Study of  the cytostatic effect of  selected molecules
ia i i  assa s e o  e nu e  o  e aining ia e e s a e  e ea en  u  o ide i e 
in o a on a ou  e unde ing e anis s a  a  ause an an o i e a e o  o o i  e e  
on e s  e e o ed o  o e  ana sis i  o idiu  iodide s ained e s o easu e 
e e  o ound 2 and 7 ou d indu e e  e a e a ons in ung and o a  an e  e  ines  o  
is u ose  a e esen a e e  ine o  ea  e o  an e  9 and  as se e ed o  ung 
and o a  an e  es e e  
e  e ases e e o a ed e een 9 e s a  ad een in u a ed o   o  8  i  
e  o  2 and 7 gu e 31  i  es e  o e i e ea ed e s as on o  M  and is a n as 
a osi e on o  o  e  e a es  in M ase Mue e  et al.   e dis i u on o  e e s 
a ong e di e en  ases o  e  e 1   and M  as a e  a e ed a e  e ea en  
i  e  o  s n e  a a ine ana ogues o   o  8  n is a  e  o u a ons in ea  
ase o o ed a si i a  a e n o e on o  e s  o i a e  a ound a  o  e s e ained 
in 1 ase  1 1  in  ase and  in M ase  e a a  o  e s e osed du ing 
  o o ound 7 i  as ound a  o o on o  e s in 1 ase anged signi an   
o a ed o 1  in on o  e s  e eas e  e ases e ained una e ed a e  8  
s e e ed  e e osu e o  a osi e on o  a ied e o o on o  e s in di e en  
ases o  e  e   edu ed e a oun  o  e s a  e e in 1  and in eased e e s in 
ase  and M    a e  o ound addi on  eading o a g ea  a u u a on o  e s in M 
1 9
RESULTS
ase a  8  8  o a ed o  in un ea ed e s  e ana sis did no  iden  an  signi an  
di e en es e een on o  and ea ed e s  i  e e e on o  a s ig  in ease in 1 ase o  
e s ea ed i  e ana ogue 7 du ing   e e o e  a en as a o e  anion ans o e s do no  
e a a  a e  e  o i e a on on 9 e  ine   
Fi ure 31. Cell cycle distri u on in A549 and CAL27 cells exposed to synt e c tam amine analo ues. e  e 
ana sis o   9 and  e s ea ed i  o ounds 2 o  7 o   o  8   as used as osi e 
on o  uan a on o  di e en  e  e ases as easu ed using e o  o e  ased M  e  
e assa  i  e a  g a s indi a e e anges in e e  e og ession as e ean ±  o  ee 
inde enden  e e i en s   a s a   signi an  di e en es  e een  1  o  e s ea ed i  7 and   
e sus M  a     and  e een 1  and M  o     e sus  M  a  8  a s a  signi an  esu s 
a e indi a ed as   and   1
ua ous o a  an e  e s e e su e ed o e sa e ea en  and a e  in u a on i  e 
 o  2 and 7 o   o  8  no ange in dis i u on o  e  e ase o u a ons as o se ed 
i  es e  o on o  e s gu e 31  ei e  o ound 2 o  7 auses a e  e a es  in  
e s  
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3. Anion transport in cells and its effect on intracellular pH
s s o n a o e  e s n e  a a ine ana ogues a e good ion ans o e s  o assess o e in 
de ai  e a i  as ans e ane anion ans o e s o  e o os  o o i  o ounds  2 and 
7  in vitro e e i en s e e e o ed on  i oso e ode s  
o ide oaded i oso es e e sus ended in an iso oni  o ide ee so u on  and o ide e u  
a i i a ed  ese o ounds as oni o ed using a o ide se e e e e ode   e end o  
e e e i en s  esi es e e sed  e addi on o  de e gen  and e na  e e ode eading 
onside ed as 1  o ide e ease  uan a on o  e ans o  a i  as a ied ou   
e ea ng e e e i en s using se e a  on en a ons o  e s udied o ounds and e o ing 
i  ana ses o  e esu s gu e 3  and 3  e esu ng  a ue e esen s e a oun  o  
o ound needed o e ease  o  e en a su a ed o ide in e e s a e o  e e e i en s 
3  s  e  a ues o ained o  2 and 7 e e  nM and  nM es e e  in e assa  in o ing 
a 3 as e e na  so u on and  nM and 88  nM es e e  in e assa  in o ing a 3 as 
e e na  so u on  e i a  on e  a ues o  e e e na  anion is onsis en  i  an e ange 
e anis  in i  o ide e u  o  e in e io  o  e esi e is a o anied  in u  o  e 
e e na  anion  us e uding e o a on o  an e e o e i a  g adien  e e a e ig e  
i o i i i  o  ni a e o a ed o i a ona e a es is a e  anion o e di u  o e a  in o 
e e ane d o o i  o e and en e e ig e   o se ed  is ans o  e anis  as 
een s udied  us in de ai  and e esu  de ons a es a  2 and 7 a e e  o en  aniono o es 
o o ng e e e ans e ane anion ans o  in esi es a  o  oadings e nando et al.  1
Fi ure 32. Potent transmem rane anion transport ac vity o  synt e c tam amine analo ues in liposomes and cellular 
models.  o ide e u  u on addi on o  o ound 2 o  7 a  di e en  on en a ons o esi es o osed o   
ua ed s o s o es ond o e esu s o ained using a 3 as e e na  u e  iangu a  s o s o es ond o 
e esu s o ained using a 3 a  as e e na  u e  a  a e e esen s an a e age o  a  eas  ee di e en  
e e i en s  a  o  e e na  u e  a 3  s ua ed s o s  o  a 3 a  iangu a  s o s  in e o ide 
e u  o o ed  2 o  7 1 μM  ue and ed s o s  es e e   idine o ange s aining on 9 e s ea ed 
i  e i e M  1  μM o ound 2  7 and NT  non ans o e  o ound  o  1  ages a e e esen a e o  
ee inde enden  e e i en s  a e a   μ
111
RESULTS
n e i  as o o o a ed a  o  o ounds  2 and 7  e e good o ide anion a ie s in 
i oso e ode s  se ond  a idine o ange  assa s e e e o ed in u an ung adeno a ino a 
e s 9  o ana e odi a ons in e u a  a idi  o a en s  e a i i  o  aniono o e 
2 and 7 o odu a e soso a   as o a ed o a i d o ound a  is s u u a  e a ed 
o e  u  i  dis a s odes  a i  as anion a ie  and i  i  e onside ed as a non
ans o e nega e ans o e  (NT) in ese assa s  in e  is a s ig  a oni  and i o i i  d e  
i  is a a e o  e ea ng e  and o gane e e ane s u u e  n e i  as ene a ed in o a idi  
in a e u a  o gane es  i e soso es o  a e endoso es   is o ona ed and a ed inside ese 
o a en s  s a esu  o  i s o ona on unde  a idi   ondi ons  en  is e i ed i  ue 
ig  e o ona ed d e e i s o ange uo es en e  Mean i e  e non o ona ed uo o o e 
e i s g een uo es en e in o e  a s o  e e  
e s e e ea ed i  1  μM o  ea  o ound o  1  e o e s aining i   and as i  an e 
o se ed in e gu e 3  in ose e s ea ed i  e anion ans o e s e o ange uo es en e 
in e a idi  o a en s disa ea ed  indi a ng an  de o ona on and e e o e an in ease 
in e  o  ese o gane es  Mean i e  in e s ea ed i  NT  e o ange d e o es onding 
o e a idi  o a en s e ained as in on o  e s ea ed i  e e i e  M  is esu  
is in ag ee en  i  e iono o i  a i  o  ese o ounds a  a i i a e ans o  o  anions 
i e o ide and i a ona e a oss e e ane o  e u a  o a en s  is a  auses an 
a e a on o  e soso a   and in u n esu s in soso a  d s un on
e e o e  ese o ounds a e een a a e i ed as good anion ans o e s in e u a  
e anes and su se uen  i  as een o ed a  is ans o  is in ed o an in ease in 
soso a  
eside is  a e  e osu e o e  o  o  o ounds o    a assi e a uo i a on o  e 
o as  o  9 e s as o se ed oug  ase on as  i os o  gu e 33  ese esi es 
a ea ed in g ea e  nu e  a e  ea en  i  o ound 2 an i  7  o e e  a e  ea en  
i  e NT a d  an  esi es e e o se ed in e o as  
Fi ure 33  Cytoplasmic vacuoliza on induced y 
synt e c tam amine analo ues. ase on as  
i os o  i ages o  9 e s ea ed i   
o  o ounds 2 o  7 and 1  μM o  NT o    
a e a  1  μ  ages a e e esen a e o  
ee inde enden  e e i en s  
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e de ided o oni o  is o ess o    in o de  o s ud  i s e o u on and o se e i  
o gane e as su e ing a uo i a on  s s o n in gu e 3  e ad e iden e o  e esen e o  
a uo es o  3  a e  addi on o  1  μM o  o ound and ese esi es e e en ain ained o e  
  o  ea en    e end oin  o  e e e i en  es e ia  in ose e s e osed o o ound 
2  e  dea  as o se ed sugges ng a  e  s e ing o  e  u s  ad o u ed  o  i a  ea u es 
o  ne o  e  dea  is nding ein o es e a  a  e a uo i a on e en  a  de end on e 
os o  i a an e aused  e o ound anion a ie  a a i
Fi ure 34. Cytoplasmic vacuoliza on a er treatment. i e ou se i ages o  9 e s ea ed i  1  μM o  
o ound 2 o  7 du ing   a e a   μM  
113
RESULTS
3.1. Characterization of  induced cytoplasmic vacuolization
e aniono o es igge  a o ess o  a uo i a on in e o as  ese esi es a  a e 
di e en  o igin  on one and e  ou d a ise inside e e  o  o gane es o  esi es a  s e  o  
on e o e  and  e  a  o e o  e e a e u a  ediu  as a esi e de i ed o  a ino  
o  endo  o ess  n is ega d  e ied s  o iden  i  e o  o gane e as unde going 
is a uo i a on o ess  o assess is o e e  e s e e ea ed i  e  o  ea  o ound 
o    and e es ed se e a  o gane e a e s  i uno uo es en e  ong e  e s  es ed 
3  M 1 and 1  a e s o  au o agoso es  soso es and ea  endoso es  es e e  
u o ag  in o es e engu en  o  in a e u a  e e en s in o dou e e ane esi es 
a ed au o agoso es  n is ase  e i o u u e asso ia ed o ein 1 ig  ain 3 3  a e  
de e s ei e  oso i  o  a ed 3  o  e au o agoso e asso ia ed o  3  n gu es 
3  and 3  i  an e o se ed o  e e as a assi e in ease o  e 3 a e  a e  e osu e 
o e ion a ie  o ounds  n on o  e s  ea ed i  e e i e M  e e as a s ig  
do ng o es onding o e 3  oso i  o  and asa  e e s o  au o ag  e eas e e as 
a uge au o ag  indu on in ea ed e s  indi a ed  au o agoso es o a on  o e e  is 
a e  does no  o o a i e i  e a uo es o ed a e  e ea en  Mo eo e  au o ag  a so 
in o es au o agoso es de i e  o e soso es o  usion and deg ada on o  ei  a go  e 
soso a  d o ases  n o de  o de e ine e e  e a uo es a ise o  soso es  e used 
an an od  agains  M 1 o ein  i  is o a ed on e soso e e ane  is a e  as 
es ed a e  e sa e ea en  ondi ons  and as i  an e o se ed in gu e 3  and 3  M 1 
i uno uo es en e e ea ed an in ease and a ange in e dis i u on o  e a e  o a ed 
o on o  e s  u  as in e e ious ase  soso es did no  o o a i e i  e gene a ed a uo es  
u a o  e s a e a e o in e na i e a o o e u es and uids o  e su ounding ediu  
 endo  a ing a a s  in uding endo osis and ino osis  e a e  1 iden es 
ea  endoso es  e s  endo  o a en  a  e ei es in o ing a go e enius e  a  1983  
e ana sis o  e i uno uo es en e i  1 a e  did no  iden  ea  endoso es as a 
ossi e o gane e a  unde en  e o ess o  a uo i a on a e  ea en  i  ou  o ounds  
e do ed a e n o  1 as e  si i a  e een on o  and ea ed e s and e e as a so no 
o e a  e een e  a e ing and e esi e in ase on as  i ages gu e 3  and 3
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Fi ure 35. Synt e c tam amine analo ues treatment does not induce s ellin  o  autop a osomes  lysosomes or early 
endosomes  uno uo es en e in 9 e s ea ed i   o  o ound 2 o     as e o ed i  di e en  
an odies a  e ogni e se e a  e u a  o gane es ed  and e e o a ed o e dis i u on o  o as i  a uo es 
o se ed  ase on as  i os o   is i u on o  e au o agoso a  a e  3   dis i u on o  soso a  
a e  M 1  dis i u on o  e ea  endoso e a e  1  e nu eus as oun e s ained i  M 3 
ue  a e a   μ  ages a e e esen a e o  a  eas  ee inde enden  e e i en s  
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RESULTS
Fi ure 36. Exposure o  A549 cells to compound 7 IC75 or 6  does not induce s ellin  o  autop a osomes  lysosomes 
or early endosomes. n ed e dis i u on o  di e en  e u a  o gane es   au o agoso a  a e  3   soso a  
a e  and  ea  endoso e a e  1  e nu eus as oun e s ained i  M 3 ue  e o a on o  
e a e s as o a ed o e dis osi on o  o as i  a uo es o se ed  ase on as  i os o  a e a   
μ  ages a e e esen a e o  a  eas  ee inde enden  e e i en s  
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Ma o ino osis is a e o  endo osis a  in o es e u a e o  e a e u a  uid and 
nu ien s in esi es no n as a o inoso es  ese esi es a ise o  e usion o  o ed 
a e i odia i  e as a e ane  n e inside e e  e  a u e and use i  e soso e 
o deg ade e on en s  o  a e e ed a  o e e ane  s egu a on o  is o ess an 
ead o e  dea  as o u s in e uosis  e ana ed e e  esi es aused  e ea en  i  
anion ans o e s e e o ed  a o ino osis  o  is u ose  e used uo es en a e ed 
de an  a uid ase a e  e o o o  is ased on e in o o a on o   a ig  o e u a  
eig  oda ine a e ed de an o  e e a e u a  ediu  in o a o inoso es  i  an 
e o se ed as uo es en  esi es  i os o i  e ods  e e o e  9 e s e e in u a ed 
i  de an and en e osed o e  o  o ound 2 o    M M  a e o ed e uosis 
indu e  as used o ea  e s as a osi e on o  n e i age gu e 3  i  an e o se ed a  
M M  odu es esi es us  i e o ound 2  i  e di e en e a  e  a e ed i  ed
a e ed de an  e eas esi es o ed  2 a e nega e o  ed a e ed de an s aining  n e s 
ea ed i  2  de an a ea s o en e   di usion u  no   a o ino osis  e e o e  e 
ossi i i  a  a o ino osis is e e anis  a  o igina es e a uo es as een dis a ded  
 e sa e e  e de ided o  o o e   a e  sin e is ig  onse ed o ein 
is no a  o a i ed o e i o ond ia  in e e ane s a e  o e a ua e is  e e o ed an 
i uno uo es en e i  e an o o e  an od  a e  ea ng 9 e s i  e  o  
ou  o ounds o    n on o  e s  as o a ed i in e i o ond ia i  s o ed e 
i a  o o og  and dis i u on o  ese o gane es in u u ed e s gu e 38  n ea ed e s e 
a e  see ed o e o a ed en osing e esi es  
Fi ure 37. Tam amine analo ues 
treatment does not induce 
met uosis. 9 e s e e 
e osed o a e ed de an 1  io  
ea en  i   o  o ound 
2 o  i  1  μM o  M M  a 
e uosis indu e  o    e e s 
e e e a ined a e  ea en  and 
a o inoso e de i ed a uo es 
indu ed  M MM  e e a e ed 
i  e uid ase a e  de an  
e eas a uo es o ed i  
o ound 2 e e no  a e ed  a e 
a   μ
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RESULTS
e e o e  e esi es a  e ossi e s o en i o ond ia  e e e ess  gi en e a  a  
 is a o ein oose  asso ia ed o e inne  i o ond ia  e ane unde  no a  sio ogi a  
ondi ons and a  e e a e an  s u i a  an ause i s e ease in o e o as  e used 
ano e  a e  o o o o a e e e ious esu  
e ose an an od  agains  an ou e  e ane ans o ase o  e i o ond ia  MM  is 
i o  e e o  is es onsi e o  e e ogni on and ans o a on o  nu ea en oded e o eins  
s s o n in e gu e 39  MM  o ed o s ain e e anes o  e a uo es in e s e osed o 
o  o ounds  e eas in e s ea ed i  e i e M  e a e  s o ed e a ange en  
and s u u e i a  o  i o ond ia  e e o e  i  as ossi e o on ude a  e ea en  i  
anion ans o e s auses an e ao dina  s e ing o  i o ond ia in 9 e s
Fi ure 38. Cytoc rome C 
immuno uorescence. 9 
e s e e e osed o  
o  s n e  a a ine 
analogues 2 and 7 o     e 
i o ond ial a e  in ed  
o e la s e esi les o se ed 
in on as  ase i ages  
u leus as s ained i  
M 3  ale a   μ  
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Fi ure 39. Immuno uorescence o  mitoc ondrial marker TOMM20  9 ells e e ea ed i   o  o ound 
2 o    e an od  agains  e ou e  e ane anslo ase o  e i o ond ia ed  o e la s i  e esi les 
o se ed in on as  ase i age  e nu leus as oun e s ained i  M 3 lue
i  e ai  o  u e  s ud  e i o ond ial s elling o ess  e de ided o a  ei  anges 
in o olog  du ing e s  3 ou s a e  ea en  n o de  o e o  e oni o ing  e s a l  
ans e ed 9 ells i  e  las id e Mi o  a i o ond ial a ge ng se uen e 
o  su uni   o  e 8  o ein  e ells e e en e osed o e  o  o ound 2 o  3  
and i ages e e a en e e   inu es  s a esul  e ould o se e e e olu on o  i o ond ial 
s elling o e  e gu e  e o e d ug as added  Mi o  la eling in on ol and ea ed ells ad 
e sa e a e n  i o ond ia a ea ed unal e ed i  no al si e and s a e  s e og esses  
e i o ond ia o  ells e osed o ea en  egan o in ease in si e  e ed do ng ela e o 
ese o ganelles g aduall  e a e ed a uoles   as ossi le o e i  o  e a uoles o se ed 
in ase on as  o e la  i  e ed a uoles o  e a e Mi o  Mean ile  i o ond ia o  
on ol ells e ained unal e ed  
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Fi ure 40. Mitoc ondrial s ellin  a er synt e c tam amine analo ues treatment. 9 ells o e e essing 
e Mi o  las id  i  a ge s i o ond ia ed  e e ea ed i   o  o ound 2 o  3  
Mi o ond ial s aining as o a ed o a uoli a on o se ed in ase on as  o og a s  ale a   μ
1
n o de  o o se e e i o ond ial s elling in o e de ail an in e e ious e ou se 
i age  e e e s o  ano e  i age gu e a  a en a e  e osu e o e  o  e s n e  
a a ine analogue du ing 3  i  an in ease in agni a on
n addi onal es  as e o ed o de e ine e s a us o  e i o ond ial e ane o en al 
 a e  ea en  i  in u n is a e  a a e e  o  e alua ng i o ond ial un on  n 
is ega d  e used Mi o a e M ed M os  a i o ond ia s e i  d e sui a le o easu e 
anges in  sin e i s e en on and uo es en e is de enden  on a o e   e e  9 
ells e e ein u a ed i  Mi o a e  o  1  and ea ed i   alue o  o ound  o  i  
1  M  used as a e i le  o  3 o e ou s  e i ages e e a en a e  e end o  e ea en  
o a ing on ol ells i  ea ed ells i ages gu e 1  e ould o se e a e a a le 
di e en e in i o ond ial o olog  s on e ious o asions  on ol ells s o ed la en ous 
o  do ed i o ond ia  ile in ea ed ells i o ond ia g aduall  s elled o a la ge  si e a uole  
s i o ond ia in eases in si e  e uo es en e o  Mi o a e  dissi a ed un l i  o le el  aded 
in o e la ge  a uoles  n addi on  e e e i en  as a ied ou   al e ing e o de  o  ea en  
us 9 ells e e s  ea ed i  o ound 2 o  3  and en e Mi o a e  as added  n 
ese ases no uo es en e as o se ed  su o ng a  e s n e  a a ine analogue al e s 
e  and Mi o a e  anno  e a u ula ed  e e o e  ou  ndings indi a e a   is los  
du ing e s elling o ess a e  o ound ea en
Fi ure 40a. Mitoc ondrial s ellin  
a er compound 2 treatment. 
e Mi o  s a le 9 ells e e 
ea ed i   o  o ound 2 o  
3  Mi o ond ial s aining o e la s 
e a uoli a on o se ed in ase 
on as  i ages  ale a   μ
1 1
RESULTS
Fi ure 41. Mitoc ondrial s ellin  and loss o  mitoc ondrial mem rane poten al ( ) a er synt e c tam amine 
analo ues treatment. on o al i ages o  9 ells ea ed i   nM Mi o a e M ed M os du ing 1  and 
en o ound 2 o  3  Mi o ond ia i  no al  a e s ained in ed  u leus as oun e s ained i   
lue  ale a   μ  ages a e e esen a e o  a  leas  ee inde enden  e e i en s
n e o e  and  e e o ed an assa  o e alua e e e  i o ond ial a i  as a e ed 
 e s elling a e  o ounds ea en  e els o  adenosine i os a e  de ne e 
ene g  s a e in li ing ells and a e de enden  ainl  on i o ond ial un on sin e is ole ule 
is o ed in ese o ganelles  e anal sis e ealed gu e  an  de ease o   in e e 
in e al o  3    a e  ea en  and a d o  o  o e an  o    o  ea en  e e o e  
i o ond ial s elling leads o i o ond ial d s un on  and is a o anied  a de ease in 
ellula   le els 
Fi ure 42. Intracellular ATP levels 
in treated A549 cells. n a ellula  
 on en  as de e ined a e  
ea en  i   o  o ound 
2 in a e ou se e e i en  
ela e a oun s e e al ula ed 
as e a o o  lu ines en e o  
ea en  g ou  ela ed o ei  
es e e on ol  n e  
a a ine analogue 2 auses 
 de le on  e i en s e e 
a ied ou  in i li a es  and 
esul s a e s o n as ean ±  
    1  
1
n addi on  in o de  o s ud  is eno enon o e dee l  ans ission ele on i og a s 
e e o ained o  on ol and ells ea ed i  o ound 2 o  7  ans ission le on Mi os o  
M  e esen s a use ul e ni ue o s ud  e a i e u e o  ells and e o ologi al 
eno ena a  o u s a e  e ea en  i  s n e  a a ine analogues  M odu es 
i ages a  a e ig e  agni a on and g ea e  esolu on an on o al i os o  ende ing 
is e nolog  a a le o  de e ining a ide a ie  o  ellula  s u u es  M i ages e ealed 
i o ond ial s elling la  a o s  gu e 3  in ose ells a  ad een ea ed i  e  o  
o  o ounds o    es e iall  i  o ound 2  Mo eo e  e a u ula on o  an  au o ag
ela ed s u u es su  as au o agoso es  au ol soso es and dense l soso es as also isuali ed 
in ea ed ells  ese esul s o ela e i  e o u en e o  i o ond ial s elling a e  ea en  
as ell as au o agoso es a u ula on  i  a  e due o i ai en  in e au o agi  u  
aused  l soso al d s un on
Fi ure 43. Transmission electron micro rap s rom 
control and treated A549 cells it  compound 2 
and 7 or 6 .  Mi o ond ial s elling la  a o s  
as ell as dou le e ane esi les a u ula on 
au o agoso es and au ol soso es  e e o se ed  




e iousl  as e lained in e e ious se on  i  as ound a  e anion ans o e s o ounds 
de ease ia ili  o  di e en  an e  ell lines as ell as  de i ed o  u o s o  a en s i  
lung an e  n is ega d  o unde s and e ole ula  ell dea  e anis s igge ed  ese 
o ounds  ells e e e osed o e in i i o  on en a on   and  o  o ound 2 and 7 
o    and su se uen l  o ein le els o  di e en  ell dea  a e s e e anal ed  es e n lo  
n s  la e  sin e ese o ounds ause i o ond ial d s un on as ell as  odi a ons 
in a idi  o a en s  e e ed e e  e a i  o  o eins ela ed o M s a il  as 
odula ed  d ug ea en  n ells  e e s o  e M  a il  su  as 38  an e a a ed  
s ess s uli  i  in u n an egula e ell dea  de ending on e du a on and agni ude o  a  
s ess  igu e  s o s a  ea en  i  o  o ounds g ea l  in eased 38 os o la on 
in 9 ells in a dose es onse anne  n e ase o  o ound 2  a signi an  a a on o and 
ee old in ease  o  38 ould e o se ed o  e  and in e ase o  o ound 7  i  
ig e  on en a ons  e e as ee old in ease
Fi ure 44. p38 MAPK ac va on  9 ells e e ea ed i  s n e  a a ine analogues a  ei    
and  alues o    and o ein e a s e e used o de e ine anges in s ess inase 38 M  and i s 
os o la on o ein le els  o ein le els e e no ali ed i  ei  es e e loading on ols in ulin  in ea  
lo  old anges in o ein e ession le els e e uan ed and e e ed o non ea ed ells  a a s o  e ean 
± M o  ee inde enden  e e i en s  a s all  signi an  esul s a e indi a ed as    and   1
1
is ind o  signal as een e o ed o a a e a o osis a e  so e s esses olado and 
e eda   n is sense  e e ed e e  e o ounds eli i  an a o o  e e  in 9 
ells  o ding o esul s s o n in gu e  and gu e  a e    o  ea en  i  e di e en  
s o  o ound 2  e e e a le o o se e a lig  a a on o  as ase 9 and 3  and a signi an  
lea age o  ei  su s a e  i  e  i  a  a e o u ed in a as ase inde enden  
anne  n e ase o  o ound 7  e de ease o  e o as ase 9 and 3 as ell as  lea age 
a e e en o e su le  in e e e as a dl  an  a a on o  e a o  a e s o  a o osis a e   
 e ied o e  e e  o e o en  a o osis a a on ould e seen i  e sa e ea en  
o e  e  us  9 ells e e in u a ed i  e es e e  alues o  o  o ounds o  8 
  n one side  e e as a slig  d o  o  o as ases 9 and 3 a e  o  o ounds ea en  
is de ease o  e ina e o s as signi an  o  o  o eases in o ound 2  and us  o  
o as ase 3 in o ound  n e o e  side  ei  es e e a e o s  as ase 9 and 3 ould 
e o se ed  inall  e ea do n o  e  su s a e a ea ed a e  ea en  i  o  
o ounds  signi an l  onl  i  e ig es  dose o  o ound 2
1
RESULTS
Fi ure 45. Apoptosis induc on a er compound 2 treatment. 9 ells e e ea ed i  o ound 2 a  ei    
and  alues o   and 8  nal sis o  a o o  o eins  es e n lo  n ea  lo  o ein le els e e no ali ed 
i  ei  es e e loading on ols  old anges in o ein e ession le els e e uan ed and e e ed o non
ea ed ells  a a s o  e ean ± M o  ee inde enden  e e i en s  a s all  signi an  esul s a e indi a ed 
as    and   1
1
Fi ure 46. Apoptosis induc on a er compound 7 treatment. 9 ells e e e osed o   and  alues o  
o ound 7 o   and 8  nal sis o  a o o  o eins  es e n lo  n o  in ulin e e used as loading on ols 
o no ali e o eins le els in ea  lo  old anges in o ein e ession le els e e uan ed and e e ed o non
ea ed ells  a a s o  e ean ± M o  ee inde enden  e e i en s  a s all  signi an  esul s a e indi a ed 
as    and   1
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RESULTS
n addi on  e used oe s  s aining o de e  o a n ondensa on and a o o  odies 
o a on  o  all a s o  a o osis gu e  e a ied ou  is e e i en  a e  8  o  
ea en  i   oin  e e e ad o se ed a as ase a a on ea  in es e n lo  anal sis  
Fi ure 47. Morp olo ical analysis o  t e nuclei induced y synt e c tam amine analo ues it  Hoec st. 9 ells 
e e ea ed i  o ound 2 and 7 a  ei   o  8  and s ained i  oe s   u lea  o  o a n ondensa on 
and so e a o o  odies i  lue uo es en e e e o se ed   
e esul s e ealed a  a ong e e aining ells  so e o  e  e  e nu leus in a  and a 
s all o on o  ea ed ells s o ed o a n ondensa on o  a o o  odies  ese a s indi a e 
a  ea en  igge s e a a on o  e a o o  o ess  and e e is a ell su o ula on a  
dies  is e anis  u  on e o e  and  in os  ea ed ells  a o osis does no  end u  eing 
e onl  es onsi le o  ell dea
onse uen l  e de ided o in es ga e e e  ano e  ell dea  o ess as in ol ed in e 
o se ed o o i i  along i  indu ed a o osis  onside ing a  e ad e iousl  o se ed 
an in ease in 3  i uno uo es en e  indi a e o  au o agoso e o a on  e de ided o 
e alua e e e ession o  o eins ela ed o e o ess o  au o ag
es e n lo  anal sis s o ed a  e li ida ed o  o  3 3  signi an l  aug en  o  
lo  on en a ons o  o ound 2  gu e 8  is g ea  in ease as also o se ed in ells 
ea ed in a dose de enden  anne  i  o ound 7 gu e 8  n addi on  e  a e  as 
e a ined  is o ein a ili a es e deg ada on o  o ein agg ega es oug  au o ag  and i  is 
deg aded du ing e o ess  s an e o se ed in e gu e   as no  deg aded u  a u ula ed 
a e  ea en  u ula on o   as o se ed in e ea en  i  o  o ounds  eing 
s a s all  signi an  in e ase o  o ound 7  and  is esul  a  indi a e an a u ula on 
o  non deg aded au o agoso es  and e e o e a lo ade in e au o agi  o
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Fi ure 48. Expression o  autop a ic markers LC3II and p62. ise o  3  and e a u ula on o   esul  in an in ease 
in au o agoso es a u ula on o  and a lo ade o  e au o agi  u  9 ells e e ea ed i    and  
alues o  a a ine analogues o    n as used as loading on ol o no ali e o ein le els in ea  lo  old 
anges in o ein e ession le els e e uan ed and e e ed o non ea ed ells  a a s o  e ean ± M o  ee 
inde enden  e e i en s  a s all  signi an  esul s a e indi a ed as    and   1
nal sis o  a o osis and au o ag  a e s e ealed a  on one and  e e as a a on 
o  a o o  ell dea  and on e o e  and  sin e e le els o  so e au o agi  a e s e e 
in eased  an au o agi  e anis  o  ell dea  ig  e lausi le  o u e  anal e e e  
ei e  e anis  as in ol ed in e o o i  e e  indu ed  s n e  a a ine analogues  ell 
dea  in i i o s e e used  n e ase o  a o osis  a an as ase in i i o  M  as added 
e o e ea en  i  di e en  on en a ons o  o ound 2 o    n e ase o  au o ag  
an in i i o  o  e 3  in ol ed in e ea l  s e s o  au o ag  a a on  3 M  as added io  
o ound ad inis a on  o e e  ese in i i o s ailed o a enua e ell dea  unde  ese 
ondi ons  ell ia ili  as no  e o e ed gu e 9  sugges ng a  a a on o  as ases is no  
u ial o  e o o i  e e  indu ed  ese o ounds no  is e au o agoso es o a on and 
ei  a u ula on  
1 9
RESULTS
no e  ossi ili  a  e a  ea en  i  ou  o ounds a  igge  a o ess o  ell dea  
li e egula ed ne osis  also no n as ne o osis  in e 1 and M  a e essen al o  e a a on 
o  e ne o osis a a  e in es ga ed ei  ole a e  e osu e o o  o ounds o    
s an e o se ed in gu e  e e as a dose es onse in ease in 1 o ein  s a s all  
signi an  in e ase o  analogue 2
e a o  un on o  1 inase a i  in ne o osis is o e ui  3  au o os o la e  
and o  a un onal ne oso e  i  in u n os o la es M  an e e u one  o  ne o osis  
n is ega d  e ied o dis e n e e  e ne oso e su s a e as os o ila ed a e  
ea en  i  ou  o ounds  u  an es e n lo  and as de e ed i  e M  an od
en e  al oug  1 in eased a e  o ounds ea en  e ne oso e su s a e M  as 
no  a a ed  n addi on e e ed e esen e o  as ase 8  sin e ne o osis is in i i ed  a 
su a ole ula  o le  in ol ing  as ase 8  and  e g e e  al  1  s an e seen in 
e gu e  a e  ea en  i  ou  o ounds  es e iall  i  2  e e as a a on o  as ase 
8 and us ne o osis e ession  e e o e  i  ese esul s  e dis a ded ne o osis as e 
ossi le e anis  o  dea  
Fi ure 49. Cell via ility a er treatment it  cell deat  in i itors. 9 ells e e e ea ed i  e ell dea  
in i i o s  1  μM  and 3 M   M  o  1  and en o ound 2 as added a  3 and  μM  ell ia ili  as 
easu ed  M  assa  ell dea  in i i o s ail o e o e  ell ia ili
13
Fi ure 50. Expression o  necroptosis related proteins and caspase 8. 9 ells e e e osed o   and  
alues o  o ound 2 o  7 o    a a ine analogues indu ed as ase 8 a a on and e e o e ne o osis 
e ession  o ein le els e e no ali ed i  ei  es e e loading on ols a n o  in ulin  in ea  lo  old 
anges in o ein e ession le els e e uan ed and e e ed o non ea ed ells  a a s o  e ean ± M o  
ee inde enden  e e i en s  a s all  signi an  esul s a e indi a ed as    and   1
inall  e anal ed e e  e esen a e ea u es o  ne osis  su  as i e e si le las a 
e ane da age o   odu on  e e igge ed a e  ou  ea en  
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RESULTS
oe s  s aining  o ined i  e inding d e o idiu  iodide  e e used o easu e 
ne osis and a o osis in ande  a e  ea en  i  o ound 2 o  7 i  ei  es e e  value 
o  8  gu e 1  u e o e  oe s  333  allo s de e ng anges in ell nu leus o olog  
su  as o e ondensa on and o a on o  a o o  odies  is ell e ean  uo o o e e i s 
lue uo es en e en is in e ala ed in o  n e o e  and   is e ea le in ells a  
ave los  las a e ane in eg i  su  as ne o  ells  u leus o  on ol ells e ained oe s  
333  e eas  as e luded  ei  in a  ell e ane  n ea ed ells e ould o se ve blue 
ounded nu lei in living ells  blue ondensed nu lei in e ase o  a o o  ells o  ed u le nu lei 
s ained i  bo  d es  in ose ells a  ave los  e in eg i  o  ei  las a e b ane  en e 
ne o  ells  is indi a es a  a  o  ell o ula on ends u  d ing b  ne osis
Fi ure 51. Hoec st and PI stainin  o  A549 cells exposed to compound 2 and 7 IC50 or 48 . u leus in blue e esen  
viable ells o  a o o  bodies  de ending on ei  ondensa on s a us  e o  ells a ea ed in ed o  u le due o 
e en  o   a e  losing e in eg i  o  e ell e b ane  ale ba   μ  
e ise  e o ding a video o e a ine ells ea ed a  a ig e  dose o  o ound  i  ase 
on as  i os o  e ould obse ve a  s n e  a b a ine analogues also ovo ed ellula  
s elling  i  nall  led o las a e b ane b ea do n  bo  i al ea u es o  ne osis  ull 
video a ea s in e su le en a  in o a on o  odilla et al. a e  e e e esen  a u es a  
di e en  e oin s o  e video gu e  
Fi ure 52. Contrast p ase ima es o  A549 cells plasma mem rane reakdo n.  video o  9 ells e osed o  o  
o ound  du ing 1   as e o ded  a u es a  di e en  es   3 and   e esen  e evolu on o  ell dea  
o ess a  ul ina es i  e e b ane u u e  ale ba   μ  
no e  a o  involved in ne o  ell dea  is  odu on and a u ula on  o  i s evalua on  
e used e Muse  ida ve ess i  based on di d oe idiu   eagen  a  as e ensivel  
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been used o de e   in ells o es  e nandes and i a   n o una el  e e ission 
aveleng  o  ou  o ound in e e ed i  is uo es en  obe and a lea  esul s in e e a on 
ould no  be ob ained  
a en oge e  ese esul s su o  e idea a  s n e  a b a ine analogues a  s  indu e 
ell dea  b  a o osis a o anied b  e a va on o  au o ag  bu  os  ells end u  olla sing 
in a ne o  ell dea
u  inves ga ons so a  ave ovided us b oad in o a on abou  e ell dea  e anis  
o  a on o  e s n e  analogues o  a b a ines  ese s all ole ules  ose o o i i  in 
an e  ells de ends on ei  anion ans o  a a i  indu e i o ond ial s elling and l soso al 
d s un on  i  in u n lead o au o ag  blo ade and ne o  ell dea  in lung an e  ells  e 
iden a on o  o en al ole ula  a ge s i in e ell ould g ea l  en an e ou  unde s anding 
o  e ole ula  e anis  o  a on o  ese o ounds
o u a onal e ods  li e ole ula  do ing  a e o onl  used a oa es in d ug dis ove  
is e odolog  uses in u s o  in o a on abou  e ole ula  s u u e o  an  ligand d ug  o  
a ge  o ein  and  oug  o u a onal binding si ula on  edi s o en al a ge s o  a given 
d ug o  vice versa  is si ula on is based on e use o  di e en  algo i s b  i  o ole ules 
in e a  i  ea  o e  un l e  a ui e e o e  o ien a on and on o a on o o  an 
ene ge all  avo able o le
i  e u ose o  nding ossible ole ula  a ge s o  o ound 2  and in ollabo a on i  
i o  ualla  esea  g ou  a elona u e o u ng en e   o ein ne g  ands a e 
lo a on e odolog  so a e as used o  s ud ing o ein ligand in e a ons a ong o e 
an one und ed an e  d ug a ge  o eins and ou  o ound 2  is so a e as e abili  
o  a ing la ge on o a onal ea ange en s s o as all  ove  a la ge e e oi e o  o ein 
s u u es  ong all e esul s   a ea ed o be a good d ug a ge  andida e o  o ound 2  
sin e i  s o ed ve  good binding esul s i  is ligand
o ound 2 gu e 3  as a si ila  s u u e as eviousl  des ibed o  o e  anion ans o e s 
su  as a b a ine o  odiginine de iva ves a a alve de et al.  1  o o e a o et al.  1  
e ole ule as a on uga ed s s e  i  a d o obi  ou e  s ell  su ounding a d o ili  
o e  o  ee si ila  a ino g ou s a ing one delo ali ed osi ve a ge  ll ee  o ons 
a e a able o in e a  i  anions su  as lo ide and bi a bona e ions o o e a o et al.  1  
o  i  a nega vel  a ged o ein g ou  o  glu a a e lu  o  as a a e s  esidues  o ing 
ee d ogen bonds as s o n in gu e 3  o dingl  ou  esul s s o  o ound 2 e e abl  
in e a ng lo  o ein ligand binding ene gies  i  lu and s  side ains  
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 si ula ons s o  e  binding si e as e ene ge all  e e ed one o  o ound 2 
binding gu e 3  n a ula  o di e en  ligand o ien a ons e e ound o  is o e  bo  
in e a ng i  e a bo l g ou  in s 9  igu e 3  ole ules in u le and in o e a bon 
a o s  o eve  ou  o e  ossible o e s i  avo able in e a on ene gies e e also dis ove ed  
as s o n on gu e 3  and 3  using blue i les  s in e  si e  e addi onal o e s involve 
also e in e a on o  e ligand i  an s  o  lu  esides e la ge  o e  e o e  o e s 
a e o ed b  s alle  le s a  see  a o ia e o  e a  o ound 2 s s e  Mo eove  in 
all ve si es o ound 2 s o s odes o  binding i  o ien a on e e e bul ie  e bu l g ou  
is oin ng ou a d e binding le  and us i l ing ossibili es o  dis u ng in e a ons o   
i  o e  o eins see in discussion sec on 4.1  n o de  o uan  e binding s eng  lide  
e s o ing as a lied o e  de ived bes  oses  e o le es s o ed s o es be een  o 
9  al ol  i  s ould o es ond o  ediu  o lo μM e e i en al a ni es
Fi ure 53. Induced t dockin  or synt e c tam amine analo ue 2 it  AKT2.   o ound 2 ole ule in o le  i  
a a bo l g ou  o  an s  o  lu esidue bonds s o n in ello   inding ene g  o le agains  e dis an e o e 
o ein en e  ob ained o  e o ound 2  s si ula on  e bla  and blue i les unde line e bes  in e a on 
ene g  o le es   o ound 2  bes  indu ed  do ing oses ini a in  ll si es a e lo a ed a ound a lu o  s  
esidue  s o n in i les  ll i les use bla  olo  i  lo a ed a  e  binding si e and blue olo  else e e  o ound 2 
ole ules a e unde lined using s e es i  di e en  a bon a o  olo s  o ein s u u es a e s o n in ibbons  
e  ob aining good ini al do ing s o es o  ou  o ound i  e  o ein oug   and  
in o de  o u e  a a e i e is o en al binding  e de ided o oni o  e in e a on be een 
 and s n e  a b a ine analogue 2 b  u a e las on esonan e  assa s   is eal
e in e a on anal sis e esen s a valuable e od i  allo s ine  and a ni  evalua on 
and de e ina on o  binding s e i i  be een o eins and s all ole ules  inding assa s e e 
e o ed using e ia o e s s e   e s  i obili ed e e o binan  o ein  on a 
13
senso  su a e and anal e o ound 2  as in e ed in solu on ove  e su a e at concentrations ranging 
from 0.15 μM to 10 μM  anges in  es onse e e olle ed and anal ed using e so a e in luded 
in e s s e  ia o e  valua on o a e  ese anges  e essed in  esonan e uni s  
s o ed e asso ia on and disso ia on u ves o  e in e a ons be een  and o ound 2 
gu e  allo ing in u n o ob ain e a ni  u ve gu e  and ine  and a ni  ons an s 
gu e  
Fi ure 54. o ound 2 binds o  inding o  o ound 2 on en a ons anging o  1  μM o 1  μM  o 
i obili ed  as anal ed b   as des ibed in e ods   sso ia on and disso ia on e e i en al u ves a e 
s o n in olo  and bla  a es e esen  e ed da a  ni  u ve  ine s and a ni  da a
e da a olle ed s o ed a binding ons an   esul ng o  e ela ons i  be een e 
disso ia on ons an  d  and e asso ia on a  o  e o de  o  nano ola  o  e a ni  u ve  
e ob ain a  o  1  ± 113 nM  ese values e e ed e ig  a ni  o  o ound 2 o e ligand  
sugges ng a  e s all ole ule o s a o le  i  
13
RESULTS
n o de  o de e ine e e  is in e a on a e s i s a al  a vi  e in uba ed 9 ells 
i  in easing on en a ons o  e o ound o    o de e   levels b  i unoblo  is 
es  evealed a  ig  doses o  e o ound no  onl  de eased e e ession o  os o la ed 
 bu  also aused a d o  in o al o ein on en  gu e  is esul  sugges  a  anion 
ans o e  o ound a e s  a a  b  di e  binding o e o ein  leading o a de ease in 
e o al o ein a oun  a o anied b  a de ease o  i s a vi  ese da a ovide eli ina  
esul s abou  is anion ans o e  e e  on e  a a  u en l  ou  g ou  is inves ga ng in 
de  is i o an  egula o  a a  in an e  as a ossible a ge  o  e e anis  o  a on o  
e d ug
Fi ure 55. Decrease o  p osp o-AKT and total AKT. 9 ells e e ea ed i  in easing on en a ons o  
o ound 2   and  o    e a vi  and o al a oun  o   as di inis ed a e  e ea en  
o ein levels e e no ali ed i  ei  es e ve loading on ols a n  in ea  blo  old anges in o ein 
e ession levels e e uan ed and e e ed o non ea ed ells  a a s o  e ean ± M o  ee inde enden  
e e i en s  a s all  signi an  esul s a e indi a ed as    and   1
5.2. miRNA expression analysis after compound treatment
Mi o s i s  a e e eiving u  a en on sin e e  e e ound o be involved in e 
o ess o  a inogenesis and u o  og ession  egula  e ession a e ns o  i  ave been 
iden ed in seve al an e s  on e ing ada ve advan ages o an e  ells  Mo eove  e en  s udies 
ig lig  a  i  a  in uen e es onses o  an e  ells o e o e a  Magee  i and 
a o alo  1  
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i  e u ose o  nding a se  o  i  involved in an e  a  a  be a ge ed b  e s n e  
a b a ine analogues  e used a an e  ela ed i  a a  and s udied e al e a on o  e i  
e ession o le in lung an e  ells a e  o ound 2 ea en  
e de ided o u li e u an an e  a a  inde  i   a a  M 31  i  o les 
e e ession o  3  i s al ead  no  o be di e en all  e essed in u o s ve sus no al 
ssue  is a a  is a use ul ool o anal e e i s os  elevan  o u o igenesis and iden  
abe an l  e essed i s be een no al and an e  ells  n ou  ase  e a a  de e ed 
e ession anges in ea ed an e  ells o a ed o non ea ed an e  ells  
o ding o ou  es olds see material and methods sec on 1 .  ea en  i  o ound 2 
al e ed a o al o  1  i s able 1  i  no ange obse ved in e e aining 3  i s o  e 
a a  ong e odi ed i  e ound so e a  ave been e o ed o be s e i all  al e ed 
in lung an e  in luding i 1 3  i 3 a  i 1 8a 3  and i   
miRNA Name miRNA Previous Name miRBase acession number
sa-miR-7-5p sa i M M
sa-miR-18 -5p sa i 18b M M 1 1
sa-miR-20 -3p sa i b M M
sa-miR-21-3p sa i 1 M M 9
sa-miR-23 -5p sa i 3b M M 8
sa-miR-30a-5p sa i 3 a M M 8
sa-miR-103a-3p sa i 1 3  sa i 1 3a M M 1 1
sa-miR-106 -3p sa i 1 b M M
sa-miR-130a-5p sa i 13 a M M 93
sa-miR-146a-3p sa i 1 a M M 8
sa-miR-148a-3p sa i 1 8a M M 3
sa-miR-148a-5p sa i 1 8a M M 9
sa-miR-205-5p sa i M M
sa-miR-212-3p sa i 1 M M 9
sa-miR-224-3p sa i M M 9198
sa-miR-663a sa i 3 M M 33
sa-miR-1287-5p M M 8 8
Ta le 15. Di eren ally expressed miRNAs a er treatment it  compound 2  n ed  ose i s ose e ession 
de eased and in g een ose i s ove e essed a e  ea en
13
RESULTS
e ondl  o iden  e a ge  genes o  ese i s  and en e e an e  a a s involved 
a e  e ea en  e used ou  e e i en all  valida ed i gene in e a ons da abases 
a ase v  i a ase v  i e o ds v  and i Ma  v  is bioin o a s 
anal sis see material and methods sec on 1 .  s o ed a  ese i s egula e e e ession 
o  o e an ee und ed a ge  genes  e o en sou e so a e os a e as used o build a 
bio ole ula  in e a on ne o  i  e os  al e ed i s and ei  o es onding a ge  genes 
gu e  is ne o  en o asses all e a  da a gene a ed o  e bioin o a s anal sis  
e elli ses e esen  e al e ed i s  in g een o  ed as e  a e u egula ed o  do n egula ed  
es e vel  and e e angles a e e genes egula ed b  one  o o  ee i s blue  g a  o  
g een olo  es e vel  
nal sis o  e al e ed gene se  evealed a  an e  ela ed a a s as 3  e e e 
os  a e ed b  ese i s  a ula l  b  i  i 3a  i 3 a  i  i
18b  i 1 8a 3  and i 1 3a 3  
Mo eove  an  i s e e ela ed o e egula on o  a o osis and au o ag  a a s  o  
ins an e  i  egula es  a ge  genes involved in a o osis  a ong i  s ands ou   
ell l o a  e  i s ose a ge  genes a i a e in e a o o  o ess a e i
 i 3 a  i 1 3a 3  i 1 8a 3  and i 1 3  a ge  genes i li a ed in au o ag  
a e less abundan  and a e egula ed ainl  b  i 3 a  and i
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Fi ure 56. Net ork o  tar et enes o  t e altered miRNAs upon compound 2 treatment. a ge  genes in o a on as 
e ieved o   di e en  da abases  e o  as build using e o en sou e so a e os a e  e g een and ed 
elli ses indi a e e u  and do n egula ed i s  es e vel  e blue  lila  and gold e angles indi a e e a ge  
genes a  a e egula ed b  one  o o  ee i  es e vel
n e e ad all e da a olle ed  e e o ed a o e in de  anal sis o using on e 
i li a on o  ese i s in e above en oned a a s ela ed o an e  i s  b  evie ing 
li e a u e  e ob ained in o a on abou  o  ese i  a e e essed in an e  e e o e  i  
as ossible o dedu e e ole a  e  e e  as o en al u o  su esso  genes o  on ogenes  n 
is ega d  e ound a  ou  o ound de eased e e ession o  seve al i s des ibed as 
on o i s o  in eased u o  su esso  i s  e onside ed a  in ese ases  e  a  ave 
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a ole in e o ound an an e  e e  n e o e  and  e dis a ded o  ou  anal sis ose 
i s in i  ei  o en al ole a o ding o e bibliog a  ould ave an o osi e e e  o  
e obse ved an an e  esul s  i e ise  so e i s e e e luded o  u e  anal sis due o 
e la  o  in o a on ega ding i s biologi al ole in lung an e
e di e en all e essed i s o  e a a  a  e anaged o e ieve eaning ul 
in o a on ega ding ei  egula on in lung an e  a e s a ed in e ollo ing able




sa-miR-103a-3p M M 1 1 n ogene
an o en o et al.  
13  an et al.  1
sa-miR-106 -3p M M n ogene
M  u et al.  1  
Wang et al.  1
sa-miR-148a-3p M M 3 o n u o  su esso ang et al.  1
sa-miR-148a-5p M M 9 o n u o  su esso  i et al.  1
sa-miR-18 -5p M M 1 1 a e
Mi o et al.  9  a i  
et al.  1  un et al.  
13
sa-miR-205-5p M M n ogene iang et al.  13
sa-miR-212-3p M M 9 o n u o  su esso
abino i s et al.  9  
 n o ona o et al.  1  
11
sa-miR-21-3p M M 9 n ogene
el es ovo et al.  
1
sa-miR-663a M M 33 n ogene ang et al.  1
Ta le 16. miRNAs selected accordin  to t eir poten al an cancer unc on. n ed and g een es e vel  do n egula ed 
and u egula ed i s a e  ea en  i  o ound 2  ese i s a e lassi ed as o en al on ogenes o  u o  
su esso  onside ing di e en  s udies a  ave e o ed ei  e ession in lung an e
n e ne  s e  e sele ed e genes  egula ed b  e a o e en oned i  a  e e involved 
in e a a s a  an be ela ed o e indu on o  an an an e  e e  i  e e a o osis  
a oau o ag  and 3  is as a ied ou  using  o o n lo edia o  enes 
and eno es  a a  da abase  geno e  egg  is is a la o  a  olle s 
ul le a a  a s e esen ng e e i en al no ledge on ole ula  in e a ons  ea on and 
ela on ne o s i in e ells and o ganis s  n e e sele on o ess as o le ed  e buil  
a ne  ne o  i  os a e so a e en o assing sele ed genes and ei  i s gu e 
1
Fi ure 57. Di eren ally-expressed miRNAs and t eir tar et enes interac on net ork  een and ed elli ses s and 
o  u egula ed and do n egula ed i s a e  o ound 2 ea en  es e vel  n e angles  genes ela ed o 
3  a a  a o osis and a oau o ag  enes involved in a oau o ag  a e s o n in lig  blue and 3
 in in  enes involved in o a a s a e in o ange o  lig  g een  e esen ng a o osis and 3   
a oau o ag  and 3  M  ose genes a  a e i li a ed in e ee a a s a e in ello  M
ending o e a ge  genes a  a ea ed in e ne o  genes su  as  os a ase and 
ensin o olog  and   do ain and leu ine i  e ea  o ein os a ase  egula ed 
b  e do n egula ed i 1 3a 3  and i  and genes li e  o  M  elo o a osis 
vi us on ogene ellula  o olog  egula ed b  e u egula on o  i 1 8a 3  and i 1 3  us  
be ig lig ed  is i  e ession o le gene a ed a e  ea en  i  o ound 2 ig  be 
ela ed i  e o o i  e e  obse ved in 9 ell line  
n an  ase  ese a e eli ina  esul s edi ed b  e obse ved i  odi a ons  o 
o obo a e e i li a on o  ese genes in e o o i  e e  indu ed b  o ound 2  e ould 
ave o valida e ea  o  ese o en al a ge  genes in u e  e e i en s
6. Evaluation of  compounds therapeutic effect in in vivo studies
evious esul s i  o ound 2 and 7  su  as ei  ig  o o i i  in lung an e  ell lines 
and a en de ived  sugges ed a  ese o ounds a  be o en al an u o  d ugs in 
an e  i e odels  o dingl  an u o  e a  as s  assessed in an e o i  enog a  odel  
using a sub u aneous odel in ollabo a on i   illanueva ns u  d nves ga i  io di a de 
ellvi ge  Mi e bea ing sub u aneous 9 u o s e e ea ed i  o ounds 2 o  7  g g 
1 1
RESULTS
in saline i   o  M 8  een 8  o  ve i le on ol  o  M 8  een 8  in 
al e na ng da s du ing  da s   e sa e e  ea en  i   s anda d e o e a eu  
d ug  as a ied ou  in o de  o o a e ei  e a  levels  
igu e 8 s o s e esul s o  ea ng i e bea ing 9 u o s i  o ound 2 o  7 o
and CDDP  o  o ounds  a  a dose o   g g  odu ed a s a s all  signi an    1  
edu on in u o  eig  o a ed o e on ol g ou  and i  as si ila  o e  indu ed 
edu on  o eve  e o bina on o  ou  o ounds i   did no  lead o a s ne gis  e e  
o an l  as a single agen  e ea en  i  o ounds 2 o  7 did no  odu e an  obvious 
o i i  e a o o i i  and ne o o i i  dia ea o  signi an  bod  eig  loss  
Fi ure 58. E ect o  synt e c tam amine analo ues (2 and 7) in esta lis ed A549 uman adenocarcinoma su cutaneous 
tumors. Mi e g ou  e e ad inis e ed i  o ound 2 o  7 a   g g in al e na ng da s du ing  da s o   
a   g g da    and 1  igni an  di e en es in ean u o  eig s o a ed o on ols e e obse ved i  
all single o ounds ea en s  o s ne gis  e e  as obse ved in o bina on ea en s  a s all  signi an  
esul s a e indi a ed as    and   1
n a eli ina  s ud  e es ed ou  o ounds in a u ine o o o i  lung odel develo ed 
b   illanueva  We sele ed is odel sin e i  e odu es e i a  si e o  e o on u an 
lung an e  and is able o e esen  e o on si es o  e as asis  n o una el  due o e ni al 
di ul es  e g ou s e e edu ed o 3 o   ani als e  ondi on  iven a  ou  ndings a e based 
on a li i ed nu be  o  ani als  e esul s o  is anal sis s ould be ea ed i  onside able 
au on  es i e is  i  as obse ved a  bo  o ounds edu ed u o  og ession in is odel  
es e iall  o ound 7 gu e 9  a en oge e  ese eli ina  esul s indi a e e o en al 
e a eu  e e s o  ou  o ounds agains  lung an e
1
Fi ure 59. An tumor e ects o  tam amine analo ues in an ort otopic model o  uman NSCLC  a  g a  s o ing e 
ean u o  volu e in u ine lung o o o i  odel ea ed i   g g o  o ound 2 and 7 o   da s  a s all  






1. Chemical structure, anion transport activity and cytotoxicity
al and lung an e  a e lis ed a ong e os  o on es i a o  diseases  being e la e  
one o  e ain auses o  o ali  in e o ld  es i e ne  advan es in diagnosis and lini al a e  
e su ess o  onven onal ea en s is s ll li i ed  es e iall  in e o e a  e e o e  i  is 
ne essa  o iden  ne  ole ules i  di e en  e anis s o  a on and o e e e veness o 
g  agains  ese es o  an e s  in e an e  ells ave a eve sed   g adien  a  su o s 
ei  develo en  in e las  ea s  e dis u on o  ioni  o eos asis as been des ibed as a 
ne  s a eg  agains  an e  Webb et al.  11  onse uen l  anion ans o  o ounds su  as 
odigiosin  oba o la  and salino in  a ong o e s  a e being s udied as o en al e a eu  
agen s o  an e  e e o as and Mon ane  3  u a et al.  9  e e o as and inas  
1  oa d and i e  13  a u al a b a ines  se onda  e aboli es de ived o  a ine 
inve eb a es a e and aul ne  1983 oliev  oso a a and no o o  11  a e also a a il  o  
anion a ie  o ounds i  dive se biologi al a vi es a bone et al.  1  s a esul  o  e 
sea  o  novel o ounds i  e ien  ans o e  a vi  in ollabo a on i  obe o uesada s 
esea  g ou  nive si  o  u gos  ne  ole ules de ived o  is a il  e e s n esi ed  
u u all  e o ounds in ese se ies s a e a bi ole o e  i al o  na u al o ounds  
ese s n e  a b a ine analogues ossess an a o a  ena ine g ou  bea ing ei e  ele on 
dona ng o  ele on i d a ing subs uen s as ell as a e e oa o a  idine  g ou  eside 
is  ea  analogue as a a en  de iva ve  in i  in addi on o e evious odi a ons  a 
ben lo  g ou  e la ing e e o  g ou  a a e is  o  e na u al o ounds as in odu ed 
e nando et al.  1  e va iabili  on e subs uen s on e s a s e i  li o ili i  a a e  o 
e o ounds  is li o ili i  as a di e  i a  on e anion ans o  a vi  o  ese s n e  
a b a ine analogues nig  et al.  1  
Fi ure 60. C emical structure o  synt e c tam amine analo ues 
ese o ounds  as ell as o e  na u al a b a ines  ave been des ibed as o en  
ans e b ane anion ans o e s in li oso al odels  a ili a ng lo ide and bi a bona e e ange 
a oss li id e b anes e nando et al.  1  e o ounds o  su a ole ula  o le es 
i  anions oug  e o a on o  s ong d ogen bond in e a ons and a e a able o o o e 
lo ide and bi a bona e ans o  oug  bila e s gu e 1
1
Fi ure 61. Model or anion transport mec anism induced y synt e c tam amine analo ues. is gu e as odu ed 
using e vie  Medi al  i age ban
e en l  as a esul  o  i s ans o  a vi  seve al s n e  a b a ine analogues ave s o n 
o en  an an e  a vi  in a anel o  an e  ell lines  in luding u an elano a  lung a ino a  
olo e al adeno a ino a and a a  adeno a ino a ells e n nde  et al.  1  e nando 
et al.  1  n is esis  e esul s ob ained ela ed o ei  an an e  o e es i  ose 
o ounds bea ing al o bi ole oie es e nando et al.  1  a e e ended o seve al 
o al and lung an e  ell lines  ell viabili  as edu ed i  e a o i  o  e es ed analogues 
in bo  o al and lung an e  ell lines  e os  o en  o ound  analogue 2 as sele ed along 
analogue  i s va ian  i  ben lo  g ou  as e os  o ising an an e  o ounds  is ai  
o  o ounds s o ed  values a e    o  ea en  belo   μM in e esen a ve ell lines o  
bo  es o  an e   i d o ound  NT o  non ans o e  sele ed o  u e  e e i en s due 
o i s odes  ans o  a a i  is s u u all  ela ed o e s n e  a b a ine analogues and 
ave s o ed signi an l  ig e   values  en e  anion ans o  a vi  a  be di e l  ela ed o 
ellula  o o i i  
i ila  s udies a ied ou  i  indole based a b a ine analogues  ano e  ba  o  s n e  
o ounds de ived o  e na u al a ine al aloids  s o ed ig e   values in lung an e  ell 
lines o o e a o et al.  1  en e  ou  o ounds a e e os  o en  a ong e di e en  se ies 
o  a b a ine analogues in e s o  o o i i  o  lung adeno a ino a ells  u e o e  ou  
o ounds ave oved o be o e e e ve an o e  aniono o es sin e e en l  da a ublis ed 
o  e e a eu  a ono o e salino in ave s o ed  values anged o   o 1  M o  
lung an e  9 ell line a a  et al.  13  e o a ison be een  values ela ve o ese 
analogues i  ose ob ained i  is la n s anda d e o e a eu  agen  used in e lini  
o  bo  o al and lung an e  s o ed a  o ounds bea ing al o bi ole oie es a e 
1
DISCUSSION
o e o en  an is la n  e is la n  value ob ained in ou  g ou  is onsis en  i  evious 
ublis ed da a an et al.  9   n addi on  s n e  a b a ine analogues a e o e e ien  an 
ge i abine in vitro  onside ing a  i  as an  value a ound 1  M a e    o  ea en  eda 
et al.  11  i et al.  1  e e o e  a b a ine analogues in vitro values a e in e ange o  e 
os  u en l  used e o e a eu s in e ea en  o  lung an e
ele ed o ounds e e also es ed in  an e  s e  ells  de ived o  a en s o  isola ed 
o  9 ells and o ound 2 s o ed o be es e iall  o en  agains  a en de ived  is u o  
sub o ula on  involved in u o  ini a on  ossesses a a i  o  sus ained sel ene al  on ibu es 
o e as a  disse ina on as ell as o a ui ed e o e a  esis an e in an e  alen  et al.  
1  us ese esul s a e ve  en ou aging o  lung an e  ea en  and e even on o  u o  
e u en es  n is vie  s udies i  indole based a b a ine analogues ave also de ons a ed 
a  e  a e able o seve el  edu e  viabili  o o e a o et al.  1  eside is  a  ind o  
anion ans o e  indu es ell e b ane e ola i a on  i  in u n leads o  di e en a on  
is a  ould in ease  sensi vi  o e o e a  o  adia on a ieving g ea e  e a  and 
avo able lini al esul s o o e a o et al.  1  n is ega d  o e  aniono o es su  as e 
a on sele ve iono o e salino in as de ons a ed a  i  as s e i  o i i  agains  s 
in di e en  es o  u an an e s in vitro u a et al.  9  Wang  11  indi a ng a  e 
a li a on o  ese ind o  o ounds ig  be a ve  o ising e a
ll is o  led us o on lude a  sele ed s n e  a b a ine analogues de ons a e be e  
a a i  as o o i  o ounds  bo  in an e ous ell lines and in a en de ived  an s line 
e o e a  ea en s  sugges ng a  e  ig  be o ising ne  e o e a eu  agen s
2. Anionic unbalance and cellular stress
ells a e ons an l  sub e ed o di e en  o s o  endogenous and e ogenous s uli  an  o  
i  an indu e s ess  ese insul s a  in e e e i  ellula  o eos asis  su  as o ia   
da age o  ioni  i balan e  ini a e es onses o ain ain e balan e a  is needed o  ell su vival  
and i  is is no  e ove ed  e  a  igge  ell dea  e anis s  
 o eos asis and e ain enan e o  o on g adien s a oss o ganella  e b anes a e e  o 
ell su vival  un on and oli e a on ase  ins ein and lo s i  9  n one and  un on 
o  o ganelles is sub e ed o e es ablis en  and ese va on o  an in e nal di e en a ed  a  
ovides o al envi on en al ondi ons o  e o e a on o  e ain e aboli  a a s  n e 
o e  and  all o eins de end on  o ese ve ei  s u u e and un on  Mo eove  di e en  
on en a ons o  o ons a ong o a en s and osol gene a e + g adien s essen al o e 
gene a on and onve sion o  ellula  ene g  i  in u n is an in eg al a  o  an  e aboli  
ea ons ase  ins ein and lo s i  9  is nel  ad us ed un on  a ied ou  ainl  b  
ans o  o eins lo a ed on e ell e b ane  an be odula ed b  endogenous o  e ogenous 
ole ules  as ell as  in so e a ologi al si ua ons  an lead o i anges a  ave been i li a ed 
in bo  ell oli e a on and ell dea  agadi oss ann  u  and e u eu   e e o e  ou  
1 8
sele ed s n e  a b a ine analogues  as o en  lo ide bi a bona e e ange s  ould ave 
di e  onse uen es on bo  o las a  and o ganelle  
soso es a e a idi  o ganelles es onsible o  e deg ada on o  bo  in a  and e a ellula  
o onen s  via endo osis o  au o ag  es e vel  o  is eason  is o ganelle on ains a 
la ge a a  o  d olases designed o a aboli e all es o  a o ole ules en and Mi us i a  
1  ei  a aboli  a vi  de ends on e ig l  a idi   o  e l soso al lu en   
idi   is ainl  gene a ed b  ases  a la ge ul e i  en e o le  a  ou les e 
ene g  o   d ol sis o u  o ons a oss e l soso e e b ane in o e l soso e lu en  
onside ing a  is o on a u ula on gene a es a ans e b ane vol age  ano e  ion us  
ove o dissi a e is a ge  n is ega d  in addi on o e o on u  seve al ion annels 
ave been iden ed in e l soso e e b ane  o  e a le l + an o e s l  and a+ + 
annels  o  on ibu e o a idi a on o ensa ng l soso al e b ane a ges oug  u  o  
oun e ions  su  as + o  l  oving ou  o  in o e l soso e  es e vel  Mindell  1  u and 
en  1  
n e e ells in e nali e ese s n e  a b a ine analogues  seve al ellula  o esses o u  
onve ging in e o en  o o i  e e  obse ved  o ding o e e o al se uen e o  even s 
a  a e la e inside e ell  s n e  a b a ine analogues 2 and 7 ause e loss o  a idine 
o ange uo es en e o  a idi  o ganelles i in e s  ou  o  e osu e  i  indi a e l soso al 
dea idi a on  is in ease in l soso al  is onsis en  i  an anion a ie  a vi  a oss ellula  
e b anes  si ila l  o a  obse ved in li oso al odel  n a idine o ange assa  as a nega ve 
on ol  e used ano e  s n e  a b a ine analogue NT  due o i s odes  anion a ie  a a i  
ven oug  NT is s u u all  si ila  o ou  o ounds  i  as lo e  li o ili  value  and e e o e 
i  does no  ave e sa e a a i  o inse  in e li id e b anes  o  is eason  a e  ea en  
i  NT  e a idi  o a en s ain ain i al  s aining unli e ose ea ed i  2 and 7 
ure , results sec on .
u  su osi ons o e lain is eno enon a e based on ans o  a vi  assa s  We esu e 
a  s n e  a b a ine analogues a ili a e e en an e o  bi a bona e in o e l soso e and 
o o e e e u  o  lo ide ou side e l soso e  avo ing ele o e i al g adien  gu e  
n one and  in e nali ed 3
 ould o bine i  e + esen  in e l soso e o ing a boni  
a id  i  being uns able in a ueous solu on  is ans o ed in o a e  and a bon dio ide a  
an di use eel  oug  e e b ane  n is ase  e bi a bona e en  ould a  as a bu e ing 
s s e  in easing e  o  e l soso e  n e o e  and  a e  lo ide ou u  e ele i al 
o en al a oss e e b ane ould be unbalan ed  n is ega d  is ould ause a o on lea age 
ing o dissi a e e ele i al g adien  i i io and einbe g  11  Mo eove  i  ould in uen e 
l soso e ans o e s  su  as e lo ide o on an o e  l  i  ig   o o ensa e 
e la  o  lo ide ulling ou  +  
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Fi ure 62. Lysosomal anion transport model induced y selected synt e c tam amine analo ues and its consequence 
on intracellular and lysosomal pH. is gu e as odu ed using e vie  Medi al  i age ban
n e es ngl  i  as e en l  been e o ed a  oba o la  ano e  aniono o e ela ed o e 
odiginine a il  a  as been evalua ed in lini al ials o  di e en  an e  ondi ons  a idl  
lo ali es o e l soso es and also indu es l soso al al ali a on a a et al.  1  a elos 
e  al  1  i all  an in ease in l soso al  ould de ive o  + lea age  a de e ve o on 
u  o  l soso al e b ane e eabili a on M  o a  1  eside is  i  as e en l  been 
des ibed a  ig  lu inal lo ide in e l soso e is i al o  l soso e un on   being ig l  
de le ed in l soso al s o age diso de s a abo  eung and is nan  1  e e o e  de e s 
in e no al un oning o  e l soso e as a esul  o  i s al ali a on a  a e  ellula  o eos asis 
and a e asso ia ed i  seve al u an diseases neide  and ue vo  1  e ano uebla and 
o a  1  Mo eove  i  a  lead o d s egula on o  au o agi  u  i  ill be des ibed in e 
ollo ing se on  
n e o e  and  l soso al al ali a on a  also be de ived o  M  i  is ela ed o ell 
dea  o a and oe e  8  allu i  avo an ed o and oe e  1  is o ess involves 
e elease o  l soso al a e sin o eases  and a a al d o  o  osoli   a  allo s ei  
a va on  e ending on e ell e  and e na u e and in ensi  o  e s ulus  M an ini a e 
o  a li  di e en  es o  ell dea   as been e o ed a  a al M  an ini a e a o o  
a a  oug  e leavage o  a va ie  o  subs a es gedal et al.  1  i an et al.   
1
e eas e ensive and a id M  esul s in ne osis allu i  avo an ed o and oe e  1  
e ni  a ne  esen and u  1  n is sense  e in ease in l soso al  a  de ive o  M  
and be on ibu ng o ell dea
n e o e  and  s n e  a b a ine analogues a  also indu e a lo ide bi a bona e 
e ange a  e las a e b ane  a e ng o e in a ellula   ending o e i al ion 
on en a on inside e ell  lo ide is less abundan  an bi a bona e odis  and  e    
i u s   Ma sudai a   en e e ove en  o  ions igge ed b  o ounds ould be e 
en  o  lo ide inside e ell and e e ulsion o  bi a bona e ou  o  e ell  is ould leave e 
osol i  a lo  bu e ing a a i  agains  e o on lea age o  e l soso e  and e e o e 
is ould be a idi ed  n o una el  i  as no  ossible o easu e e de ease o  i aused b  
ou  sele ed o ounds due o e ni al li i a ons o  uo es en e in e e en e  o eve  in e en  
s udies i  indol based a b a ines s u u all  ela ed o ou  o ounds  i  as been oved 
a  ese o ounds ause a signi an  in a ellula  a idosis a d o  o  u  o   uni s  as a 
onse uen e o  e anion ans o  and  is ig  be es onsible o  ini a ng e o ess o  ell 
dea  o o e a o et al.  1  Manuel Man esa et al.  1  
n e es ngl  a e en  esea  as been ublis ed in i  e  e o  o  is la n  a s  line 
ea en  indu es a idi a on o  e o las  ea l  a e  e ea en  n addi on  ei  s udies 
su o  e o esis a  e abili  o on ol and ain ain an al aline i o o e ell su vival 
a e  ea en  i  is la n i anova et al.  1
2.2. Mitochondrial swelling 
Mi o ond ia a e essen al o ganelles a  e o  ul le un ons in e ell  e  a e a  e o e 
o  ellula  ene g  e abolis  being e si e o  os   gene a on oug  e  le   
and e ele o e i al g adien  gene a ed a oss e inne  o  o e b anes b  e ele on 
ans o  ain   o eve  i o ond ia e o  an  oles be ond ene g  odu on  ese 
o ganelles an on ibu e o ell dea  b  s u ng o  e ene g  su l  odu ing da aging ee 
adi als o  eleasing dea o o ng o eins   u  o esses an be a  o  a og a ed o ess 
o eli ina e ose unneeded o  abno al ells  o  e  an de ive o  an un lanned es onse o an 
ove el ing s ess een  allu i and oe e  1  
Mi o ond ia volu e egula on is a ouse ee ing ellula  un on essen al o  ain aining 
e s u u al in eg i  o  e o ganelle aasi  et al.   Mi o ond ial volu e o eos asis 
is on olled b  os o  balan e be een osol and i o ond ia  n eased olloidal os o  
essu e en an es e a e  in u  leading o a i  s elling  a en l  e u  o  a + and +  
i  in u n a  be asso ia ed i  e ove en  o  o e  ions  la  a i al ole in siologi al 
and a ologi al s elling o  i o ond ia avadov  a a ubo  and Ma a ov  1  anges 
in i o ond ial si e i in a siologi al ange s ula e i o ond ial un on and e abolis  
ales a  199  o eve  e essive i o ond ial s elling  esul ed o  al e a ons in ion 
o eos asis in e o las  and i o ond ial a i  o o ises i s un on and in eg i  
avadov  a a ubo  and Ma a ov  1  
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n siologi al ondi ons  e inne  i o ond ial M  e b ane is nea l  i e eable o all ions  
in luding o ons  is allo s e o ida ve os o la on o le es o gene a e a o on g adien  
e ui ed o d ive  s n esis  eside is  is a ge i balan e a  esul s o  e gene a on o  an 
ele o e i al g adien  a oss e M o s e basis o  e i o ond ial ans e b ane o en al  
en e  ain enan e o  e o on g adien  is u ial o  ellula  bioene ge s oe e  allu i  
enne  e  al   n addi on  and ove gene a on o   o  in a ellula  al iu  ove load auses 
e o ening o  i o ond ial e eabili  ansi on o es M  in e M  M  is a o anied b  
a d o  o  e i o ond ial e b ane o en al  un on olled en  o  solu es and a e  in o 
e a i  i  auses o ganelle s elling and a  ul ina e in e u u e o  e ou e  e b ane 
ales a  9  W en i o ond ial e b ane e eabili a on MM  o u s  o eins o  e 
i o ond ial in e e b ane s a e a e eleased in o e osol  e e e   o o e ell dea  b  
ul le e anis s oe e  allu i  enne  e  al  allu i  lo g en   oe e  9  
n e e ells in o o a e e s n e  a b a ine analogues  e ollo ing even  a  o u s 
i in e ell is a uge o las i  va uoli a on due o i o ond ial s elling  as de ons a ed 
b  seve al s e i  a e s o  is o ganelle  u  o esis o e lain is eno enon is a  ion 
ans o  a ied ou  b  ou  o ounds ould gene a e an os o  i balan e be een e osol 
and e i o ond ia  igge ing assive i o ond ial s elling and a e ng i s o e  un oning  
Mo eove  a e  signi an  o ganelle s elling  loss o   as indu ed b  o ound 2  o ding o 
li e a u e   o u s along i  a bioene ge  isis a a e i ed b   ove odu on and  
s n esis a es  oe e  allu i  enne  e  al   suall  easu e en  o   is used o 
assess ell viabili  and o o i i  sin e ells need  o sus ain viabili  n addi on  e a oun  
o   a  e ains in a ell is lin ed o e e o  dea  a  as been igge ed  sin e a o osis 
o eeds i  ellula   levels a e ain ained  e eas ne osis an o u  in an inde enden  
anne  eis  et al  199  
n is ega d  i  as also been a a e i ed a  in ells a e  o e  ellula  s esses su  as a u e 
is e i  in u  i o ond ial de ola i a on and MM  o u s  i  in u n led o a la ge a li ude 
s elling ose  et al.   and ellula   de le on ouslin  oge and u  199  Mo eove  
i  as been des ibed a  e in e en  in i o ond ial e eabili  indu es  odu on 
a andie  eve ve and on aine  
en e  e esu e a  i o ond ial d s un on obse ved a e  a b a ine analogues ea en  
a  ause an ene ge  ailu e and  odu on  on ibu ng o ei  o o i  e e  n a  
ea en  i  o ound 2 aused a de ease in e ole ellula  a oun  o   i  oin ides i  
i o ond ial s elling and e loss o  e MM  e e o e  a b a ine analogues a  ave si ila  
e e s an i o ond ial un ou le  o ounds  su  as a bon l  anide  i uo o en o  
en l  d a one  i  auses de ola i a on o  i o ond ial e b ane and dis u on 
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4. Synthetic tambjamine analogues molecular mechanism of  action
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n ou  ase  e ai  o  is eli ina  s ud  as e iden a on o  d s egula ed i  a e  
a b a ine analogue 2 ea en  and ei  o en al ole in e o o i  e e  o  is o ound 
agains  e 9 lung an e  ell line  s a esul  e ound a  ea en  al e ed i  ose 
a ge  genes a e ainl  involved in an e  ela ed a a s  su  as 3  o  a o osis
s e lained in e esul s se on  a ong odi ed i s a  a ea  in gu e  results sec on 
.  e sele ed ose i s in i  e ea en  ad a o en al an an e  e e  and ose 
i  in i  e ea en  ig  odu e e o osi e e e  o e e e ed e e no  in luded in 
subse uen  anal ses  is is e ase o  i s su  as i  i 1 8  i 13 a and i 3 a  i  
a ole o  o en al u o  su esso  in an e  bu  i  ave been do n egula ed b  e ea en  
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un o et al.  1   Wang et al.  13   ao et al.  1  u et al.  1  u et al.  1  n 
one and  is ould be due o e a  a  e bibliog a i  da a a e o  o e  ellula  odels  
and in ou  odel ese i s a  no  ave a  ole  n e o e  and  e an e  ell a   o 
odula e i  e ession as a e anis  o  esis an e
n e o e  and  a e s so e es s o  in o a on on e ning o e a il  o  a a ula  
o  o  i  is a ens i  e i s 1 a 3  b 3  3  and 3b  o ding o 
li e a u e  i 1 a as been e o ed as a u o  su esso  in seve al an e s i et al.  1  en 
et al.  13  e ise  i b levels ave been s o n u egula ed in ssues i  se onda  
u o s de ived o  lung an e  u et al.  1  i  as been des ibed as an on o i  ui et 
al.  1  eve eless  e e is a dl  an  in o a on ela ed o e s e i  i  s ands and i s 
un on in an e  a ing in o a oun  a  e  and 3  a  o  e i  de ived o  e sa e 
e i s  ave di e en  e ession a e ns  abundan e and a ge s  ese i s e e also no  
in luded in e ollo ing anal ses  
o ding o e en  s udies  i  and i 1 3 a e onside ed bio a e s o  e diagnosis 
o  lung an e  ells sin e e  a e u egula ed in lung an e  ssues en o a ed i  e 
o es onding eal  lung ssues anai a a et al.   andi et al.  1  iang et al.  13  u  
ea en  i  o ound 2 in ibi s ei  e ession and ig  edu e 9 oli e a on b  nega vel  
egula ng e 3  su vival a a  ure , results sec on .  ei  a ge  genes   and 
 onside ed u o  su esso  genes  ig  be osi vel  egula ed and a  an agoni e e 
3  signaling a a  avoiding e a va on o   is is onsis en  i  s udies in  
e o ng a  i  in eases  signaling and d ives alignan  eno es a ge ng  and 
 i et al.  13  Mo eove  e e is eviden e in o e  an e  es  su  as olo e al an e  
e e i 1 3 o o es oli e a on and ig a on due o  loss o  un on eng et al.  1  
i e ise  u egula on o  i 1 8a 3  indu ed b  o ound  usuall  do n egula ed in lung 
an e  Mon ani e  al  1 n o ona o e  al  11  ould di e l  e ess e e ession o  genes 
a  a ili a es an e  develo en  o  o ela e i  bad ognosis  as o  e a le e an a o o  
o ein  ang e  al  11  e and ue  1  i ila l  i 1 8a a ge   in eg in subuni  
al a  a ell ad esion o ein a  an lead u o igenesis and o ela e i  oo  ou o e in  
da i e  al   n is sense  i 1 8a edia ed do n egula on o   and 8 in eg in 
subuni  be a 8  e ession ave esul ed in e in ibi on o  alignan  og ession o  u o  ells in 
gas i  an e  seng e  al  11  n e sa e a  so e ing si ila  ould a en i  i 1 8a 
a ge  genes 1  insulin li e g o  a o  e e o  and 1 insulin e e o  subs a e 1  i  
ave been s o n o la  i al oles in e develo en  and og ession o  va ious u o s endulu i 
e  al  1  n is ega d  u and olleagues ave s o n a  ove e ession o  i 1 8a in b eas  
an e  ells ould su ess oli e a on  olon  ell o a on and u o  angiogenesis a ge ng 1 
and  u e  al  1  n e a o ellula  a ino a  i 1 8a is signi an l  de eased as in lung 
an e   e en  s ud  a ied ou  i  e a o ellula  a ino a in vi o and in vivo odels  ound 
a  es o a on o  i 1 8a e ession signi an l  e essed e e i elial esen al ansi on 
and e as asis b  a ge ng M  e l ni oso guanidine u an os eosa o a ans o ing 
gene  signaling ang e  al  1  Mo eove  i 1 8a and i 1  ave been des ibed as a 
nega ve egula o  o  M  in e a o ellula  and gas i  a ino a  es e vel  u e  al  11  an 
e  al  13  n is sense  M  o eins a e onside ed o en al e a eu  a ge s in  ei e  
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DISCUSSION
1  en e  i s in ibi on an s o i 1 8a and i 1  u egula on ould el  o su ess 
an e  develo en  ese ndings sugges  a  i 1 8a as ell as i 1  u egula ed in 9 
ells a e  e osu e o o ound  a  un on as o en al u o  su esso s oug  dive se 
e anis s
l oge e  is i  e ession o le gene a ed a e  a b a ine analogue 2 ea en  ig  
be ela ed i  e o o i  e e  obse ved in 9 ell line  n an  ase  ese a e eli ina  
esul s edi ed b  e obse ved i  odi a ons a e  o ound ea en  o o obo a e e 
i li a on o  ese genes in e o o i  e e  indu ed b  o ound 2  e ould ave o valida e 
ea  o  ese o en al a ge  genes in u e  e e i en s
5. Therapeutic effect of synthetic tambjamine analogues in LC in vivo mouse models
ung an e  is e leading ause o  an e ela ed dea  o ld ide  o ding o s a s al da a  i  
is onside ed a  i  as oo  ognosis  ve  al  o  eo le diagnosed i  lung an e  die i in one 
ea  and  e  ea   su vival  is  less  an  18  a a and Mousa  1  ung an e  ea en  is 
di ul  due o i s ig  o le i  n e as  de ades  e e ave been seve al on ibu ons o e 
i oved anage en  o  lung an e  n one and  e e o e a  egi ens ave been o i ed  
and ne  e a eu  agen s  agains  e sa e o  di e en  e anis s  ave been develo ed ao 
and an  11  n is sense  e os  e uen  u en  s anda d e o e a eu  egi ens 
a e based on is la n o bined i  ge i abine  vino elbine  o  e o oside i s  et al.  1  
l oug  la nu based e o e a  egi ens ave oved o be ini all  e e ve  signi an  
ela se a es a e s ll obse ved due o d ug esis an e a ea an e able  1  n e o e  and  
e e e gen e o  a ge ed e a ies  as a esul  o  be e  unde s anding o  an e  biolog  as been a 
signi an  advan age o e ove all ou o e o  is disease ao and an  11  nevi abl  a en s 
ave develo ed esis an e be ause o  e e e gen e o  an insensi ve ellula  u o  sub o ula on  
sele ed b  a a ologi  essu e a ine  et al.  1  eel and ivona  1  n is sense  
e e is g o ing eviden e su o ng a  s o  a e o esis an  sub o ula on a  ossess e 
abili  o egene a e e e e ogeneous u o  ass Ma onag  et al.  1  us  e develo en  
o  ne  o o i  agen s a  a e also a ge ed o e  e ains an i o an  a ea o  lini al esea  
in lung an e  
e o e s a ng an an e  d ug ials  a a eu al o anies and inde enden  esea e s 
ondu  e ensive e lini al s udies  ni al odels ave been essen al in an e  esea  o 
e a ine eli ina  e a  o i i  and a a o ine s  o da e  a va ie  o  ouse odels 
a  i i  u an lung an e  ave been develo ed  enog a  odels e ui e e ans lan a on 
o  i a  u an an e  ssue ag en s o  ells in o lungs o  i uno o o ised i e  ei e  
sub u aneousl  o  o o o i all  ella  gan and Mo is  1  o o i  odel  o a ed o e 
sub u aneous one  s o s advan ages sin e i  ovides e o e  i oenvi on en  o  ans lan ed 
ells and e e s losel  lung an e  lini al a olog  ella  gan and Mo is  1  
n eli ina  s udies  e e a eu  a a i  o  ou  o ounds 2 and 7 as es ed in bo  an 
e o i  and an o o o i  ouse odel  n i e bea ing 9 ells sub u aneousl  in e ed  bo  
o ounds signi an l  edu ed u o  si e as CDDP did  e s line ea en  u isingl  no 
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be e  ou o e as obse ved i  si ul aneous ea en  CDDP lus a b a ine analogues 2 o  7  
n e o o o i  i e odel  a de ease in u o  g o  as obse ved  es e iall  i  o ound 7  
iven a  ou  ndings a e based on a li i ed nu be  o  ani als  e esul s o  ese anal ses s ould 
onse uen l  be in e e ed i  a e  eve eless  bo  o ounds o obo a e ei  o o i  e e  
obse ved in vitro  and ave o ising e a eu  e e  agains  lung an e  i e ise  ese o ounds 
ave been s o n o edu e viabili  in s de ived o  a en  u o s and o  ell lines  is an be 
onside ed an advan age o  ou  o ounds  sin e e e veness o  s anda d e a  is li i ed due o 
o e es o   o ula on  su  as d ug esis an e and sel ene al  agu et al.  1  adi a ng 
s i  s n e  a b a ine analogues a  edu e e o u en e o  d ug esis an e and e 
in iden e o  u o  ela se  us a ieving be e  esul s i  onven onal ea en s
n addi on  a b a ine analogues ould be a onvenien  al e na ve e a eu  s a eg  o 
ove o e e esis an e o oa o o  e o e a eu  agen s  i  a e os  o  e onven onal 
e o e a eu  agen s available a  e o en  i e en  a oa es a  a e able o indu e ne o  
ell dea  ave been e o ed  o  e a le  o od na i  ea en   involves e gene a on 
o   b  a o osensi ing ole ule eviousl  a u ula ed in e u o  oug  e i adia on o  
neo las  a ea i  a s e i  aveleng  obe son  vans and b a a se  9  odu ed  
a va e ne osis and ne o osis e anis s a ong o e  signaling a a s o iano et al.  1
i  a u ula es e e en all  in u o  ells  ubse uen  i adia on o  e neo las  a ea igge s 
a as ade o  o o e i al ea ons a  leads o e o a on o  ig l  ea ve o gen s e ies 
es onsible o  ell ina va on  o od na i  ea en s in vi o a e e o ed i  e  in
alo anine n  being able o indu e ell dea  even in b eas  an e  enog a  la ing as ase 3 
W i a e et al.   i e ise  in li e a u e as also been des ibed o  o e  e i al agen s 
o o e ne osis o  egula ed ne osis a  an be used as an al e na ve a  o e adi a e a o osis
esis an  an e  ells  is is e ase o  ono iol  s i onin o  e s all ole ule ba o la  i et al.  
uan and u  9 asi  is o anon and ulda  13  
l oug  a ge ng ne o osis and o e  es o  og a ed ne osis as been o osed as 
an an u o  ea en  s a eg  ne o  and ne o o  an e  ells elease da age asso ia ed 
ole ula  a e ns M s  a  a  a  as indu e s o  in a a on  n one and  M s a  
ave a o e ve un on b  ale ng e i une s s e  o  e esen e o  d ing u o  ells and 
igge ing e i unogeni  u o  ell dea  e nande  uebene  and abe  1  n e o e  
and  i  as been des ibed a  ell dea  lin ed o e elease o  M s a  also igge  oni  
in a a on and e eb  o o e e develo en  and og ession o  u o s Man ovani et al.  
8   is e e o e ne essa  o e lo e and la i  ese on e ns o a ili a e e develo en  
and ad inis a on o  ese e a eu s i  a ne  e anis  o  a on  a en oge e  s n e  
a b a ine analogues a  be an a a ve an u o  ea en  s a eg  in ose ases a  do no  
es ond o onven onal e o e a  and es e iall  o  a o o  esis an  a en s  
Alto et er  t ese synt e c tam amine analo ues ave een c aracterized as potent anion 
transporters and  may e promisin  an tumor molecules. T ese compounds tri er massive 
mitoc ondrial s ellin  and lysosomal alkaliza on  ic  in turn leads to autop a y lockade. T ese 
p enomena cause cell stress t at leads to t e ac va on o  cell deat  mec anisms  suc  as apoptosis 
and necrosis  ein  t e la er t e main responsi le or t e induced cytotoxicity. In addi on  at t e 
molecular level t ese compounds tar et AKT pat ay  requently altered in uman cancers. 
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DISCUSSION
Fi ure 63  Model or t e mec anism o  ac on o  selected synt e c tam amine analo ues on LC in vitro model. is gu e as 






1  n e  a b a ine analogues a e o en  anion ans o e  o ounds i  a o en  
o o i  e e  in o al and lung an e  ell lines  ele ed analogues o ounds 2 and 7  also 
odu e o i i  in lung an e  s e  ells de ived o  a en  u o s  
 ele ed s n e  a b a ine analogues ause assive s elling o  i o ond ia and l soso al 
dea idi a on  ese eno ena gene a e e d s un on o  bo  o ganelles  Mi o ond ia 
lose ei  e b ane o en al and onse uen l  a ellula  de le on o    e sa e e  
l soso al d s un on leads o a blo ade o  au o ag  
3  ellula  s ess gene a ed b  s n e  a b a ine analogues indu es an in ease in e a vi  
o  e s ess senso  o ein 38 M
 ele ed s n e  a b a ine analogues indu e e a va on o  a o osis along i  e 
au o ag  o ess  al oug  ells end u  olla sing in o a ne o  ell dea  as e ain dea  
e anis  es onsible o  e o o i i  o  e o ounds  
  as been iden ed as a o en al ole ula  a ge  o  e s n e  a b a ine analogue 
2  and i  indu es a de ease in o ein a vi  and in e o al a oun  o   o ein
 ele ed s n e  a b a ine analogues  2 and 7  oved o be e e ve e a eu  
o ounds s o ing a signi an  de ease in u o  g o  in a sub u aneous i e odel as 











Mature miRNA ID or Gene Sym ol miScript Primer Assay Catalo  
1 M M 81 sa le a 3 M 8
M M sa le a M 31
3 M M 8 sa le b 3 M 8 81
M M 3 sa le b M 31
M M sa le M 31 9
M M sa le d M 313
M M 8 sa le e 3 M 831
8 M M sa le e M 31
9 M M sa le M 89
1 M M 1 sa le g M 833
11 M M 8 sa le i 3 M 83 1
1 M M 1 sa le i M 31
13 M M 1 sa i 1 3 M 83 8
1 M M 1 sa i 1 3 M 83
1 M M 98 sa i 1 M 31 3
1 M M 99 sa i 1 1 3 M 83
1 M M 1 1 sa i 1 3a 3 M 31 1
18 M M 1 sa i 1 M 31 8
19 M M 1 sa i 1 a 3 M 8393
M M sa i 1 b 3 M 8
1 M M 8 sa i 1 b M 3
M M 1 sa i 1 M 31
3 M M sa i 1 a 3 M 8
M M 3 sa i 1 a M 31
1 M M sa i 1 b M 31 9
M M 8 8 sa i 1 M 1 1 1
3 M M 8 sa i 1 3 M 1 18
M M 1 sa i 1 M 3 1
M M 83 sa i 1 8 3 M 38
M M 8 sa i 1 8 M 1 38
M M sa i 1 3 M
8 M M sa i 1 a 3 M 8
9 M M 3 sa i 1 a M 3 3
1 M M 9 sa i 1 b 1 3 M 8 1
11 M M 3 sa i 1 b M 9
1 M M sa i 1 3 M 3 3
13 M M sa i 1 M 3
1 M M sa i 1 3 M 3 3
1
1 M M 9 9 sa i 1 M 3 8
1 M M sa i 1 M 8
1 M M sa i 1 8 3 M 8 8
18 M M 8 sa i 1 8 3 M 313
19 M M 8 8 sa i 1 8 M 1 9
M M sa i 1 9 M 3
1 M M sa i 13 a 3 M 3
M M 93 sa i 13 a M 8 3
3 M M 91 sa i 13 b 3 M 3 1
M M sa i 13 3 M 3 8
1 M M 9 sa i 13 M 31 9
M M sa i 133a 3 M 31 3
3 M M sa i 133b M 31 3
M M sa i 13 M 31 3
M M 9 sa i 13 a 3 M 9
M M 8 sa i 13 a M 8
M M 98 sa i 13 b 3 M 31
8 M M 8 sa i 13 b M 3
9 M M 8 sa i 13 M 3 9
1 M M 9 sa i 13 M 3 8
11 M M 3 sa i 138 M
1 M M sa i 139 3 M 8
13 M M sa i 139 M 3 93
1 M M 9 sa i 1 3 M 8 3
1 M M 31 sa i 1 M 3
1 M M 3 sa i 1 1 3 M 3
1 M M 98 sa i 1 1 M 8 8
18 M M 3 sa i 1 3 M 31 1
19 M M 33 sa i 1 M 1
M M 3 sa i 1 3 3 M 3 1
1 M M 3 sa i 1 3 M 3 8
M M sa i 1 M 8 1
3 M M 1 sa i 1 3 M 8 8
M M 3 sa i 1 M 3 8
1 M M 8 sa i 1 a 3 M 8 1
M M 9 sa i 1 a M 3 3
3 M M sa i 1 b 3 M 8
M M 8 9 sa i 1 b M 3
M M 1 sa i 1 a M 3 9
M M 3 sa i 1 8a 3 M 3
M M 9 sa i 1 8a M 8 3
8 M M 9 sa i 1 8b 3 M 31 8
9 M M 99 sa i 1 8b M 8 3
1 M M 9 sa i 1 9 3 M 3
11 M M sa i 1 9 M 3
1 1
SUPPLEMENTARY INFORMATION
1 M M 1 sa i 1 M 3
13 M M sa i 1 1a 3 M
1 M M 38 sa i 1 3 M 3 91
1 M M 39 sa i 1 3 3 M 8 1
1 M M 3 sa i 1 3 M 31 9
1 M M sa i 1 M 3 98
18 M M 8 sa i 1 3 M 8 8
19 M M sa i 1 M 31 8
M M 8 sa i 1 a M 31 8
1 M M 8 sa i 1 b 3 M 8 99
M M 1 sa i 1 b M 8 9
3 M M 9 sa i 1 M 31 93
M M 1 sa i 1 3 M
1 M M sa i 1 M 9
M M sa i 181a 3 M 9
3 M M sa i 181a M 88
M M 9 sa i 181b 3 M
M M sa i 181b M 99
M M 8 sa i 181 M 88 1
M M 8 1 sa i 181d M 31
8 M M sa i 18 3 M 88
9 M M 9 sa i 18 M 88
1 M M sa i 183 3 M 88 9
E11 M M 1 sa i 183 M 31
E1 M M sa i 18 M 3
E13 M M 11 sa i 18 3 M 88
E1 M M sa i 18 M 3
E1 M M sa i 18 M 3
E1 M M sa i 18 3 M 3 1
E1 M M 891 sa i 18a 3 M 38
E18 M M sa i 18a M 31 1
E19 M M 1 1 sa i 18b M 31 1
E M M 8 sa i 19 a M 8911
E 1 M M 1 18 sa i 191 3 M 31 8
E M M sa i 191 M 3 8
E 3 M M 3 sa i 19 3 M 89
E M M sa i 19 M 3 89
1 M M 9 sa i 193a 3 M 31
M M 1 sa i 193a M 893
3 M M 819 sa i 193b 3 M 31 9
M M sa i 193b M 8939
M M 1 sa i 19 3 M 31
M M sa i 19 M
M M 1 sa i 19 3 M 89 3
8 M M 1 sa i 19 M 3 3
1
9 M M sa i 19 a 3 M 89
1 M M sa i 19 a M 31 3
11 M M 1 8 sa i 19 b M 31
1 M M sa i 19 3 M 89
13 M M 8 sa i 198 M 338
1 M M 3 sa i 199a 3 M
1 M M 31 sa i 199a M 1
1 M M 3 sa i 199b M 3 31
1 M M 3 sa i 19a 3 M 319
18 M M 9 sa i 19a M 8988
19 M M sa i 19b 3 M 31 8
M M 8 sa i a 3 M 3 38
1 M M 1 sa i a M 9 9
M M 318 sa i b 3 M 9 1
3 M M 1 sa i b M 9 3
M M 1 sa i 3 M 3
1 M M sa i M 9 3
M M 811 sa i 3 M 9 3
3 M M sa i 3a 3 M 3
M M 93 sa i 3 M 3 8 1
M M sa i M 3 3
M M 919 sa i 3 M 1 93
M M sa i M 3 8
8 M M sa i M 3 8
9 M M 93 sa i a 3 M 9
1 M M sa i a M 3199
11 M M sa i b 3 M 9
1 M M 1 13 sa i b M 3
13 M M sa i 1 3 M 38 1
1 M M 9 sa i 11 3 M 1
1 M M 8 sa i 11 M 38 8
1 M M 9 sa i 1 3 M 381
1 M M 9 sa i 1 3 M 9 8
18 M M 1 sa i 1 3 M 31
19 M M sa i 1 M 38 9
M M sa i 1 M 9 9
1 M M 3 sa i 1 a M 91
M M 9 9 sa i 1 b M 91
3 M M sa i 1 M 38 3
M M sa i 18 M 9
1 M M sa i 19a M
M M 8 sa i 1 3 M 38
3 M M 9 sa i 3 M 9
M M 9 sa i M 91
M M 8 sa i 3 3 M 38 1
1 3
SUPPLEMENTARY INFORMATION
M M sa i 3 M 918
M M sa i 3 M 3
8 M M 9198 sa i 3 M 31
9 M M 81 sa i M 38 8
1 M M 9 sa i M 91
11 M M 8 sa i 3a 3 M 31 33
1 M M 9 sa i 3a M 31
13 M M 18 sa i 3b 3 M 31
1 M M 8 sa i 3b M 31
1 M M 8 sa i 3 M
1 M M 81 sa i 3 M 3
1 M M 98 sa i M 9 1
18 M M 8 sa i a M 9 39
19 M M sa i b 3 M 9 33
M M 83 sa i b M 3 3
1 M M 8 sa i a 3 M 3 1
M M 1 sa i a M 9
3 M M 19 sa i b 3 M 31 8
M M 88 sa i b M 9
1 M M 8 sa i 8 M 3
M M 9 sa i 9 M 1 1
3 M M sa i 9 M 31
M M 9 1 sa i 98 M 9
M M 8 sa i 9a 3 M 3
M M 3 sa i 9a M 9 8
M M 1 sa i 9b 3 M
8 M M 81 sa i 9 3 M 3 9
9 M M 3 sa i 9 M 93 3
1 M M 88 sa i 3 1a 3 M 931
11 M M 8 sa i 3 a 3 M 9331
1 M M 1 sa i 3 b 3 M 39
13 M M 1 sa i 3 b M
1 M M 1 sa i 3 3 M 3913
1 M M 18 sa i 3 d 3 M 39
1 M M 88 sa i 3 a 3 M 93
1 M M 8 sa i 3 a M 3
18 M M 89 sa i 3 b 3 M 93 9
19 M M sa i 3 b M 3
M M sa i 3 M 93
1 M M 1 sa i 3 d 3 M 939
M M sa i 3 d M 938
3 M M 93 sa i 3 e 3 M 9 8
M M 9 sa i 3 e M 9 1
1 M M 89 sa i 31 M 3 9
M M 1 sa i 3 a M 1
1
3 M M sa i 3 3a 3 M 3 19
M M 9 sa i 3 3a M 31 1
M M sa i 3 3 M 1 3
M M 1 sa i 3 M 8
M M 1 sa i 3 M 39 1
8 M M 9 sa i 3 M 3 9
9 M M sa i 3 M 39 8
1 M M sa i 3 8 3 M 81
J11 M M 1 sa i 33 3 M 31 38
J1 M M sa i 331 3 M 39 9
J13 M M sa i 331 M 31
J1 M M 3 sa i 33 3 M 9
J1 M M sa i 33 M 39
J1 M M sa i 33 3 M 1
J1 M M 3 sa i 338 3 M 399
J18 M M sa i 339 M 399
J19 M M sa i 33a 3 M 9 9
J M M 91 sa i 33a M 33
J 1 M M 33 1 sa i 33b M 819
J M M sa i 3 3 M
J 3 M M 9 sa i 3 M 31 9
J M M 3 sa i 3 3 M 11
1 M M 98 sa i 3 3 M 18
M M sa i 3 M 31
3 M M 3 sa i 3 M 31 3
M M sa i 3 a 3 M 9 3
M M sa i 3 a M 3318
M M sa i 3 b 3 M 819
M M sa i 3 3 M 9 8
8 M M 8 sa i 3 M 333
9 M M 3 sa i 3 1 M 3
1 M M sa i 3 3 3 M 9
11 M M 1 sa i 3 a 3 M 318 1
1 M M 19 sa i 3 3 M 9 83
13 M M sa i 3 3 M 3
1 M M 3 sa i 3 1a 3 M
1 M M sa i 3 3 M
1 M M sa i 3 3 3 M 3181
1 M M 88 sa i 3 a 3 M 9 11
18 M M sa i 3 a M 9
19 M M 8 sa i 3 M 318 9
M M 9 sa i 3 a 3 M 39
1 M M 1 sa i 3 b 3 M 399
M M sa i 3 3 M
3 M M 3 sa i 3 3 M 9
1
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M M 3 sa i 3 8a 3 M 9 9
1 M M 9 sa i 3 9 3 M 9
M M 33 sa i 3 9 M 9 3
3 M M 3 sa i 381 3 M 11
M M 3 sa i 38 M 3183
M M 38 sa i 383 M 13
M M 1 39 sa i 9 3 M 89
M M 1 38 sa i 9 M 9
8 M M 1 1 sa i 1 3 M 1
9 M M 3339 sa i 1 M 1
1 M M 1339 sa i a M 1
11 M M 13 sa i 3 3 M 1 9
1 M M 8 sa i 3 M 9 81
13 M M 13 1 sa i M 18
1 M M 3393 sa i M 9 9
1 M M 1 3 sa i 9 M 193
1 M M 81 sa i 3 M 318
1 M M 1 sa i 33 3 M 1
18 M M 1 1 sa i 9a M 8
19 M M 33 sa i 9b M 3
M M 1 31 sa i 1a M
1 M M 1 3 sa i M 318 1
M M 8 sa i 3 M 9
3 M M 31 sa i M 318 8
M M 1 3 sa i 83 3 M 9 1
M 1 M M 1 sa i 83 M 9 8
M M M 1 sa i 8 M
M 3 M M 1 sa i 8 M 9
M M M sa i 8 3 M 3189
M M M 1 sa i 8 M 8
M M M 318 sa i 8 b 3 M 98
M M M 3 sa i 88 3 M 9
M 8 M M 8 sa i 89 3 M
M 9 M M 8 sa i 91 M 31899
M1 M M 81 sa i 9 M 333
M11 M M 31 1 sa i 93 3 M 9 9
M1 M M 813 sa i 93 M 98
M13 M M 81 sa i 9 3 M 33
M1 M M 81 sa i 9 3 M 3
M1 M M 8 sa i 9 3 M 319
M1 M M 8 sa i 9 M 3 1
M1 M M 8 sa i 98 M 3 8
M18 M M 8 sa i 99a M 3
M19 M M 3 sa i a M 3 1
M M M 8 sa i 3 M 33838
1
M 1 M M 8 sa i M 1
M M M 8 8 sa i 3 M 98
M 3 M M 1 sa i M 38 38
M M M 8 9 sa i M 3193
1 M M 88 sa i 8 3 M 98 3
M M 8 8 sa i 11 M 993
3 M M 8 3 sa i 1 3 M
M M 883 sa i 1 a 3 M 319 8
M M 8 sa i 1 a 3 M 9
M M 8 sa i 18b M
M M 8 8 sa i 18 3 M 3
8 M M 8 9 sa i 19a 3 M 338
9 M M 83 sa i 19 3 M 1 3
1 M M 8 3 sa i 19d 3 M 8
11 M M 8 9 sa i 19e 3 M 1 1
1 M M 8 3 sa i b M 338 9
13 M M 8 sa i 3 M 13
1 M M 8 sa i e M 3
1 M M 8 8 sa i g 3 M 319
1 M M 8 sa i 3 M
1 M M 3389 sa i 3 M 1 3
18 M M 33 sa i M 1
19 M M 3 1 sa i 3 M 1 1
M M 3 3 sa i 3 M 91
1 M M 3 9 sa i 8 M 3 198
M M 3 sa i 8 M 1 8
3 M M 3 sa i 88 M 88
M M 3 sa i 9 M 91
1 M M 3 sa i 9 M 1 3 9
M M 3 9 sa i 1 M 9
3 M M 3 3 sa i M 998
M M 3 sa i M 1
M M 3 sa i 8 M 19
M M 8 sa i 1 3 M 1 339
M M 3 91 sa i M 11
8 M M 3 9 sa i M 3389
9 M M 81 sa i 9 M 1 39
1 M M 3 99 sa i 3 M 1 3
11 M M 33 sa i 3 M 8
1 M M 33 sa i 3 M
13 M M 33 sa i M 313
1 M M 33 sa i 3 M 1 1
1 M M 9 sa i M 3 9
1 M M 33 sa i 1 M 39
1 M M 33 sa i 3a M 3
1
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18 M M 9 sa i 8 M 1 1
19 M M 9 sa i M 1 9
M M sa i M 3 11
1 M M 39 sa i M 181
M M 9 8 sa i 88 3 M 1 1
3 M M 9 sa i 88 M 1 8
M M 9 sa i 9 a 3 M 9
1 M M 3 18 sa i 9 b 3 M 3 1
M M 93 sa i 93 M 33
3 M M sa i 9 3 M 1
M M 9 sa i 9 3 M 1 9
M M 1 sa i 9 M 1
M M 1 sa i 9 3 M 1 913
M M 9 sa i 9 M 33
8 M M 9 sa i 98 M 33
9 M M 11 sa i 99a 3 M 1 9
1 M M 9 sa i 99a M 3 1 8
11 M M 8 sa i 99b 3 M 3 1
1 M M 89 sa i 99b M 3 1
13 M M 1 el i 39 3 M 19 89
1 M M 1 el i 39 3 M 19 89
1 1 M 33
1 8 M 33 1
1 M 33 19
18 9 M 33







Ima es o  altered miRNAs a er compound 2 treatment and t eir tar et enes:  
Fi ure S1. miR-103a-3p and its tar et enes in detail
Fi ure S2. miR-106 -3p and its tar et ene in detail
Fi ure S3. miR-1287-5p and its tar et enes in detail
   
Fi ure S4. miR-130-5p and its tar et enes in detail
1 9
SUPPLEMENTARY INFORMATION
Fi ure S5. miR-146a-3p and its tar et enes in detail
Fi ure S6. miR-148a-3p and its tar et enes in detail
Fi ure S7. miR-148a-5p and its tar et enes in detail
Fi ure S8. miR-18 -5p and its tar et enes in detail
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Fi ure S9. miR-205-5p and its tar et enes in detail
Fi ure S10. miR-212-3p and its tar et enes in detail
Fi ure S11. miR-21-3p and its tar et enes in detail
Fi ure S12. miR-224-3p and its tar et enes in detail
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SUPPLEMENTARY INFORMATION
Fi ure S13. miR-23 -5p and its tar et enes in detail
Fi ure S14. miR-30a-5p and its tar et enes in detail
Fi ure S15. miR-663a and its tar et enes in detail
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Fi ure S16. miR-7-5p and its tar et enes in detail
ANNEX I
In colla ora on it  t e roup o  Pro essor P illip Gale (University o  Sout ampton  UK)  e per orm 
a series o  in vitro studies it  anionop ore compounds  squaramides and t iosquaramides. T is 





e ans o  o  biologi all  elevan  ions a oss os oli id bila e s e b anes is a vi al 
o ess a  elies on annel o eins  l e a ons in ei  e ession o  a vi  a e ela ed o a ide 
ange o  a ologies  e ies o  s ua a ide and ios ua a ide de iva ves i  di e en  uo ina on 
deg ees  ave been s n esi ed  e in vitro a vi  o  ese anion ans o e s as been s udied  
e os  o o i  s ua a ides igge  a o osis in elano a ell lines i   values in e lo  
i o ola  ange as ell as odi  e in a ellula   indu ing e basi a on o  a idi  o ganelles  
is eli ina  s ud  ovides a basis o  unde s anding e e anis  o  a on o  ese o en al 
an an e  o ounds  
INTRODUCTION 
e ion ans o  in biologi al s s e s  a ula l  lo ide and bi a bona e  is ve  i o an  as 
i  on ols ul le o esses  e iono o es alled s ua a ides and ios ua a ides ave been 
develo ed given e g o ing de and o  anion a ie  ole ules a  ove o e e e e  o  de e ve 
ion annels in so e diseases  
n one and  s ua a ides ole ules a e o ed b  ou e be ed ing s s e s de ived o  
s ua i  a id   e design and in o o a on o  d ugs i  ese e i al en es in o edi inal e is  
og a s as been ui e s a e so a  es i e is  s ua a ide o ounds ave been inves ga ed o  
a ange o  a ge s and ave s o n o en al e a eu  e e s agains  a va ie  o  a ologies li e 
angas disease a asi  illness  l o et al.  1  o  oni  obs u ve ul ona  diso de  Ma n 
et al.  1  n addi on  so e ole ules on aining s ua a ides oie es ave been o o ed o e 
lini  o  ins an e o  e ea en  o  gas oduodenal ul e s an o e  i o and Jones  11   
n e o e  and  o ounds i  iou ea g ou s ad eviousl  s o n o o  as o en  
lo ide bi a bona e e ange agen s in li oso al odels uss ae  et al.  1  e e o e  
ios ua a ides ave been gene a ed o  e o bina on o  s ua a ides and iou eas uss ae  
et al.  1  Mo eove  so e ole ules a  belong o is ne  g ou  o  anion a ie s dis la  a 
s i able ans o  be avio  is eans a  unde  siologi al ondi ons ese o ounds ave 
lo  ans o  a a i  a oss li id bila e s  e eas a  lo e   be o e a ve ans o e s  is 
ea u e a  se ve as a o en al ool o a va e lo ide ans o  i in a idi  envi on en s  and o 
be able o a  avo abl  in dive se diseases li e an e  uss ae  et al.  1  
Fi ure A1. u u es o  a i od iou ea and s ua a ide
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n is eli ina  s ud  e de ided o e lo e e an oli e a ve a vi es o  ese anion 
ans o e  i  a se  o  in vitro e e i en s in di e en  an e  lines  i  ill se ve as a basis o  
unde s anding e e anis  o  a on
MATERIAL AND METHODS
Evaluated compounds
e se  o  s ua a ides and ios ua a ides i  di e en  uo ina on deg ees e e s n esi ed 
b   ili  ale and olleagues o  e e a en  o  e is  nive si  o  ou a on  
Fi ure A2. u u es o  ono  and bis s ua a ides 1 1  and ios ua a ides 13 1  es ed in is esis
Cell lines and culture condi ons 
u an lung adeno a ino a ell line 9  u an elano a ell line 3  and u an 
os a  a ino a ell line 3  e e u ased o  e e i an e ul u e olle on  and 
e e ul u ed in MEM   ul u e ediu  as su le en ed i  1   1  l eni illin  
1  g l s e o in  and  M glu a ine  ells e e g o n in a u idi ed a os e e o  ai  
on aining   a  3  
Cell via ility assay
ell viabili  as de e ined b  e M  assa  d e en  ell lines e e la ed in 9 ell i o e  
la es   be o e ea en  a  a on en a on o  1 1  in 1  μ  o  g o  ediu  e  ell  o  single 
dose e e i en s  ells e e in uba ed in e absen e o  in e esen e 1  μM o  e 1  s n e  
18
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s ua a ides  on ol ells e e in uba ed onl  i  d ug diluen  M   ange o  on en a ons 
o  99 o  μM o  e os  o o i  s ua a ides  2 and 9  o  a ange o  93 o 1  μM  in 
e ase o  s ua a ide 7  e e used o  dose es onse e e i en s  e   ou s in uba on  1 M 
o  M  3 di e l ia ol l di en l e a oliu  b o ide  dilu ed in 1   as added 
o ea  ell o  an addi onal  ou s  e ediu  as e oved and a 1  μ  o  M  as added 
o ea  ell in o de  o dissolve e M  o a an e i i a e  bso ban e as easu ed a   n  
on a Mul s an ul ell la e eade  ell viabili  as e essed as a e en age o  on ol and  
e esen s e on en a on o  d ug ausing  in ibi on o  e in ease in abso ban e o a ed 
i  on ol ells  a a a e s o n as e ean value ± S.D. o  ee inde enden  e e i en s  e  
values e e al ula ed i  a ad is   so a e
Vital uorescence microscopy  Acridine Oran e stainin
e living ul u ed ells e e s ained i  a idine o ange  3  ells   1 3 ells  g o n 
in a 1 ell la e i  ove  sli s o    and e e in uba ed i  o  i ou  e  s ua a ides 2  7 
and 9 a  ei   dose o  1  o  a  e  dose o  1  M  as used o  on ol ells  e a ds 
ells e e as ed i e i  1   and in uba ed i   μg   solu on o  3  in a   and 
o e ed o  lig  inall  ove  sli s e e as ed ee es i  1   su le en ed i  1  
 and en e a ined i  a  e li se E8  i os o e l e  33 38  n
Hoec st 33342 stainin  
3  ells e e seeded in a 1 ell la e i  1   ound s e ile ove sli s a  a on en a on 
o    1  ells    be o e e ea en  e a ds  ell edia as e oved and es  edia 
i  e o es onding d ug dose as added   3  ells e e in uba ed in e absen e on ol 
ells  o  in e esen e o  1  μM o  ios ua a ides 2  7 and 9 o  8  e  is e  edia as 
en i uged i e a   g as ing i  1   o olle  e oa ng ells  e eas e a a ed ells 
e e as ed 3 es i  1   
ells oa ng and a a ed  e e s ained i  e nu lea  oun e s ain oe s  333  a  a 
on en a on o   g  o  3  in a  3  in da  ondi ons  en  ells e e as ed i e i  1 
   e a ed ells e e en i uged i e a   g and as ed i  1     as dis a ded 
and ells e e esus ended in 1  μ  o  gl e ol  9 1   ells in gl e ol e e de osi ed in slides 
and e ells on e ove sli s e e la ed ove  e  Moun s e e e a ined uo o e i all  i  a 
i on eli se E8 i os o e i on  using e 33 38  n  l e
Assessment o  cell cycle arrest
3  ells e e s n oni ed ain ained in no al ul u e ondi on i  onl    o  a 
e iod o   be o e ini a e e e e i en  en ells ea ed i ou  and i  e s ua a ides 2 
and 9 a  e  dose o      and 8   ells e e olle ed and en ed in  e anol a   
ove nig  e a ds  ells e e as ed in 1   and ell elle  as en esus ended i   μl 
o  Muse  ell le eagen  o  3  in a   in da  ondi ons  luo es en e as easu ed b  o  
o e  on a alibu  ed i  a 88 n   lase  and da a e e anal ed using ell ues  o 
so a e e on i inson  an Jose   and Mod i   ell le anal sis so a e e i  so a e  
o s a  ME
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RESULTS
Compounds cytotoxic e ect on cancer cell lines
ua ides ad been lassi ed in evious a e s as good anion ans o e s  o de e ine e 
e e s o  e u bing ion o eos asis on o ganelles and ells  e a ied ou  ell viabili  s udies in ee 
di e en  an e  ell lines  e in vitro o o i  a vi  o  s ua a ides 1 o 1  and ios ua a ides 
13 1  as es ed on a olle on o  di e en  an e  ell lines o  dive se o igin  u an lung 
adeno a ino a ell line 9  u an elano a ell line 3  and u an os a  a ino a ell 
line 3  i s  o  all  e used a single oin  s eening assa  i  all e above en oned o ounds 
a  1  μM gu e 3  oug  e olo i e i  es  o  M  e levels o  o a an sal s odu ed e e 
easu ed and uan ed in o de  o evalua e ell viabili  ua a ides 2 and 9 e e a ula l  
o o i  in 3  ell line being e os  sensi ve one  ile no signi an  e e  as obse ved a e  
ea en  i  e o e  s ua a ides o  ios ua a ides a  e sa e dose and e
Fi ure A3. Cell via ility measured y MTT assay a er 24  o  squaramide compounds treatment  ingle oin  s eening 
o  o ounds 1 1  1  μM  on a olle on o  di e en  an e  ell lines  o  ig  o le  3  9 and 3
ose es onse e e i en s e e e o ed and  values e e al ula ed o  o o i  
o ounds s ua a ides 2 and 9  as ell as o  e non o o i  one  s ua a ide 7  ese 
e e i en s e e a ied ou  in 3  9 and 3 ell lines o    e ob ained esul s 
o obo a e o  s ua a ide 2 is e os  o en  o ound  s o ing  values belo  1  μM 
in e ee ell lines s udied  o ound 9 s o ed values lose o 1  μM  being 3  e os  
sensi ve ell line o is o ound  n e ase o  o ound 7  i  ig e   values  e os  




ua a ide ua a ide 7 ua a ide 9
3 ±1 89 IC25 1 ±3 1 IC25 3±1 1
8 8 ± 3 IC50 1 ± 38 IC50 8 3±1 19
9 9± IC75 1 1 ±1 1 IC75 9 9±1 1
A549
ua a ide ua a ide 7 ua a ide 9
1 9± 3 IC25 1 13±1 3 IC25 8 ±
± 8 IC50 9 13± 11 IC50 11 13±
8 9 ± IC75 3 99± IC75 13 9± 13
PC3
ua a ide ua a ide 7 ua a ide 9
1 ± IC25 8 ± 1 IC25 1 13±
3 3± IC50 1 9± 88 IC50 1 9 ±1 1
19 ± 1 IC75 ±1 IC75 18 11±
Ta le A1.   values μM  o  s ua a ides 2  7 and 9 on 3  9 and 3 an e  ell lines
Dysre ula on o  lysosomal pH
in e ese o ounds s o ed anion ans o  a vi  in e li oso e assa s oug  l 3 
 an o  o  + l  s o  uss ae  et al.  1  1  e soug  o de e ine e e  e  
ould s o  ans o  a vi  inside ells  on ibu ng o ei  o o i i  e in vitro iono o i  
a vi  o  e o o i  o ounds as s udied in 3  elano a ell line  using vi al s aining i  
a idine o ange  is ell e eable d e  as a ea  base  a u ula es in a idi  o a en s  
su  as l soso es  e e i  is o ona ed and s o s o ange uo es en e e ission  e eas i  e i s 
g een uo es en e a  ig e   llison and oung  19 9   W en 3  ells e e s ained i   
g anula  o ange uo es en e as obse ved in e o las  igu e  a b  sugges ng a  e 
o ange uo es en e is due o a idi  o ganelles  su  as l soso es and endoso es  ells ea ed i  
non o o i  s ua a ide 7 s o ed no anges gu e  e  u isingl  ells ea ed i  e 
o o i  s ua a ides 2 and 9 also did no  s o  a signi an  disa ea an e o  o ange e ission en 
ad inis e ed a  ei   value gu e  g  bu  a  ig e  on en a ons  values  e o ange 
olou  did disa ea  gu e  d  ese esul s indi a e a  bo  o ounds e e a able o  
indu ing  dis a ge a oss e l soso al e b ane  
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Fi ure A4. Acridine Oran e stainin  o  melanoma A375 cells a er exposure to squaramides 2  7 and 9 at t e IC50 or 1  
or IC75 dose or 3  a  b  un ea ed ells   2 a   on en a on  d  2 a   on en a on  e  7 a   on en a on  
 7 a   on en a on  g  9 a   on en a on   9 a   on en a on  ells i  o las i  g anula  o ange 
uo es en e e e obse ved a  b  e and  ells i  disa ea an e o  o las i  o ange uo es en e e e de e ed in 
d and 
Cytotoxic squaramide compounds induce apopto c cell deat
s as been seen in evious se ons e o ounds a e o o i  e e o e  e an ed o 
anal e e ell dea  indu ed b  ese s ua a ides  o osis is a g l  egula ed o  o  ell 
dea  in i  ells a vel  a i a e in ei  o n des u on  is ell dea  an be igge ed b  
di e en  s ulus su  as sus ained anges in i e Mili o et al.    ell a  is unde going 
a o osis de ons a es  a ong o e  o ologi al a a e is s  nu lea  ondensa on and  
ag en a on  i  an be de e ed b  s aining i  oe s  333  and uo es en e i os o  
oug  is e ni ue e ied o e a ine all ese nu lea  al e a ons a e  e e osu e o e 
di e en  s ua a ides in 3  ells gu e  
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Fi ure A5. Hoec st 33342 stainin  o  A375 cells a er exposure it  squaramides 2  7 and 9 at 10 μM: a  un ea ed ells  
b  s ua a ide 7   s ua a ide 2 and d  s ua a ide 9  ells i  no al nu lea  o olog  e e obse ved in gu e 
a and b  ells i  nu lea  ondensa on and a o o  bodies e e s o ed in gu e   and d
n gu e  un ea ed 3  ells ave i al ounded nu lei igu e a  ollo ing ea en  
i  e s ua a ides 2 and 9 1  μM o  8 ou s  e ells s o ed nu lea  ondensa on gu e  
and d  and e o a on o  a o o  bodies as obse ved  on ing a  ese o ounds indu e 
a o o  ell dea  o eve  i  e non o o i  s ua a ide 7 e a ea an e o  e nu leus 
as no al gu e b
Cell cycle p ases distri u on a er treatment
n ase e d o  in viabili  obse ved in evious e e i en s as aused b  ell le a es  
e u e  anal ed e s ua a ides 2 and 9 e e s on ell le dis ibu on  ul u ed 3  ells 
e e ea ed a  di e en  es i  e os  o en  o ounds and anal ed b  o  o e  
gu e   slig  odi a on in e o o on o  ells in 1 and  ases as de e ed i  bo  
s ua a ides a   and 8   o eve  e os  signi an  anges e e obse ved in e e en age 
o  a o o  o ula on i  an in ease o  1 8  and 1 8  a  8  o  ea en  i  s ua a ides 
2 and 9 es e vel  ese esul s indi a e a  e o ounds a e essen all  o o i  sin e e  
do no  ause ell le a es  onse uen l  a ing in o a oun  e evious esul s  e obse ved 
de ease in viabili  ould be aused ainl  b  a o o  ell dea  
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Fi ure A6.  lo  o e  anal sis o  e  o  3  ells i ou  ea en  on ol  o  a e      and 8  s ua a ides 
2 and 9 ea en  a  e  dose  u be s e esen  e e en age o  ells in ea  ell le ase  iole  olo  
e en age o  ells in 1 ase  s i ed ba s e en age in M ase  ed olo  e en age o  ells in  ase and blue 
olo  e en age o  a o o  ells  a a s o n a e e esen a ve o  ee inde enden  e e i en s i  si ila  esul s 




e ans o  o  anion lo ide a oss ell e b anes egula es ul le biologi al o esses 
su  as in a ellula   e b ane o en al and ellula  volu e a  a e essen al in ul le 
siologi al o esses su  as ell ig a on  oli e a on and di e en a on ale  e o s and 
uesada  13 abela e  al  9  is i o an  o ess is no all  egula ed b  ans e b ane 
ion annels  Mal un on o  an  o  ese annels esul s in e develo en  o  diseases no n as 
annelo a ies  as in e ase o  s  b osis s o   e e o e  in e es  in develo ing 
aniono o es a  an es o e lo ide e eabili  as e en l  in eased i e  al  1  n addi on  
in e las  de ades  ion annels and ans o e s ave e e ged as d ive s o  e an e  og ession 
sin e an e  ells su e  a e aboli  s i  asso ia ed i  in eased a id odu on and u egula on 
o  a id e uding ans o e s in las a e b ane  e i and u u an  11  is al e ed ans o  
esul s in al ali a on o  i in an e  ells o a ing o no al ones  n is sense  i  as been s o n 
o  aniono o es a  a e able o odi   and ioni  g adien s be een in a ellula  o a en s 
ause o o i i  in an e  ells  a o ding e ossibili  o  using ese ole ules as an an e  
agen s o o e a o e  al  1  
u  se  o  s ua a ides and ios ua a ides ave been iden ed as o en  anion ans o e s 
in li oso al odel b  a alie uss ae  and olleagues uss ae  e  al  1  1  is u bing 
ion o eos asis on o ganelles and ells an igge  ell dea  u  an onie o and oi  1  o e  
al  1  n is ega d  o ound  and 9 de eased ell viabili  es e iall  in u an elano a 
ell line  e eas e es  o  o ounds e ibi ed edu ed o i i  us  e os  o en  ones  
esen ng  values belo  1  μM in all es ed ell lines  ig  ave a o en al un on as an an e  
o ounds  as ell as odigiosin o  s n e  a b a ine analogues  anion ans o e s a  ave 
s o n in vi o an an e  a vi  Jona an  essle  e  al   o o e a o e  al  1  and ose 
a  ba el  a e  ell viabili  ig  be sui able andida es as o en al d ugs o  e ea en  o  
annelo a ies i e  al  1
n e o e  and  e ea en  o  e 3  ell line i  e os  o o i  s ua a ides  2 and 
9  aused a loss o  e o ange un a e a a e is  o   i  is asso ia ed i  a idi  o ganelles 
su  as l soso es o  endoso es  soso es  essen al o ganelles o  deg ada on and ellula  
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a b s t r a c t
Current pharmacological treatments for lung cancer show very poor clinical outcomes, therefore, the
development of novel anticancer agents with innovative mechanisms of action is urgently needed.
Cancer cells have a reversed pH gradient compared to normal cells, which favours cancer progression
by promoting proliferation, metabolic adaptation and evasion of apoptosis. In this regard, the use of iono-
phores to modulate intracellular pH appears as a promising new therapeutic strategy. Indeed, there is a
growing body of evidence supporting ionophores as novel antitumour drugs. Despite this, little is known
about the implications of pH deregulation and homeostasis imbalance triggered by ionophores at the cel-
lular level. In this work, we deeply analyse for the first time the anticancer effects of tambjamine ana-
logues, a group of highly effective anion selective ionophores, at the cellular and molecular levels.
First, their effects on cell viability were determined in several lung cancer cell lines and patient-
derived cancer stem cells, demonstrating their potent cytotoxic effects. Then, we have characterized
the induced lysosomal deacidification, as well as, the massive cytoplasmic vacuolization observed after
treatment with these compounds, which is consistent with mitochondrial swelling. Finally, the activation
of several proteins involved in stress response, autophagy and apoptosis was also detected, although they
were not significantly responsible for the cell death induced.
Altogether, these evidences suggest that tambjamine analogues provoke an imbalance in cellular ion
homeostasis that triggers mitochondrial dysfunction and lysosomal deacidification leading to a potent
cytotoxic effect through necrosis in lung cancer cell lines and cancer stem cells.
 2016 Elsevier Inc. All rights reserved.
1. Introduction
Correct ion exchange through cellular membranes is an essen-
tial process for maintaining osmotic balance and intracellular pH
(pHi) [1], which are key parameters controlling many biological
processes. In fact, variations in cellular concentrations of certain
ions coordinate the signals that converge on cell cycle checkpoints
[2], regulating the proliferative capacity of cells and their differen-
tiation. Similarly, the triggering of the apoptotic programmed cell
death also depends on ion fluxes mediated by cellular ion channels
[3]. Therefore, when cellular pH is not preserved at a favourable
level, different pathologies may appear, as it is the case of cancer.
Cancer cells undergo a pH deregulation during the process of car-
cinogenesis, resulting in the acidification of the extracellular pH
(pHe) and the alkalinisation of the pHi. This adaptive reversed
pH gradient is decisive for survival and propagation of tumours,
promotes metabolic adaptation, evasion of apoptosis and facili-
tates the metastatic dissemination of tumour cells. Consequently,
pH is recently being considered as another hallmark of cancer [4].
Among different cancers, lung cancer remains a major public
health problem since it is the leading cause of mortality related
to this disease, accounting for more than 1.5 million deaths in
2012 [5]. Early diagnosis and advances in first-line treatments
http://dx.doi.org/10.1016/j.bcp.2016.11.022
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are not entirely effective in reducing this high mortality since con-
ventional treatments have limited success. Therefore, the identifi-
cation of novel anticancer compounds focused on different
mechanisms of action is eagerly needed [6,7].
Based on the specific altered pH of cancer cells, modulation of
intracellular pH has recently been proposed as a new therapeutic
strategy against cancer. In this regard, a diverse group of aniono-
phores, lipid soluble compounds that facilitate the transport of
anions across cell membranes, have recently emerged as promising
anticancer compounds [8,9]. Indeed, prodigiosin, a tripyrrolic nat-
ural product with anticancer properties, represents one of the first
described anionophores [10–13]. It has been reported that its bio-
logical activity is partly due to its ability to deacidify acidic com-
partments within cells, which may cause a drop in pHi, and
therefore the onset of apoptosis in cancer cells [9,11,14]. Emulating
that characteristic, different anionophores have been designed and
evaluated [15]. We have focused our attention on the bioactive
marine alkaloids tambjamines, a class of natural anionophores that
has shown interesting cytotoxic effects [16,17]. We have recently
synthesized novel synthetic tambjamine analogues bearing aro-
matic substituents in the enamine moiety, as well as explored dif-
ferent substitution patterns on characteristic alkoxy group of the
central pyrrole ring. These compounds proved to be very efficient
anion exchangers in liposome models, promoting both chloride
and bicarbonate transport [18–20]. As a result of this anionophoric
activity, compounds bearing 4-alkoxy-2,20-bipyrrole moieties have
shown to possess interesting anticancer activities in a wide panel
of cancer cell lines [19]. Moreover, a different type of tambjamine
analogues, in which the characteristic 2,20-bipyrrole unit is
replaced by a 2-pyrrolylindole, have recently shown the ability to
hyperpolarize the cellular membrane as well as differentiate and
induce cell death in lung cancer stem cells [20], which are promis-
ing properties for their potential use in cancer therapy.
Despite the identification of this class of anion selective iono-
phores as novel potential anticancer drugs, very little is known
about the effects at the cellular level of the facilitated anion trans-
port and the implications of unbalanced homeostasis and pH
deregulation in the cytotoxicity exhibited by anionophores. In
the present work, we analyse in detail for the first time the cellular
and molecular mechanisms of action that lead to the cell death
triggered by these potent anionophores in several lung cancer cell
lines and cancer stem cells (CSC).
2. Materials and methods
2.1. Compounds synthesis
Tambjamine analogues (Fig. 1a) were synthesized as previously
reported [19]. Drugs were dissolved at 10 mM in DMSO and stored
at 20 C. Subsequent dilutions for biological assays were made in
culture medium.
2.2. Cell lines and culture conditions
Human lung cancer cell lines A549 (adenocarcinoma), DMS53
(small cell carcinoma), H460 (large cell carcinoma) and SW900
(squamous carcinoma) were obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA), and maintained in
DMEM (A549) or RPMI medium (Biological Industries, Beit Hae-
mek, Israel). All media were supplemented with 100 U/mL peni-
cillin, 100 lg/mL streptomycin, and 2 mM L-glutamine, all from
Biological Industries and 10% foetal bovine serum (FBS; Gibco,
Paisley, UK). Cancer stem cells were obtained from resected patient
tumour samples or isolated from cancer cell lines and character-
ized through evaluation of stem cell surface markers (CD166,
CD44, CD90, CD133 and EpCAM) by flow cytometry. Moreover,
tumorigenic properties of tumour spheres were assessed through
subcutaneous transplantation in NOD.CB17-Prkdcscid/NcrCrl mice
(Jackson Laboratories, Bar Harbor, ME, USA) and tumour growth
curves were monitored. For detailed procedures and results see
Supplementary information in Ref. [20]. CSC were cultured as a cell
suspension in RPMI medium supplemented with 50 lg/mL Epider-
mal Growth Factor, 20 lg/mL basic Fibroblast Growth Factor, 1
Insulin-Transferrin-Selenium, 0.4% BSA and 2% B27TM (Gibco). Cells
at passage 10–25 were grown at 37 C under a 5% CO2 atmosphere.
2.3. Cell viability assay
Cell viability was determined by the MTT assay [21]. Cells
(1  105 cells/mL) were seeded in 96-well microtiter plates and
incubated for 24 h to allow cells to attach. Afterwards, they were
treated for 24 h with 10 lM of each compound for single point
experiments and dose-response curves were performed ranging
from 0.78 to 100 lM to calculate the inhibitory concentrations
(IC) of 25%, 50% and 75% of cell population. The drug concentra-
tions corresponding toIC25, IC50, and IC75 values were used in sub-
sequent experiments. Cisplatin and DMSO were used as positive
and negative controls, respectively. In the case of positive control,
concentrations ranging from 1.56 to 200 lM were tested. For inhi-
bition assays, the apoptotic inhibitor Z-VAD-FMK (10 lM) (BD Bio-
sciences, San Jose, CA, USA) or the autophagic inhibitor 3-
Methyladenine (3-MA) (5 mM) from Sigma-Aldrich (St Louis, MO,
USA) was added 30 min prior to compound 2 addition. After
24 h, 10 lM of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo
lium bromide diluted in 1 PBS (MTT, Sigma-Aldrich) was added
to each well for an additional 4 h. The medium was removed and
the MTT formazan precipitate was dissolved in 100 lL of DMSO.
Absorbance was read on a Multiskan multiwell plate reader
(Thermo Fisher Scientific Inc., Waltham, MA, USA) at 570 nm. For
each condition, at least three independent experiments were per-
formed in triplicate. Cell viability was expressed as a percentage
of control cells, and data are shown as the mean value ± S.D. The
IC25, IC50 and IC75 values were calculated with GraphPad PrismTM
5 software (Graph Pad Software, San Diego, CA, USA).
For single-point cell viability assays in monolayer cells (passage
10–20) and sphere-forming cells (passage 1–2), they were plated at
the desired density (1–2  103 or 2–3.5  103, respectively) in
200 lL per well in 96-well plates. One day (24 h) after seeding,
compound 2 was added in three replicates at 10 lM for each cell
line or patient’s derived cultures. Patient samples acquisition pro-
tocol and informed consent were approved by the local ethics com-
mittee. Cell viability was measured after 24 h, using the CellTiter
96TM AQueous One Solution Cell Proliferation Assay (Promega,
Madison, WI, USA) and following the manufacturer’s instructions.
Absorbance at 490 nm was detected using a VICTOR3TM Multilabel
Plate Reader (Perkin Elmer-Cetus, Norwalk, CT, USA). Cell viability
was normalized to the respective control cells and presented as a
percentage of them. For each condition, three independent exper-
iments were performed and mean ± SD is shown.
2.4. Ion-selective electrode transport assays
A chloroform solution (20 mg/mL) of 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC) (Sigma-Aldrich) was evaporated
in vacuo using a rotary evaporator and the resulting lipid film was
dried under vacuum for at least 2 h. After that, it was rehydrated by
addition of a sodium chloride solution (489 mM NaCl and 5 mM
phosphate buffer, pH 7.2 or 451 mM NaCl and 20 mM phosphate
buffer, pH 7.2) followed by careful vortexing. The obtained lipid
suspension was subjected to nine freeze-thaw cycles and twenty-
nine extrusions through a 200 nm polycarbonate Nucleopore
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membrane using a LiposoFastBasic extruder (Avestin Inc., Ottawa,
Canada). In order to remove the unencapsulated chloride, the
obtained vesicles were dialyzed against a NaNO3 solution
(489 mM NaNO3 and 5 mM phosphate buffer, pH 7.2) or a Na2SO4
solution (150 mM Na2SO4 and 20 mM phosphate buffer, pH 7.2),
respectively. For the NO3- /Cl- assays, vesicles prepared as described
above (rehydrated with 489 mM NaCl), were suspended in a solu-
tion 489 mM NaNO3 and 5 mM phosphate buffer, pH 7.2 to a final
lipid concentration of 0.5 mM in a total volume of 5 mL. Using a
chloride selective electrode (CRISON 96 52 C I.S.E. electrode) the
chloride efflux was monitored over time. After 60 s, an aliquot of
the transmembrane anion carrier in DMSO was added (the amount
of DMSO was always less than 20 lL in order to avoid influence of
the solvent molecules in the assay). After five minutes (t = 360 s), a
pulse of detergent was added (TritonTM X-100 10% dispersion in
water, 20 lL), thus vesicles were lysed. The obtained final reading
was considered as the 100% of the chloride encapsulated and used
as such. For (HCO3- /Cl-) assays, the vesicles were rehydrated with
451 mM NaCl and suspended in the Na2SO4 solution. Again, the
final lipid concentration in each experiment was 0.5 mM and the
total volume in each experiment 5 mL. A volume of the carrier
molecule was added at the beginning of the experiment (t = 0 s).
A minute later (t = 60 s), an aliquot of NaHCO3 (in 150 mM Na2SO4
buffered to pH 7.2 with 20 mM sodium phosphate salts) was added
for a final concentration of 40 mM. The chloride efflux was mea-
sured during 5 min and then the detergent was added (t = 360 s).
The data were used as described previously.
2.5. Acridine orange staining
A549 cells (1  105 cells/well) grown in a 12-well plate with
cover slips for 24 h were treated with or without the IC50 value
of the studied compounds for 1 h (DMSO was added in control
cells). Afterwards, cells were washed twice with 1 PBS and
stained with 5 lg/mL acridine orange (AO) solution for 30 min at
room temperature. Finally, they were washed three times with
1 PBS/10% FBS and fluorescence was immediately examined in
a NIKON eclipse E800 microscope (filter 330/380 nm) (Nikon Eur-
ope BV, Badhoevedorp, The Netherlands). Three independent
experiments were conducted and representative images are
shown.
2.6. Phase contrast microscopy
For cytoplasmic vacuolization, A549 cells (1  105 cells/mL)
were seeded in a 6-well plate and allowed to grow for 24 h. Subse-
quently cells were treated with the IC75 values of each compound
during 6 h and images were observed under inverted phase con-
trast microscope (Axio Observer Z1, Gottingen, Germany). For cell
monitoring, A549 cells (1  105 cells/mL) were seeded in 96-well
microtiter plates and incubated for 24 h to allow cells to attach.
Afterwards, they were treated for 24 h with 10 lM of each com-
pound. Then, images were captured following a time course from
0 (before adding drug) to 24 h with a Leica inverted phase-
contrast microscope DMIRBE equipped with digital capture soft-
ware (Leica Microsystems, Wetzlar, Germany).
2.7. Immunofluorescence microscopy
A549 cells (2  105 cells/mL) were cultured in a 12-well plate
containing glass coverslips and were incubated with the IC75 of
the studied compounds for 6 h. Cells were then washed twice with
1 PBS and fixed with 4% paraformaldehyde for 20 min. Fixed cells
were permeabilized with 0.2% TritonTM X-100 and then blocked
with 1% BSA in 1 PBS for 1 h. Cells were incubated overnight at
4 C with anti-LC3 (1:500 dilution, Cat#PM036) from MBL Interna-
Fig. 1. Synthetic tambjamine analogues significantly decrease cell viability. (A) Chemical structure of synthetic tambjamine analogues. (B) MTT cell viability assay was
performed after 24 h of treatment with synthetic tambjamine analogues at 10 lM in A549, DMS53, H460 and SW900 cell lines. (C) Concentrations ranging from 0.8 to 100 lM
of compounds 2 and 7 were used in dose-response curve experiments for ICs value calculation in A549 cell line. At the same time, in case of positive control, concentrations
ranging from 1.6 to 200 lM of cisplatin (CDDP) were tested. (D) Cell viability was tested in adherent (Adh) and cancer stem cells (CSC) derived from lung cancer patients
(FIS302, FIS303) or cancer cell lines (A549, SW900) after 10 lM of compound 2 for 24 h. Results show the mean value ± SD of at least three independent experiments.
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tional Corporation (Woburn, MA, USA) or anti-TOMM20 (1:200
dilution, Cat#612278) from BD Biosciences. In case of using anti-
EEA1 (1:1000 dilution, Cat#ab2900) and anti-LAMP1 (1:1000 dilu-
tion, Cat#ab24170) both from Abcam (Cambridge, MA, USA) cells
were permeabilized with 0.2% Saponin, for 15 min, and then
blocked with 0.2% gelatin-20% normal goat serum in 1 PBS for
1 h at room temperature.
Cells were then washed with 1 PBS and incubated with Alexa
FluorTM 555-conjugated donkey anti-mouse (Cat#A31570, Molecu-
lar Probes, Eugene, OR, USA) or Alexa FluorTM 555-conjugated don-
key anti-rabbit (Cat#A31572, Molecular Probes) at 1:400 dilution
for 1 h at room temperature. At the same time, the nuclear marker
TO-PROTM-3 iodide (1:400, Cat#T3605, Molecular Probes) was
added. Afterwards, coverslips were washed with 1 PBS and were
placed on the slides using MowiolTM (Sigma-Aldrich). The
immunofluorescence images were captured using a Leica TCS-SL
filter-free spectral confocal microscope (Leica Microsystems). Rep-
resentative images from three independent experiments are
shown.
2.8. mCherry-Mito7 stable transfection in A549 cells
A549 cells (3  105 cells/mL) were seeded in 60 mm plates and
allowed to grow up to 80% confluence. Before transfection, growth
mediumwas replaced by Opti-MEMTM mediumwithout FBS (Gibco)
and 8 lg of plasmid DNA (mCherry-Mito-7 was a gift from Michael
Davidson (Addgene plasmid # 55102) [22] was transfected using
20 lL of lipofectamineTM reagent (Invitrogen, Carlsbad, CA, USA)
per condition. After 5 h of transfection, the medium was replaced
by complete medium. Stable selection was performed by adding
G418 (Calbiochem, La Jolla, CA, USA) to the medium at 800 lg/
mL final concentration 2 days after the transfection. After 3 weeks,
the brightest cell population was selected by cell sorting using a
Moflo Astrios XPD Cell Sorter (Beckman Coulter, Miami, FL, USA).
When a stable mCherry-Mito7 overexpressing A549 cell line was
established, cells were seeded in a l-Slide chambered coverslip
(Ibidi, Martinsried, Germany), and allowed them to attach and
grow during 72 h. Afterwards, cells were exposed to IC75 of the
studied compounds and a far-red nuclear counterstain, DRAQ5
(Abcam) was applied at a 1:5000 dilution. The images were cap-
tured every 20 min for 3 h using a Leica TCS-SL filter-free spectral
confocal microscope (Leica Microsystems). Representative images
from three independent experiments are shown.
2.9. Transmission electron microscopy
A549 cells (2  105 cells/mL) grown in 100 mm plates and were
incubated with the IC75 of the studied compounds for 6 h. Cells
were fixed in a solution containing 2% paraformaldehyde, 2.5% glu-
taraldehyde in 0.1 M phosphate buffer (pH 7.2) at room tempera-
ture for 1 h and then collected as cell pellets. Pellets were kept in
a post-fixed solution containing 1% osmium tetroxide, 0.8% potas-
sium ferrocyanide in 0.1 M phosphate buffer (pH 7.2) at 4 C. After
that, cells were dehydrated in graded acetone, embedded in Spurr’s
resin and cured at 60 C for 48 h. Semithin sections (1 lm) were
cut with a glass knife, mounted on slides, stained with 1% methy-
lene blue and viewed using a light microscope to select the region
of interest. Ultrathin sections (60–70 nm) were cut using a dia-
mond knife, mounted on 200 mesh copper grids and double-
stained with 2% aqueous uranyl acetate for 30 min and Reynold’s
lead citrate for 10 min. Specimens were examined in a transmis-
sion electron microscope Jeol 1010 (Jeol, Tokyo, Japan) and digital
images were acquired using a Gatan Orius SC1000 CCD Digital
Camera (Gatan, Inc., Pleasanton, California, USA). Two independent
experiments were performed and photographs were taken from at
least three different semithin sections from each experiment.
2.10. MitotrackerTM staining
A549 cells (1  104 cells/well) were seeded in 8-well sterile l-
Slide (chambered coverslip) (Ibidi), and allowed to attach and grow
during 72 h. Then, cells were preincubated with MitoTrackerTM Red
CMXRox 500 nM during 1 h, washed with 1 PBS and exposed to
IC75 value of compound 2 for 3 h. Immunofluorescence images
were captured using a Leica TCS-SL filter-free spectral confocal
microscope (Leica Microsystems). Representative images from
three independent experiments are shown.
2.11. Immunoblot analysis
A549 cells (1  105 cells/mL) were seeded and allowed to grow
for 24 h. Afterwards, they were exposed to compounds (IC25, IC50
and IC75 values) for 24 or 48 h. Total protein extracts were obtained
from cells by the addition of lysis buffer (0.1% SDS, 1% NP-40, 0.5%
sodium deoxycholate, 50 mM NaF, 40 mM b-glycerophosphate,
200 lM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluo-
ride, serine and cysteine protease inhibitor cocktail (Roche Man-
nheim, Germany) in 1 PBS). Protein concentration was
determined by BCA protein assay (Pierce, Rockford, IL, USA) using
BSA as a standard. After that, 40 lg of protein extracts were sepa-
rated by 8–15% SDS-polyacrylamide gel electrophoresis and trans-
ferred to ImmobilonTM-P membranes (Millipore, Bedford, MA, USA).
Membranes were blocked in 5% dry milk or 5% BSA, both diluted in
1 TBS–Tween (50 mM Tris–HCl pH 7.5, 150 mMNaCl, 0.1% Tween
20) for 1 h and then incubated overnight with primary antibodies,
according to the manufacturer’s instructions. Antibodies were
obtained from the following sources: anti-caspase 3 (Cat#9662),
anti-caspase 9 (Cat#9502), anti-PARP (Cat#9542), anti-phospho-
p38 MAPK (Thr180/Tyr182, Cat#4511), anti-p38 MAPK
(Cat#8690), from Cell Signaling Technology (Beverly, MA, USA);
anti-LC3 (Cat#PM036) and anti-p62/SQSTM1 (Cat#PM045) both
from MBL International Corporation; anti-actin (I-19, Cat#sc-
1616) from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
anti-vinculin (Cat#V-4505) from Sigma-Aldrich. Antibody binding
was detected with goat anti-mouse IgG-HRP (Cat#sc-2005), goat
anti-rabbit IgG-HRP (Cat#sc-2004) and donkey anti-goat IgG-HRP
(Cat#sc-2020) all from Santa Cruz Biotechnology, and the ECL
detection kit (Amersham, Buckinghamshire, UK). Actin or vinculin
was used as gel loading controls. Results shown are representative
of Western blot data obtained from at least three independent
experiments with similar observations. Images were captured on
an Image QuantTM LAS 500 (GE Healthcare Little Chalfont, UK) and
band densitometries were retrieved using the software ImageJ ver-
sion 1.43u software (National Institutes of Health, Bethesda, Mary-
land, USA).
2.12. Statistical analyses
Results are expressed as the mean ± SEM of at least three inde-
pendent experiments. One-way ANOVAs were carried out with the
Statgraphics centurion statistical package and post hoc Tukey anal-
yses were performed. Statistically significant differences, p < 0.05
and p < 0.01, are represented by * and **, respectively.
3. Results
3.1. Compounds cytotoxic effects on cancer cell lines and cancer stem
cells
The effect on cell viability of several tambjamine analogues
(Fig. 1a), selected from a previous screening [19], was evaluated
in different lung cancer cell lines representative of the four major
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histological subtypes (A549, adenocarcinoma; SW900, squamous
cell carcinoma; H460, large cell carcinoma; DMS53, small-cell car-
cinoma) (Fig. 1b). Cell viability was measured by the MTT assay
and a significant decrease (more than 50%) was observed after
24 h with 10 lM of all the tested compounds. From these experi-
ments two derivatives (compounds 2 and 7) were selected as the
most potent compounds. Then, dose-response experiments were
conducted in A549 cells and compared to a positive control, cis-
platin as a current chemotherapeutic treatment in lung cancer.
The IC50 values obtained for compound 2 and 7 were 3.38 ± 0.98
and 1.67 ± 0.29 lM and IC75 values were 4.72 ± 0.76 and
3.57 ± 0.49 lM, respectively; while IC50 value for cisplatin (CDDP)
was more than 200 lM (Fig. 1c).
Cell viability after treatment with the most potent compound,
tambjamine 2, was also evaluated in cancer stem cells (CSC)
derived from patients or isolated from cancer cell lines (Fig. 1d).
The derived tumour spheres were deeply characterized, showing
enrichment in stem cell surface markers as well as great tumori-
genic properties in scid mice transplantation experiments (see
Supplementary information Ref. [20]). Our results show a signifi-
cant decrease in cell viability, either in CSC derived from cell lines
(A549 and SW900) or derived from tumour patient samples
(FIS302 and FIS303).
3.2. Tambjamine derivatives are effective anion transporters that
deregulate lysosomal pH
The activity as transmembrane anion carriers of the two most
cytotoxic compounds, 2 and 7, was assayed in model POPC
liposomes. Chloride loaded liposomes were suspended in an iso-
tonic chloride free solution, and chloride efflux facilitated by these
compounds was monitored using a chloride selective electrode. At
the end of the experiments, vesicles were lysed by the addition of
detergent and the final electrode reading considered as 100% chlo-
ride release. Quantification of the transport activity was carried out
by repeating the experiments using several concentrations of the
studied compounds and performing hill analyses of the results
(Fig. 2a and b). The resulting EC50 value represents the amount of
compound needed to release 50% of the encapsulated chloride in
the time scale of the experiments (300 s). The EC50 values obtained
for 2 and 7were 50 nM and 60 nM respectively in the assay involv-
ing NaNO3 as external solution and 240 nM and 880 nM respec-
tively in the assay involving NaHCO3 as external solution. The
impact on the EC50 values of the external anion is consistent with
an exchange mechanism in which chloride efflux from the interior
of the vesicle is accompanied by influx of the external anion, thus
precluding the formation of an electrochemical gradient. The rela-
tive higher lipophilicity of nitrate compared to bicarbonate makes
this latter anion more difficult to extract into the membrane
hydrophobic core and hence the higher EC50 observed. This trans-
port mechanism has been studied by us in detail and the result
demonstrates that 2 and 7 are very potent anionophores promot-
ing effective transmembrane anion transport in vesicles at low
loadings [19].
On the other hand, lysosomal pH modifications in A549 cells
were analysed using acridine orange staining [23]. This dye accu-
mulates into acidic organelles, like lysosomes or late endosomes,
and emits orange fluorescence as a result of its protonation under
Fig. 2. Potent transmembrane anion transport activity of tambjamine analogues in liposomes and cellular models. (A) Chloride efflux upon addition of compound 2 or 7 at
different concentrations to vesicles composed of POPC. Squared symbols correspond to the results obtained using NaNO3 as external buffer, triangular symbols correspond to
the results obtained using NaHCO3/Na2SO4 as external buffer. Each trace represents an average of at least three different experiments (See Section 2.2. for details). (B) Impact
of external buffer (NaNO3, squared symbols, or NaHCO3/Na2SO4, triangular symbols) in the chloride efflux promoted by 2 or 7 (0.1 lM, blue and red symbols, respectively). (C)
Acridine orange staining on A549 cells treated with vehicle (DMSO), 10 lM compound 2 or 7 for 1 h. Images are representative of three independent experiments. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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these acidic pH conditions, whilst it emits green fluorescence in
other parts of the cell, as observed in control cells (Fig. 2c). When
A549 cells were treated with IC50 values of compounds 2 or 7 for
1 h, the orange fluorescence in the vesicle compartments disap-
peared, indicating an increase in the pH of these organelles. This
result is in agreement with the ionophoric activity of these com-
pounds facilitating the transmembrane transport of anions such
as bicarbonate across cellular membranes and this pH alteration
should result in lysosomal dysfunction.
3.3. Cytoplasmic vacuolization due to mitochondrial swelling induced
by tambjamine analogues
After treatment with compounds 2 or 7, massive cytoplasmic
vacuolization was observed by phase contrast microscopy after
6 h exposure with their IC75 values (Fig. 3a). To better understand
this phenomenon, cells were monitored during 24 h after 10 lM
treatment with each compound (Fig. 3b). Cytoplasmic vacuoliza-
tion was observed as soon as 3 h of compounds addition and was
maintained up to 24 h. In the case of compound 2, cell death due
to cellular swelling and/or burst was observed within the 24 h per-
iod. This is indicative of necrotic cell death reflecting the potent
cytotoxic activity of this compound.
In order to determine which cellular organelle was undergoing
this vacuolization process, several subcellular markers were used
for immunofluorescence detection (Figs. 4 and 5). First of all, the
autophagosomal marker LC3 was evaluated and, although a high
increase on protein levels was observed, it did not colocalize with
the vacuoles (Fig. 4a). Then, the lysosomal marker LAMP1 and the
early endosomal marker EEA1 were used and different protein
localization was observed in treated cells, but again neither colo-
calized with the vacuolated organelle (Fig. 4b and c). Moreover,
the hydrophilic polysaccharide dextran-red was administered to
treated cells to monitor macro/pinocytosis, but we did not obtain
vesicle staining (data not shown). Finally, a mitochondrial protein
called TOMM20 was employed and proved to stain the membranes
of the vacuoles, indicating that mitochondrial swelling was occur-
ring after compound treatment (Fig. 5a) and ruling out vacuoliza-
tion of autophagosomes, lysosomes or endosomes.
To further characterize that the vacuolated organelle was mito-
chondria, a plasmid with the mitochondrial targeting sequence
from subunit VIII of human cytochrome c oxidase was transfected
into cells in order to monitor mitochondria. Control cells showed
typical red mitochondrial staining, whereas in cells treated with
compound 2, mitochondrial swelling was clearly observed
(Fig. 5b). Transmission electron micrographs were obtained from
control and cells treated with compounds 2 or 7 to analyse these
results in deep, and mitochondrial swelling was also observed
(black arrows, Fig. 5c). Moreover, many autophagy-related struc-
tures such as autophagosomes, autolysosomes and dense lyso-
somes are also visualized in treated cells. This process was also
studied using MitoTrackerTM Red CMXRos, a fluorescent dye whose
accumulation depends on mitochondrial membrane potential [24],
to track mitochondria (Fig. 6). Control cells showed typical fila-
mentous mitochondria, but in treated cells mitochondria gradually
swelled to a larger size structure and finally lost fluorescence. This
indicates that mitochondrial membrane potential is lost during the
swelling process after compound treatment.
Fig. 3. Cytoplasmic vacuolization induced by tambjamine analogues. (A) Phase contrast microscopy images of A549 cells treated with IC75 of compounds 2 or 7 for 6 h. (B)
Time-course photographs of A549 cells treated with 10 lM of compound 2 or 7 during 24 h. Scale bars 100 lm (A) and 50 lm (B). Images are representative of three
independent experiments.
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3.4. Molecular cell death mechanisms
Finally, to understand the molecular cell death mechanisms
triggered by these compounds, cells were treated with compound
2 and several proteins involved in stress response, autophagy and
apoptosis were analysed. Activation of p38 Mitogen-Activated Pro-
tein Kinase (MAPK) in A549 cells was observed in a dose-response
manner (Fig. 7a). This signal has been reported to activate apopto-
sis after some stresses. After 24 h of treatment with high concen-
trations of compound 2, we were able to observe a small
activation of caspase 9 and 3, as well as PARP cleavage (Fig. 7b).
Likewise, small activation of apoptotic markers was observed after
48 h treatment. To further analyse whether this apoptotic activa-
tion was involved in the cytotoxic effect induced by tambjamines,
a pan-caspase inhibitor (10 lM Z-VAD-FMK) was added before
treatment with compound 2. Under these conditions, cell viability
was not recovered (data not shown). Therefore, this result sug-
gested that although apoptosis is being triggered by these tamb-
jamine analogues, this process is not entirely responsible for the
cytotoxic effect induced by these compounds.
This led us to study the autophagic process after compound
treatment and to investigate whether it was involved in the
Fig. 4. Tambjamine analogues treatment did not induce swelling of autophagosomes, lysosomes or early endosomes. Immunofluorescence in A549 cells treated with IC75 of
compound 2 for 6 h. It was performed with different antibodies that recognize several cellular organelles (red) and were compared to the distribution of cytoplasmic vacuoles
observed by phase contrast microscopy. (A) Distribution of the autophagosomal marker LC3, (B) distribution of lysosomal marker LAMP1 (C) distribution of the early
endosome marker EEA1. The nucleus was counterstained with TO-PROTM-3 (blue). Scale bar 20 lm. Images are representative of at least three independent experiments. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 5. Mitochondrial swelling after tambjamine analogues treatment. (A) Immunofluorescence of mitochondrial marker TOMM20 in A549 cells treated with IC75 of
compound 2 for 6 h. The nucleus was counterstained with TO-PROTM-3 (blue). (B) A549 cells overexpressing mCherry-Mito7 plasmid, which targets mitochondria (red), were
treated with IC75 of compound 2 for 3 h. Mitochondrial staining was compared to vacuolization observed in phase contrast photographs. Scale bar 20 lm. (C) Transmission
electron micrographs from control and treated A549 cells with compound 2 and 7 for 6 h. Mitochondrial swelling (black arrows) as well as double-membrane vesicles
accumulation (autophagosomes and autolysosomes) were observed. Scale bar 2 and 5 lm. Images are representative of at least three independent experiments. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 6. Mitochondrial swelling and loss of mitochondrial membrane potential after tambjamine analogues treatment. Confocal images of A549 cells treated with 500 nM
MitoTrackerTM Red CMXRos during 1 h and then compound 2 for 3 h. Mitochondria with normal membrane potential are stained in red. Nucleus was counterstained with
DRAQ5 (blue). Scale bar 20 lm. Images are representative of at least three independent experiments. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
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observed cytotoxicity. At very low concentrations of compound 2
(IC25), an impressive appearance of the lipidated LC3 form (LC3-
II), indicative of autophagosome formation (Fig. 7c), was detected.
On the other hand, p62, a protein that is itself degraded by autop-
hagy, was not degraded but accumulated after treatment, indicat-
ing a blockade of the autophagic flux. To elucidate whether
autophagy was involved in the induced cell death, an inhibitor of
autophagosomes formation (5 mM 3-MA) was added prior com-
pound administration (data not shown). Cell viability was not
recovered after 3-MA administration, suggesting that autophago-
somes formation and their accumulation are not crucial for the
cytotoxic effect induced by tambjamines. Finally, at higher doses
and 24 h of treatment, tambjamines also provoked cytoplasmic
swelling, which finally led to plasma membrane breakdown
Fig. 7. p38 MAPK activation, apoptosis induction and autophagy blockade after tambjamine analogues treatment. A549 cells were treated with compound 2 IC25, IC50 and IC75
values for 24 h and protein extracts were used to determine changes in protein levels. Detection and quantification of: (A) the stress kinase p38 MAPK and its phosphorylation
levels; (B) apoptotic markers caspase 9, 3 and PARP substrate and (C) autophagic markers LC3II and p62. Protein levels were normalized with their respective loading controls
(actin or vinculin) in each blot. Fold changes in protein expression levels were quantified and referred to non-treated cells. Data show the mean ± SEM of three independent
experiments. Statistically significant results are indicated as *p < 0.05 and **p < 0.01.
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indicative of necrosis, as observed in the phase contrast images
(Fig. 3b) and the Supplementary video.
4. Discussion
Diverse synthetic tambjamine analogues have recently shown
potent anticancer activity in a panel of cancer cell lines, including
humanmelanoma, lung carcinoma, colorectal adenocarcinoma and
mammary adenocarcinoma cells [19,20]. In this study, we extend
the results obtained with those compounds bearing 4-alkoxy-
2,20-bipyrrole moieties [19] to several lung cancer cell lines and
CSC, as well as characterize in deep for the first time the cellular
and molecular events that are participating in the cell death
induced by these potent compounds.
Cell viability was significantly reduced by most of the tested
compounds in all human lung cancer cell lines studied, and com-
pound 2 showed to be especially potent against patient-derived
CSC. This tumour subpopulation possesses tumour-initiating and
self-renewal capacities, and contributes to acquired chemotherapy
resistance in cancer [25], thus these results are very promising for
lung cancer treatment and the prevention of tumour recurrences.
In this view, other anionophores such as the recently reported
2-pyrrolylindole tambjamine analogues or the cation selective
ionophore salinomycin, also induce CSC-specific toxicity [20,26],
indicating that the application of these kind of compounds might
be a very promising therapy.
Once the cells internalize these synthetic tambjamine ana-
logues, several cellular processes occur, converging in the potent
cytotoxic effect observed. On one hand, a huge cytoplasmic vac-
uolization was detected after compound treatment, which was
due to mitochondrial swelling, as demonstrated by several specific
markers of this organelle. Moreover, after significant organelle
swelling, loss of mitochondrial membrane potential was induced
by compound 2. Mitochondria in eukaryotic cells are the essential
machinery to provide energy with an aerobic environment. It has
previously been described in cells with acute cellular injury that
mitochondrial depolarization and mitochondrial membrane per-
meabilization lead to a large amplitude swelling and cellular ATP
depletion [27,28]. Therefore, mitochondrial dysfunction observed
after tambjamine analogues treatment may cause an energetic fail-
ure contributing to their cytotoxic effect.
Autophagy is a catabolic process whereby cellular components
are enclosed in double-membrane vesicles referred to as
autophagosomes, targeting them for lysosomal degradation. This
process serves as an essential cytoprotective response to patho-
logic stresses [29]. Accumulation of defective mitochondria trig-
gers its selective degradation, process known as mitochondrial
autophagy or mitophagy, maintaining a healthy population of
these organelles [30,31]. A very significant amount of the
autophagosomal marker LC3II protein accumulates after treatment
with tambjamine analogues, even at very low concentrations. This
indicates that the process of autophagy is being triggered by the
treatment with these tambjamine analogues and that the induced
mitochondrial damage may launch the process of mitophagy in
order to remove damaged organelles. This phenomenon is fre-
quently found as a result of mitochondrial stress, such is the case
of treatment with the mitochondrial chain uncoupler carbonyl cya-
nide m-chlorophenylhydrazone (CCCP)[32], or salinomycin, an
ionophore which affects mitochondrial potential [33]. On the other
hand, it has recently been reported that pHi changes modulate
both autophagy and mitophagy [34], thus the changes in cellular
pH caused by these compounds could also be contributing to trig-
ger this pathway [20].
The loss of the typical acridine orange fluorescence in acidic
organelles after exposure to our compounds indicates lysosomal
alkalization. This increase in lysosomal pH is consistent with an
anion carrier activity across cellular membranes, similarly to that
observed in model liposomes. Interestingly, it has recently been
reported that obatoclax, another anionophore related to the
prodiginine family which has been evaluated in clinical trials for
different cancer conditions, rapidly localizes to the lysosomes
and also induces lysosomal alkalization [35,36].
Lysosomes contain many different types of hydrolytic enzymes
that usually exert their maximal enzymatic activity at low pH [37].
Typically, an increase in lysosomal pH could derive from H+ leak-
age, a defective proton pump or lysosomal permeabilization [38].
This could lead to a failure in their proper functioning, resulting
in blockade of autophagy [39,40]. After tambjamine analogues
treatment, increase in the lysosomal pH derived from lysosomal
membrane permeabilization may inactivate its hydrolytic enzymes
and therefore it may block autophagy. This feature mainly occurs
because this organelle is essential in the final step of the autopha-
gic process, wherein autophagosomes fuse with lysosomes and
subsequent protein digestion occurs [41]. The autophagic sub-
strate, p62, also known as sequestosome 1 (SQSTM1), binds ubiq-
uitinated proteins for subsequent degradation in lysosomes,
where it is also degraded [42]. Our results show that there is no
p62 degradation, indicating an impairment in the autophagic flux
and consequent accumulation of unprocessed autophagosomes or
autolysosomes [43]. Moreover, the autophagy inhibitor 3-MA,
which inhibits autophagy by blocking autophagosomes formation
via the inhibition of type III phosphatidylinositol 3-kinases
(PI3K), is not able to reverse the cytotoxic effect induced by tamb-
jamines. Thus this autophagy might be contributing to the cyto-
toxic effect, but it is not responsible for it. Nevertheless,
mitochondrial dysfunction along with a defect in autophagy cata-
bolism due to lysosomal deacidification might be detrimental to
tumour cells since they produce low rates of ATP and impaired
recycling of nutrients for energy production, as well as an imbal-
ance in vesicular biogenesis and turnover. This cellular stress is
reflected by p38 MAPK activation, which may initiate apoptosis
[44], although again this process is not crucial for the observed
cytotoxicity elicited by these compounds. Therefore, the imbalance
in cellular ion homeostasis that triggers mitochondrial dysfunction
and lysosomal deacidification may be inducing cell death by necro-
sis after tambjamine analogues treatment. In this regard, the lyso-
somal permeabilization induced by obatoclax in apoptosis-
resistant anaplastic thyroid cells has been demonstrated to be suf-
ficient to induce necrosis in this resistant model, representing an
interesting therapeutic approach [36].
Overall, these new tambjamine analogues show promising
anticancer properties in lung cancer and could represent a
good therapeutic option for apoptosis-resistant tumours. These
results shed light into the cellular and molecular mechanisms
resulting from the action of these compounds. Lysosomal and
mitochondrial dysfunction led to necrosis as the main cell
death mechanism responsible for the cytotoxicity of these
compounds, which might be shared by other active small
molecule anionophores.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
This work was supported by a grant from the Spanish govern-
ment and the EU (FIS PI13/00089), a grant from La Marató de
TV3 Foundation (20132730), Consejería de Educación de la Junta
de Castilla y León (BU340U13 and BU092U16). The authors would
32 A.M. Rodilla et al. / Biochemical Pharmacology 126 (2017) 23–33
like to thank Dr. Jantus-Lewintre and Dr. Calabuig-Fariñas for their
assistance with cancer stem cell cultures. Moreover, the authors
also thank Benjamín Torrejón from CCiT (Centres Científics i Tec-
nològics, Campus de Bellvitge, Universitat de Barcelona) for his
technical support. E.H. thanks the Junta de Castilla y León (Conse-
jería de Educación) and Fondo Social Europeo for a PIRTU contract.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bcp.2016.11.022.
References
[1] C.A. Hübner, T.J. Jentsch, Ion channel diseases, Hum. Mol. Genet. 11 (2002)
2435–2445.
[2] A. Becchetti, Ion channels and transporters in cancer. 1. Ion channels and cell
proliferation in cancer, Am. J. Physiol. Cell Physiol. 301 (2011) C255–C265.
[3] V. Lehen’kyi, G. Shapovalov, R. Skryma, N. Prevarskaya, Ion channels and
transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis,
Am. J. Physiol. Cell Physiol. 301 (2011) C1281–C1289.
[4] B.A. Webb, M. Chimenti, M.P. Jacobson, D.L. Barber, Dysregulated pH: a perfect
storm for cancer progression, Nat. Rev. Cancer 11 (2011) 671–677.
[5] J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, GLOBOCAN
2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.
11, International Agency for Research on Cancer, Lyon, France, 2013. Available
from: <http://globocan.iarc.fr> (accessed on 25/07/2016).
[6] S. Cooper, S.G. Spiro, Small cell lung cancer: treatment review, Respirology 11
(2006) 241–248.
[7] R. Rosell, F. Cecere, M. Santarpia, N. Reguart, M. Taron, Predicting the outcome
of chemotherapy for lung cancer, Curr. Opin. Pharmacol. 6 (2006) 323–331.
[8] N. Busschaert, P.A. Gale, Small-molecule lipid-bilayer anion transporters for
biological applications, Angew. Chem. Int. Ed. 52 (2013) 1374–1382.
[9] P.A. Gale, R. Pérez-Tomás, R. Quesada, Anion transporters and biological
systems, Acc. Chem. Res. 46 (2013) 2801–2813.
[10] E. Llagostera, V. Soto-Cerrato, B. Montaner, R. Perez-Tomas, Prodigiosin
induces apoptosis by acting on mitochondria in human lung cancer cells,
Ann. N. Y. Acad. Sci. 1010 (2003) 178–181.
[11] R. Pérez-Tomás, B. Montaner, E. Llagostera, V. Soto-Cerrato, The prodigiosins,
proapoptotic drugs with anticancer properties, Biochem. Pharmacol. 66 (2003)
1447–1452.
[12] V. Soto-Cerrato, E. Llagostera, B. Montaner, G.L. Scheffer, R. Perez-Tomas,
Mitochondria-mediated apoptosis operating irrespective of multidrug
resistance in breast cancer cells by the anticancer agent prodigiosin,
Biochem. Pharmacol. 68 (2004) 1345–1352.
[13] N.R. Williamson, P.C. Fineran, T. Gristwood, S.R. Chawrai, F.J. Leeper, G.P.
Salmond, Anticancer and immunosuppressive properties of bacterial
prodiginines, Future Microbiol. (2007).
[14] J.L. Sessler, L.R. Eller, W.S. Cho, S. Nicolaou, A. Aguilar, J.T. Lee, et al., Synthesis,
anion‐binding properties, and in vitro anticancer activity of prodigiosin
analogues, Angew. Chem. Int. Ed. 44 (2005) 5989–5992.
[15] N. Busschaert, C. Caltagirone, W. Van Rossom, P.A. Gale, Applications of
supramolecular anion recognition, Chem. Rev. 115 (2015) 8038–8155.
[16] M. Carbone, C. Irace, F. Costagliola, F. Castelluccio, G. Villani, G. Calado, et al., A
new cytotoxic tambjamine alkaloid from the Azorean nudibranch Tambja
ceutae, Bioorg. Med. Chem. Lett. 20 (2010) 2668–2670.
[17] B.C. Cavalcanti, H.V. Júnior, M.H. Seleghim, R.G. Berlinck, G.M. Cunha, M.O.
Moraes, et al., Cytotoxic and genotoxic effects of tambjamine D, an alkaloid
isolated from the nudibranch Tambja eliora, on Chinese hamster lung
fibroblasts, Chem-Biol. Interact. 174 (2008) 155–162.
[18] P.I. Hernández, D. Moreno, A.A. Javier, T. Torroba, R. Pérez-Tomás, R. Quesada,
Tambjamine alkaloids and related synthetic analogs: efficient transmembrane
anion transporters, Chem. Commun. 48 (2012) 1556–1558.
[19] E. Hernando, V. Soto-Cerrato, S. Cortes-Arroyo, R. Perez-Tomas, R. Quesada,
Transmembrane anion transport and cytotoxicity of synthetic tambjamine
analogs, Org. Biomol. Chem. 12 (2014) 1771–1778.
[20] V. Soto-Cerrato, P. Manuel-Manresa, E. Hernando, S. Calabuig-Fariñas, A.
Martinez-Romero, V.c. Fernández-Dueñas, et al., Facilitated anion transport
induces hyperpolarization of the cell membrane that triggers differentiation
and cell death in cancer stem cells, J. Am. Chem. Soc. 137 (2015) 15892–15898.
[21] M.B. Hansen, S.E. Nielsen, K. Berg, Re-examination and further development of
a precise and rapid dye method for measuring cell growth/cell kill, J. Immunol.
Methods 119 (1989) 203–210.
[22] S.G. Olenych, N.S. Claxton, G.K. Ottenberg, M.W. Davidson, The fluorescent
protein color palette, Curr. Protoc. Cell Biol. (2007) (Chapter 21, Unit 21.5).
[23] A. Allison, M. Young, Vital staining and fluorescence microscopy of lysosomes,
Lysosomes Biol. Pathol. 2 (1969) 600–628.
[24] W. Pendergrass, N. Wolf, M. Poot, Efficacy of MitoTracker GreenTM and
CMXRosamine to measure changes in mitochondrial membrane potentials in
living cells and tissues, Cytometry Part A 61 (2004) 162–169.
[25] P. Valent, D. Bonnet, R. De Maria, T. Lapidot, M. Copland, J.V. Melo, et al., Cancer
stem cell definitions and terminology: the devil is in the details, Nat. Rev.
Cancer 12 (2012) 767–775.
[26] P.B. Gupta, T.T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R.A. Weinberg, et al.,
Identification of selective inhibitors of cancer stem cells by high-throughput
screening, Cell 138 (2009) 645–659.
[27] J.J. Lemasters, A.-L. Nieminen, T. Qian, L.C. Trost, S.P. Elmore, Y. Nishimura,
et al., The mitochondrial permeability transition in cell death: a common
mechanism in necrosis apoptosis and autophagy, Biochim. Biophys. Acta,
Bioenerg. 1366 (1998) 177–196.
[28] J.-S. Kim, L. He, J.J. Lemasters, Mitochondrial permeability transition: a
common pathway to necrosis and apoptosis, Biochem. Biophys. Res.
Commun. 304 (2003) 463–470.
[29] L. Murrow, J. Debnath, Autophagy as a stress response and quality control
mechanism—implications for cell injury and human disease, Annu. Rev. Pathol.
8 (2013) 105.
[30] D.A. Kubli, Å.B. Gustafsson, Mitochondria and mitophagy the yin and yang of
cell death control, Circ. Res. 111 (2012) 1208–1221.
[31] I. Kim, S. Rodriguez-Enriquez, J.J. Lemasters, Selective degradation of
mitochondria by mitophagy, Arch. Biochem. Biophys. 462 (2007) 245–253.
[32] K.-Y. Kwon, B. Viollet, O.J. Yoo, CCCP induces autophagy in an AMPK-
independent manner, Biochem. Biophys. Res. Commun. 416 (2011) 343–348.
[33] J.R. Jangamreddy, S. Ghavami, J. Grabarek, G. Kratz, E. Wiechec, B.-A.
Fredriksson, et al., Salinomycin induces activation of autophagy, mitophagy
and affects mitochondrial polarity: differences between primary and cancer
cells, Biochim. Biophys. Acta, Mol. Cell Res. 2013 (1833) 2057–2069.
[34] A.V. Berezhnov, M.P. Soutar, E.I. Fedotova, M.S. Frolova, H. Plun-Favreau, V.P.
Zinchenko, et al., Intracellular pH modulates autophagy and mitophagy, J. Biol.
Chem. (2016), http://dx.doi.org/10.1074/jbc.M115.691774.
[35] V.A. Stamelos, N. Fisher, H. Bamrah, C. Voisey, J.C. Price, W.E. Farrell, et al., The
BH3 mimetic obatoclax accumulates in lysosomes and causes their
alkalinization, PLoS ONE 11 (2016) e0150696.
[36] D. Champa, A. Orlacchio, B. Patel, M. Ranieri, A.A. Shemetov, V.V. Verkhusha,
et al., Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome
neutralization and necrosis, Oncotarget 5 (2016).
[37] J. Coffey, C. de Duve, The digestion of proteins by extracts of rat liver
lysosomes, J. Biol. Chem. 243 (1968) 3255–3263.
[38] P. Boya, Lysosomal function and dysfunction: mechanism and disease,
Antioxid. Redox Signal. 17 (2012) 766–774.
[39] B. Levine, G. Kroemer, Autophagy in the pathogenesis of disease, Cell 132
(2008) 27–42.
[40] M. Mrschtik, K.M. Ryan, Lysosomal proteins in cell death and autophagy, FEBS
J. 282 (2015) 1858–1870.
[41] G. Kroemer, M. Jäättelä, Lysosomes and autophagy in cell death control, Nat.
Rev. Cancer 5 (2005) 886–897.
[42] G. Bjørkøy, T. Lamark, S. Pankiv, A. Øvervatn, A. Brech, T. Johansen, Monitoring
autophagic degradation of p62/SQSTM1, Methods Enzymol. 452 (2009) 181–
197.
[43] M. Komatsu, Y. Ichimura, Physiological significance of selective degradation of
p62 by autophagy, FEBS Lett. 584 (2010) 1374–1378.
[44] T. Wada, J.M. Penninger, Mitogen-activated protein kinases in apoptosis
regulation, Oncogene 23 (2004) 2838–2849.
A.M. Rodilla et al. / Biochemical Pharmacology 126 (2017) 23–33 33

ANNEX III
- Facilitated anion transport induces yperpolariza on o  t e cell mem rane t at tri ers 
di eren a on and cell deat  in cancer stem cells . Journal o  t e American C emical Society  
2015.
- Novel indole- ased tam amine-analo ues induce apopto c lun  cancer cell deat  
t rou  p38 mito en-ac vated protein kinase ac va on . Molecular Cancer T erapeu cs  
2017. 
Colla ora on ar cles in ic  I ave par cipated c aracterizin  t e mec anisms o  ac on at cellular 
and molecular level o  indole- ased tam amines analo ues.

11
Facilitated Anion Transport Induces Hyperpolarization of the Cell
Membrane That Triggers Differentiation and Cell Death in Cancer
Stem Cells
Vanessa Soto-Cerrato,†,● Pilar Manuel-Manresa,†,● Elsa Hernando,‡ Silvia Calabuig-Fariñas,§,¶
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†Cancer Cell Biology Research Group, Department of Pathology and Experimental Therapeutics, Faculty of Medicine, University of
Barcelona, 08007 Barcelona, Spain
‡Departmento de Química, Universidad de Burgos, 09001 Burgos, Spain
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ABSTRACT: Facilitated anion transport potentially repre-
sents a powerful tool to modulate various cellular functions.
However, research into the biological effects of small molecule
anionophores is still at an early stage. Here we have used two
potent anionophore molecules inspired in the structure of
marine metabolites tambjamines to gain insight into the effect
induced by these compounds at the cellular level. We show
how active anionophores, capable of facilitating the trans-
membrane transport of chloride and bicarbonate in model
phospholipid liposomes, induce acidification of the cytosol and
hyperpolarization of plasma cell membranes. We demonstrate
how this combined effect can be used against cancer stem cells
(CSCs). Hyperpolarization of cell membrane induces cell differentiation and loss of stemness of CSCs leading to effective
elimination of this cancer cell subpopulation.
■ INTRODUCTION
Transmembrane ion channels and pumps are sophisticated
cellular machineries involved in many biological processes. As
such, ion channels constitute one of the main drug targets in
medicinal chemistry. An estimated 13% of currently approved
drugs have ion channels as their main therapeutic target, being
used for the treatment of a variety of disease conditions.1 The
most successful strategy to modulate transmembrane ion flux is
to use small molecules activators or blockers of endogenous
proteins. Nevertheless, there is an intense interest in designing
artificial ion channels and ionophores.2,3 In particular, cation
selective ionophores are widely used as antibiotics and research
tools. In the past few years, the development of small molecules
capable of facilitating the transmembrane transport of anions
has emerged as an active research field.4−6 A number of
molecules inspired by naturally occurring anionophores such as
prodiginines or by synthetic molecules containing amide,
(thio)urea, or (thio)squaramide hydrogen-bond donors have
been characterized as efficient anion transporters.7−10 The
potential biological applications of these compounds have been
less explored. In a seminal work, Magda, Sessler et al. linked the
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anionophoric activity of prodigiosin-like molecules with their
anticancer activity.11 Further work by different research groups
delineated relationships between the transmembrane transport
of anions and the cytotoxicity induced by some of these
compounds.12 Very recently, Gale, Sessler, Shin, and co-
workers have demonstrated how diamide-strapped calix[4]-
pyrroles induced apoptosis via a caspase-dependent pathway as
a result of the facilitated sodium and chloride influx promoted
by these derivatives.13
Potentially, facilitated transmembrane transport of chloride
and bicarbonate (the most abundant anions in biological
environments) could impact on cellular ion homeostasis, pH
levels, and membrane potentials. These are key parameters for
cell survival, and there is a growing body of evidence showing
their relationships with cancer development and progression.14
Dysregulated pH has been recognized as a hallmark of cancer.
Cancer cells show a reversed pH gradient compared to normal
differentiated cells, with intracellular pH (pHi) higher than
extracellular pH.15 This reversed gradient is regulated by ion
channels and pumps and facilitates cancer progression being
permissive for some of the acquired characteristics of cancer
cells, such as sustained proliferative signaling or resistance to
cell death.16 Membrane potential (Vm) also plays key roles in
cancer development and cell differentiation.17 Nonproliferating,
terminally differentiated somatic cells, such as muscle cells and
neurons, are characterized by their hyperpolarized Vm, whereas
proliferative cells, especially rapidly proliferating tumor cells,
displayed depolarized Vm. Interestingly, cancer stem cells
(CSCs), a tumor cell subpopulation that exhibits tumor-
initiating capacity, self-renewal in serial transplantation assays
and contributes to acquired chemotherapy resistance in
cancer,18 need to maintain a depolarized Vm in order to
preserve their stemness capacities.19,20 Therefore, pH modu-
lation to avoid cancer cells acquired advantages as well as
suppression of stemness properties through the modulation of
plasma membrane potential might be promising new
therapeutic strategies for cancer treatment. High-throughput
screening of selective inhibitors of CSC growth and survival has
identified the potassium ionophore salinomycin as a promising
drug candidate, although its mechanism of action is unclear.21
The potential of a synthetic chloride channel to regulate cell
membrane potential has also been reported.22
Here we report the biological activity of transmembrane
anion transporters inspired in the structure of marine
metabolites tambjamines. We demonstrate how these mole-
cules induce pHi acidification and cytotoxicity related to their
anion transport abilities. We also show how the facilitated
transport activity triggers plasma membrane hyperpolarization
leading to cancer stem cell differentiation and effective
elimination of this cell population.
■ RESULTS AND DISCUSSION
Synthesis and Anion Transport through Lipid
Bilayers. Compounds 1−3 (Figure 1) were selected for this
study. These compounds are inspired in the structure of marine
secondary metabolites tambjamines.23 They are readily
prepared by acid-catalyzed condensation of 5-(1H-indol-2-yl)-
3-methoxy-1H-pyrrole-2-carbaldehyde and the appropriate
amine. These compounds are isolated as stable yellow-orange
solids in good yields as hydrochloride salts and fully
characterized (see Supporting Information for details). The
spectroscopic data evidenced the strong hydrogen-bond
interaction between these compounds and the chloride anion.
These interactions are also evident in the solid-state structures
of compounds 1 and 2 (Figure 1). The two heterocycles and
the enamine moiety are essentially coplanar. A chloride anion is
found interacting with the pyrrole and enamine N−H groups,
whereas the indole moiety is found rotated 180° and interacting
with a second chloride anion. A conformational analysis of
these molecules both in solution and computationally is
provided in the Supporting Information. In their preferred
conformation these molecules bind the anion through the
hydrogen-bond cleft involving the three N−H groups of the
molecule.
The chloride anion binding ability of 1 and 2 was explored by
means of 1H NMR titration experiments using perchlorate salts
of these derivatives and tetrabutylammoniun chloride in
DMSO-d6. Under these conditions chloride readily replaces
the less coordinating perchlorate anion, and association
constants could be calculated at 3301 and 3778 M−1 for 1·
HClO4 and 2·HClO4 respectively. Treatment of DMSO-d6
solutions of 1·HClO4 and 2·HClO4 with tetraethylammonium
bicarbonate resulted in deprotonation of the compounds. Lack
of solubility prevented the study of these processes in pure
water. Nevertheless, the apparent pKa values of 1 and 2 were
calculated in DMSO:water 1:1 mixtures at 9.64 and 9.62. This
result as well as computational studies suggested that
Figure 1. Studied compounds. (a) molecular structures of compounds 1−3. (b) X-ray structures of compounds 1 and 2 as hydrochloride salts.
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deprotonation is not likely to occur under physiological
conditions (see Figures S89−S92). On the other hand, in
their neutral form, these derivatives are also able to bind anions
under these conditions albeit with lower affinity (see Figures
S49−S53).
The anion transport properties of 1−3 were assayed in 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
vesicles using a chloride selective electrode to evaluate the
chloride efflux promoted by these compounds. Thus, liposomes
loaded with NaCl were suspended in an isotonic, chloride-free
external medium. Chloride release promoted by 1−3 was
monitored over time, and at the end of the experiment the
vesicles were lysed by the addition of detergent, being the final
electrode reading used as 100% release of chloride. Repeating
these assays in the presence of variable amounts of compound
allowed Hill analyses and calculation of EC50 values (the
concentration of carrier needed to achieve the release of 50% of
encapsulated chloride) for comparative purposes (Table 1).
Compounds 1 and 2 proved to be extremely active trans-
membrane transporters, whereas compound 3 displayed
modest activity as anion carrier. This difference in trans-
membrane transport activity is likely due to the significantly
lower calculated lipophilicity of 3 with respect to 1 and 2 (See
Table S3). The key role of lipophilicity in the design of effective
anion transporters has been studied in several families of
compounds including tambjamine analogs.24,25
Compounds 1 and 2 were selected as their calculated
lipophilicity matched the optimal log P range for these
compounds in order to maximize their transport activity.
Compound 3 was predicted to display very limited activity. The
experimental results fully supported this hypothesis. The nature
of the external anion impacted dramatically in the rate of
chloride efflux promoted by these compounds (see Figures
S122−S123). Both a Hill parameter close to 1 and the
differences in EC50 values found when the chloride efflux is
measured in the presence of nitrate, bicarbonate, or sulfate
suggested that these compounds function as discrete carriers
promoting anion exchange through the lipid bilayer. The
relatively higher hydrophilicity of bicarbonate compared with
nitrate resulted in lower chloride efflux at higher carrier
loadings. This was unsurprising as anion exchange has already
been reported as the main mechanism accounting for the
activity as anion carriers for tambjamine derivatives. Experi-
ments using different metal chlorides such as KCl, RbCl, and
CsCl were also performed, and no significant differences were
observed (Figures S124−S126). Thus, influence of the metal
cation in the transmembrane transport event can be ruled out.
Carboxyfluorescein leakage assays also rule out the possibility
of these compounds functioning as membrane disruptors
promoting unspecific chloride leakage (Figure S136). This set
of assays demonstrated that 1 and 2 are very efficient
transmembrane transporters. Compound 3 represents an
adequate control molecule, being structurally very similar to 1
and 2 yet displaying significantly lower level of transmembrane
transport activity (Table 1).
Anionophores Induce Intracellular pH Changes and
Cellular Toxicity. In order to evaluate the ability of
anionophores 1−3 to modulate pHi, first vital staining with
acridine orange (AO) was used. When this cell-permeable dye
accumulates in acidic compartments, such as lysosomes, it
shows a characteristic orange fluorescence emission, while it
emits green fluorescence at higher pH, such as in the cytosol.
Human lung adenocarcinoma (A549) cells were stained with
AO, and typical granular orange fluorescence was observed,
corresponding to cellular acidic compartments (Figure 2a).
Treatment with active anion transporters 1 and 2 induced
complete loss of orange fluorescence, whereas treatment with
compound 3 did not modify AO emission, compared to
nontreated cells. These results evidenced an increase in the pH
of acidic organelles upon treatment with the active anion
transporters 1 and 2, as opposite to control compound 3.
We were also interested in studying variations in cytoplasmic
pH levels. This parameter has been claimed to modulate cell
proliferation and apoptosis.26 Therefore, it could be more
relevant to gain insight into the mechanisms accounting for the
cytotoxicity of these compounds. Thus, changes in pHi of A549
cells after treatment with 1−3 were quantified using the pH-
sensitive fluorescent dye SNARF-1. In its ester form, 5-(and-6)-
carboxy seminaphthorhodafluor-1-acetoxymethylester
(SNARF-1-AM) can diffuse across the cellular membrane
into the cytoplasm. Hydrolyzation of this compound by cellular
esterases yields the cell-impermeable fluorescent dye carboxy-
SNARF-1. This dye can be used for quantitative determinations
of pHi because it exhibits a significant pH-dependent emission
shift in the appropriate range. First, fluorescent signal ratios at
576 and 664 nm were determined under different pH
conditions, which allowed us to construct a calibration curve.
Then, fluorescence of SNARF-1 was measured in A549 cells.
Upon treatment with 10 μM concentration of active
anionophores 1 and 2, pHi dropped significantly. A lowering
of 0.33 ± 0.10 and 0.70 ± 0.22 pH units was measured for
compound 1 and 2, respectively, after 1 h (Figure 2b). Such
change of pHi is known to be sufficient to trigger apoptotic
processes in cells.26 Under these conditions, compound 3 only
induced minor changes of pHi inducing an increase of 0.02 ±
0.14 pH units. These results are in agreement with the
involvement of the transmembrane transport activity in the
lowering of pHi observed.
To assess whether chloride transport participated in the
cytotoxic effect exhibited by 1 and 2, cell viability was measured
in A549 cells resuspended in Hank’s balanced salt solution
(HBSS) either containing chloride or without this anion
(Figure 2c,d). Moderate yet significant differences between cell
viability in both buffers upon treatment with 1 and 2 were
observed, with reduced cytotoxicity in absence of chloride.
Table 1. Transport Activities for Compounds 1−3
EC50 NO3
−/Cl−a
compound (μM) (mol %)d Hill coefficient
1 0.101 ± 0.007 0.020 ± 0.001 1.12 ± 0.10
2 0.041 ± 0.003 0.008 ± 0.001 1.17 ± 0.14
3 17.212 ± 1.172 3.442 ± 0.234 1.13 ± 0.10
EC50 HCO3
−/Cl−b
compound (μM) (%) Hill coefficient
1 0.243 ± 0.023 0.048 ± 0.005 1.16 ± 0.15
2 0.137 ± 0.004 0.027 ± 0.001 1.49 ± 0.07
3 n.d.c n.d.c n.d.
aVesicles loaded with 489 mM NaCl dispersed in 489 mM NaNO3 (5
mM phosphate buffer, pH 7.2). bvesicles loaded with 451 mM NaCl
dispersed in 150 mM Na2SO4 (20 mM phosphate buffer, pH 7.2)
upon addition of a NaHCO3 pulse to make the extravesicular
bicarbonate concentration 40 mM. cnot determined (carrier loadings
over 5% promoted <50% chloride efflux). dmolar percentage
carrier:POPC
Journal of the American Chemical Society Article
1
Under these conditions, calculated inhibitory concentration 50
(IC50) values in the presence of chloride dropped to 8.8 and 9.6
μM from the calculated 12.4 and 12.11 μM in HBSS without
chloride for compounds 1 and 2, respectively. This result as
well as the reduced toxicity of inactive transporter 3 (see Figure
S136) again supported the involvement of anion transport in
the cytotoxic effect exerted by 1 and 2.
Membrane Potential Changes in Liposomes and
Voltage Changes in Single A549 Cells. We decided to
explore the potential of these compounds to induce changes in
the membrane polarization. We first explore this possibility in
model liposomes. Thus, membrane potential-sensitive dye
safranin O was used. The fluorescence of this compound is
affected by changes in membrane potential.27 POPC vesicles
containing NaCl were suspended in a Na2SO4 solution. As
demonstrated using chloride-selective electrode assays, com-
pounds 1−3 are unable to promote sulfate transport (see
Figures S119 and S120), and under these conditions only
chloride permeation can occur. Addition of active transporters
1 and 2 at 0.1% molar carrier:lipid resulted in a marked
decrease in safranin O fluorescence (Figure 3b). Control
experiments using the essentially inactive transporter 3 or
DMSO resulted in no significant change of fluorescence. These
results are consistent with a decrease of the membrane
potential induced by 1 and 2. Likewise, little change in safranin
O fluorescence was observed when these experiments were
carried out with no chloride electrochemical potential (Figure
3a).
We next aimed to assess the ability of anion transporters to
induce voltage changes in A549 cells. A549 cells were
transfected with the VSFP2.32 genetically encoded voltage
indicator, which permits monitoring membrane voltage changes
by recording changes in FRET efficacy between a pair of
fluorescent proteins.28,29 To determine the voltage range within
VSFP2.32 reports, voltage changes in A549 cells, VSFP2.32
expressing cells, were patch-clamped, and a voltage ramp (from
130 to −170 mV) was applied. A progressive decrease in FRET
was observed as the cell membrane was hyperpolarized to
negative voltages from −30 mV and down to −170 mV (Figure
3c). We next evaluated the effects of compounds 1−3 on
membrane voltage. The superfusion of transporter 1 induced a
robust decrease in the FRET signal (Figure 3d). The decrease
in the FRET signal indicates that treatment with this
compound hyperpolarized A549 cells. These cells normally
exhibit a resting Vm close to 0 mV that upon facilitated influx
of anions shifts to more negative values. Similar to the
transporter 1, transporter 2 also produced a decrease on FRET
signal (Figure S141), although with slightly different kinetics.
Thus, transporter 1 had a higher magnitude of the signal (0.18
± 0.03 vs 0.15 ± 0.02) and faster τ time constant (5.16 ± 0.79
vs 7.65 ± 0.58 s) than transporter 2. Finally, we attempted to
demonstrate that the critical feature of these compounds in
order to induce Vm changes was their anion transport abilities.
Thus, transporter 3, possessing much reduced potency as
transmembrane anion transporter, was then assayed in the
FRET illumination protocol, in order to monitor possible
voltage alterations (Figure 3e). This compound induced
significantly lower decreases in the FRET signal (0.03 ±
0.01) than transporter 1 and 2, thus demonstrating again that
hyperpolarization of the cell membrane was induced as a result
of the transmembrane transport facilitated by active anion
transporters.
Figure 2. Transmembrane anion transport impact intracellular pH (pHi) levels and reduce cell viability. (a) AO staining on human lung
adenocarcinoma (A549) cells. From left to right: Untreated (control) cells; cells treated with compounds 1, 2, and 3 (10 μM). Disappearance of
orange fluorescence due to basification of acidic organelles is evident upon treatment with active anionophores. (b) pHi measurements using
SNARF-1 staining. A significant decrease in pHi is observed after treatment with 10 μM of compound 1 or 2. * p < 0.05; ** p < 0.01. (c,d) Cell
viability after treatment with compound 1 and 2 in the presence (HBSS) or absence (HBSS without Cl−) of chloride ion. Higher cytotoxicity is
observed in the presence of chloride ion. * p < 0.05; ** p < 0.01.
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Cytotoxicity of Anion Transporters. The effects of anion
transporters 1−3 on A549 cancer cells as well as cell lines
derived from primary tumors from two nonsmall cell lung
cancer patients (FIS302 and FIS303) were examined. We were
interested in determine the cytotoxicity against both differ-
entiated and cancer stem cells. Thus, cells were cultured in
adherence or as spheroids and were treated 10 μM
concentrations of each of the selected compounds. The results
are shown in Figure 4. For all cell lines, viability after 24 h was
significantly diminished in A549, FIS302, and FIS303 spheroids
compared with the cells grown in monolayer by compounds 1
(p = 0.012, p < 0.0001, and p < 0.0001, respectively) and 2 (p =
0.018, p = 0.004, and p < 0.0001, respectively). On the other
hand, treatment with the much less active transporter 3 did not
significantly affect the viability of the treated cells. For
comparative purposes doxorubicin, a classic chemotherapeutic
drug, was also included in this study. These results indicate that
active anion transporters selectively inhibited CSC viability.
Similar results were also observed in a variety of other lung
cancer cells lines (H1650, H1993, PC9) (Figure S137). For
noncancerous cell lines, higher concentrations of compounds 1
and 2 are needed in order to decrease cell viability, but the
differences with cancer cells were not statistically significant
(data not shown). However, noncancerous cell lines are
immortalized, and as such they share relevant features with
cancerous cell lines. For this reason, we have performed an in
vivo efficacy study in a lung cancer mouse model using these
molecules and the results showed that therapeutic doses (6 mg/
kg) of both anion transporters were not toxic in mice, while a
decrease in tumor volume was observed (unpublished data).
Figure 3. Transmembrane anion transporters induce changes in membrane potential. (a,b) Changes in safranin O fluorescence. The anion carrier
(0.1 mol % with respect to phospholipids) was added at t = 120 s, after that the experiments were monitored over 600 s. Each trace represents the
average of three trials. Compounds 1, red trace; 2, blue; 3, gray; control DMSO, green. (a) Vesicles loaded with NaCl (28.8 mM NaCl, and 5 mM
phosphate buffer, pH 7.2, ionic strength 40 mM) were immersed in NaCl (28.8 mM NaCl, and 5 mM phosphate buffer, pH 7.2, ionic strength 40
mM, and safranin O 0.2 μM). (b) Vesicles loaded with NaCl (28.8 mM NaCl, and 5 mM phosphate buffer, pH 7.2, ionic strength 40 mM) were
immersed in Na2SO4 (9.6 mM Na2SO4, 5 mM phosphate buffer pH 7.2, ionic strength 40 mM, and safranin O 0.2 μM). (c−e) FRET changes of the
VSFP2.32 voltage biosensor. (c) Voltage ramp (shown in the middle panel, from 130 to −170 mV), (d) transporter 1, and (e) transporter 3. Shown
are the time-resolved changes in mCerulean and Citrine fluorescence emission signals in single A549 cells expressing the VSFP 2.32. The emission
intensities of mCerulean (blue trace), Citrine (yellow trace), and the ratio FCitrine/FmCerulean (red trace) were recorded simultaneously. Traces are
representative of five separate experiments.
Figure 4. Cytotoxicity assays on cancer stem cells and adherent cells.
A549, FIS302, and FIS303 adherent and CSCs. Cells were treated with
10 μM of each compound (1, 2, or 3). Doxorubicin (10 μM) was used
as control. Mean and standard deviations of three independent
experiments are shown (* p < 0.05, **p < 0.01).
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Anion Transporters Affect Expression of Cancer Stem
Cell (CSC) Surface Markers. Stemness properties of CSCs
have been associated with the expression of several cell surface
markers.30 Thus, the effect of compounds 1−3 on the
expression of lung stem cell surface markers of A549 CSCs
as well as FIS302 and FIS303, two patient-derived CSCs, was
assessed by immunofluorescence and flow cytometry. Since cell
viability in the presence of 10 μM concentrations of
compounds 1 and 2 for 24 h is very low, cells were incubated
with 2.5 μM of each compound in order to analyze potential
alterations of lung stem cell surface markers before cell death.
Incubation of A549 cells with 2.5 μM of 1 and 2 for 24 h led to
an increase of the epithelial cell adhesion molecule CD326-
(EpCAM) expression by 70% and downregulation of CD166
by 20% compared to control cells treated with DMSO. No
significant changes were observed in the expression of CD44.
Compound 3 induced no significant changes in the three
surface markers studied here compared to control cells (Figure
5a). FIS302 patient-derived CSCs treated with compounds 1
and 2 showed a 30% decrease in CD166 and CD44 expression
(Figure 5b). No significant changes were observed in the
expression of EpCAM, CD44, and CD166 in the cells treated
with compound 3 (Figure 5b). FIS303 patient-derived CSCs
treated with compound 1 showed a 50% reduction in CD166
expression. The treatment with compound 2 led to a 30%
reduction in CD166 expression. Both compounds 1 and 2 led
to a 30% decrease in CD44 expression (Figure 5c). Similar to
FIS302 cells, no significant changes were observed in the
expression of EpCAM, CD44, and CD166 in cells treated with
compound 3 (Figure 5c). Taken together, downregulation of
CD166 and upregulation of CD326 (EpCAM) populations in
A549 CSCs, and downregulation of CD166 and CD44
populations in FIS302 and FIS303 patient-derived CSC,
suggests that the CSCs properties of A549, FIS302, and
FIS303 cells are affected by compounds 1 and 2. Further
evidence came from inmunofluorescence assays (Figure 6).
Thus, the size of the tumor spheres decreases when treated
with compounds 1 and 2 compared to spheres treated with
compound 3 or DMSO, and disaggregation was evident (Figure
6).
■ CONCLUSIONS
In summary, we have studied two highly active transmembrane
anion transporters 1 and 2 capable of facilitating trans-
membrane transport of chloride and bicarbonate in model
liposomes. These compounds induce pHi acidification and
hyperpolarization of cellular membranes. We have shown that
this combined effect led to loss of stemness characteristics of
CSCs and selective elimination of this cell population. The fact
that the structurally related yet poorly effective transporter 3
did not exert any of these effects led us to conclude that
facilitated anion transport plays a crucial role in the biological
action of these compounds. We conclude that small molecule
anionophores could represent valuable chemotherapeutics for
the manipulation of CSCs behavior.
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Figure 5. Compounds 1 and 2 affect expression of cancer stem cell surface markers. (a) A549, (b) FIS302, (c) FIS303 CSCs. CSCs were treated
with 2.5 μM compound 1, 2, or 3 for 24 h, and the expression of CD326 (EpCAM), CD166, and CD44 was analyzed by flow cytometry. The
expression of these markers was relativized to those in control cells. Data represent the average of three independent experiments. Bars correspond
to standard deviations.
Figure 6. Compounds 1 and 2 induce tumor CSCs spheres disaggregation. E-cadherin expression in FIS302 tumor spheres growing in suspension
assessed by immunofluorescence. Merged projection of both cell nuclei with pattern of DAPI-staining (blue channel) and E-cadherine staining (red
channel). Scale bar is 50 μm. (a) Untreated control cells. (b) CSCs treated with compound 1. (c) CSCs treated with compound 2. (d) CSCs treated
with compound 3.
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competitividad/Instituto de Salud Carlos III (SAF2014-
55700-P), and ICREA Academia-2010. E.H. thanks the Junta
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Abstract
Lung cancer has become the leading killer cancer worldwide,
due to late diagnosis and lack of efficient anticancer drugs. We
have recently described novel natural-derived tambjamine analo-
gues that are potent anion transporters capable of disrupting
cellular ion balance, inducing acidification of the cytosol and
hyperpolarization of cellular plasmamembranes. Although these
tambjamine analogues were able to compromise cell survival,
their molecular mechanism of action remains largely unknown.
Herein we characterize the molecular cell responses induced by
highly active indole-based tambjamine analogues treatment in
lung cancer cells. Expression changes produced after compounds
treatment comprised genes related to apoptosis, cell cycle, growth
factors and its receptors, protein kinases and topoisomerases,
among others. Dysregulation of BCL2 and BIRC5/survivin genes
suggested the apoptotic pathway as the induced molecular cell
death mechanism. In fact, activation of several proapoptotic
markers (caspase-9, caspase-3, and PARP) and reversion of the
cytotoxic effect upon treatment with an apoptosis inhibitor (Z-
VAD-FMK) were observed. Moreover, members of the Bcl-2 pro-
tein family suffered changes after tambjamine analogues treat-
ment, with a concomitant protein decrease towards the prosurvi-
val members. Besides this, it was observed cellular accumulation
of ROS upon compound treatment and an activation of the stress-
kinase p38 MAPK route that, when inhibited, reverted the cyto-
toxic effect of the tambjamine analogues. Finally, a significant
therapeutic effect of these compounds was observed in subcuta-
neous and orthotopic lung cancer mice models. Taken together,
these results shed light on the mechanism of action of novel
cytotoxic anionophores and demonstrate the therapeutic effects
against lung cancer. Mol Cancer Ther; 16(7); 1224–35. 2017 AACR.
Introduction
Lung cancer is the most common cancer that threatens
human health, accounting for more than 19% of all cancer
deaths in 2012 (1). Health systems have standardized clinical
procedures for treating lung cancer patients being surgery,
conventional platinum-based doublet chemotherapy (e.g.,
carboplatin/taxol or pemetrexed), and targeted therapies
(e.g., erlotinib and other novel anti-EGFR-mutated receptors)
the main options (2). Nevertheless, conventional chemother-
apy shows low efficacy with important treatment-related tox-
icity. Therefore, development of novel efficient drugs is urgent-
ly needed. In this regard, the diversity of marine environment
provides an extraordinary array of biologically active metabo-
lites for the development of new anticancer therapeutics. In
late 2007, trabectedin (Yondelis, PharmaMar) became the first
marine anticancer drug to be approved in the European Union
(3). Over the past decade, there has been an increase in the
number of new anticancer lead compounds from marine life
that have entered in human clinical trials (4). Nowadays, more
than 592 marine compounds are included in the pipeline of
modern pharmaceuticals discovery programs, showing prom-
ising antitumor and cytotoxic activities (5). The natural alka-
loids tambjamines were originally isolated from marine inver-
tebrates including bryozoans, nudibranchs, and ascidians (6).
Tambjamines possess a wide spectrum of pharmacological
properties and seem to be involved in the chemical defense
mechanisms of the organisms from which they derive (6).
Structurally, these alkaloids are characterized by a 4-methox-
ybipyrrole moiety shared by other families of natural products
such as the prodiginines (7). It is already well known that
prodiginines have proapoptotic activity against several cancer
cells including lung, breast, and hematopoietic, showing
the ability to overcome the multidrug resistance phenotype
(8–10). Tambjamines, like prodiginines, are very efficient
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anion exchangers (anionophores) in model liposomes pro-
moting both chloride and bicarbonate transport, which are the
most abundant anions in biological environments (7, 11, 12).
Their anionophoric activity has an impact on cellular ion
homeostasis, intracellular pH levels, and cell survival (11,
12). Recently, we have demonstrated that synthetic tambja-
mine analogues induce intracellular pH acidification and cyto-
toxicity in lung cancer cells and human-derived cancer stem
cells (CSC), and how this is related to their anion transport
abilities (13). Cancer stem cells are defined as immortal cells
within a tumor that have the ability to perpetuate themselves
through self-renewal, to spawn differentiated progeny (non-
CSCs) and contribute to acquired chemotherapy resistance in
cancer (14). Moreover, their facilitated transport activity trig-
gers hyperpolarization of plasma membrane in lung cancer
cells and differentiation and cell death in CSCs, leading to an
effective elimination of this tumor subpopulation (13).
Although substantial work has already been done concerning
chemical characterization of tambjamines and the impact of their
anionophoric properties in cell survival and differentiation, their
molecular mechanism of action still remains unclear. Here, we
report a detailed study of how cancer cells respond to several
highly active indole-based tambjamine analogues at the transcript
and protein levels. Moreover, we have elucidated the molecular
cell death mechanism induced by these compounds as well as




Compounds 1 to 11 were synthesized by condensation of 5-
(1H-indole-2-yl)-3-methoxy-1H-pyrrole-2-carbaldehyde with
the appropriate amine using acetic acid as catalyst. Detailed
synthetic procedures and characterization data are provided in
the Supplementary Information (S1–S36).
Cell lines and culture conditions
The human lung cancer cell lines, adenocarcinoma (A549,
CCL185), squamous carcinoma (SW900, HTB59), small-cell car-
cinoma (DMS53, CRL2062), and large-cell carcinoma (H460,
HTB177) were obtained from ATCC. All cell lines were tested and
authenticated byATCCusing short tandem repeat analysis. All cell
lines were cultured (passage number 10–25) following ATCC
recommended media (Biological Industries) supplemented with
10% heat-inactivated FBS (Gibco, Thermo Fisher Scientific Inc.),
100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L
L-glutamine, all from Biological Industries. Cells were grown at
37C in a humidified incubator (Thermo Fisher Scientific Inc.)
with 5% CO2 atmosphere. The cells were mycoplasma tested
using a standard PCR technique after thawing.
Establishment of lung cancer patient–derived primary cultures
This protocol was approved by the local Ethics Committee
(PR003/13) and the studies were conducted in accordance with
the Declaration of Helsinki ethical guidelines, upon signed
informed consent. Freshhuman lung cancer tissueswere obtained
from 20 patients with primary lung cancer (age range 55–81
years) undergoing lobectomy or pneumonectomy at Bellvitge
University Hospital from April 2013 to March 2014. Histologic
diagnosis was determined based on microscopic features of
carcinoma cells. Freshly obtained tumor tissue (within 1–2 hours
after surgical removal) was washed in RPMI1640 medium (Bio-
logical Industries) containing100U/mLpenicillin and100mg/mL
streptomycin. Blood vessels and connective tissue were carefully
removed and the cancerous area was then minced into small
pieces less than 1 mm3 using a scalpel. Chopped tissue was
resuspended in RPMI1640 medium containing collagenase II
(Sigma-Aldrich) at a concentration of 200 U/mL and digested
for 2 to 4 hours at 37C in a humidified incubator. The enzymatic
digestion was stopped when most of the cells were in a single cell
suspension. Following two washes in RPMI1640, cells were
transferred into standard tissue culture coated flasks (TPP, Trasa-
dingen) and cultured in the defined keratinocyte-serum free
medium (DK-SFM, Gibco, Thermo Fisher Scientific Inc.) supple-
mented with 100 U/mL penicillin, 100 mg/mL streptomycin, 2
mmol/L L-glutamine, 20 ng/mL EGF (Sigma-Aldrich, Merck
KGaA), 10 ng/mL basic-FGF (Sigma-Aldrich, Merck KGaA), 2%
B27 (Gibco, Thermo Fisher Scientific Inc.), and 0.25 mg/mL
amphotericin B (Sigma-Aldrich, Merck KGaA). All lung cancer
patient derived cultures were maintained at 37C in a humidified
incubator (Thermo Fisher Scientific Inc.) with 5% CO2. Culture
medium was changed every 2–3 days. Cells were passaged after
detachment with TrypLE Express (Invitrogen, Thermo Fisher
Scientific Inc.), when the cells reached 80%–90% confluence. We
were able to establish two lung cancer primary cultures (PC), one
derived from an adenocarcinoma tumor (PC#8) and the other
derived from a squamous cell carcinoma (PC#13), which were
used for subsequent viability assays. Lung cancer patient–derived
PCs were characterized by immunofluorescence, according to
their epithelial or mesenchymal biomarker expression, using
cytokeratin-8 (catalog no. IF13, Oncogene, Merck KGaA) for the
epithelial phenotype and vimentin (catalog no. 3932, Cell Sig-
naling Technology Inc.) for the mesenchymal phenotype.
Cell viability assays
Cell viability was evaluated using the methylthiazoletetrazo-
lium (MTT, Sigma-Aldrich, Merck KGaA) colorimetric assay. Cells
were harvested (104 cells/well) in 96-well plates in a final volume
of 100 mL and allowed to grow overnight. At the following day,
vehicle solution (DMSO, Sigma-Aldrich, Merck KGaA) or exper-
imental compounds were added at a single point (10 mmol/L) or
at different ranging concentrations (0.8–100 mmol/L for com-
pounds 1 and 2, 1.6–200 mmol/L for cisplatin) to the assay plate.
Cells were incubated for 24 hours and after the treatment period,
10 mL of MTT (5 mg/mL) were added and the plates were
incubated for 4 hours at 37C. Crystals were dissolved in 100 mL
of DMSO, after which the reading was taken spectrophotomet-
rically at 570 nm using a multiwell plate reader (Multiskan FC,
Thermo Fisher Scientific Inc.). Cell viability and inhibitory con-
centration (IC) values were obtained using GraphPad Prism V5.0
for Windows (GraphPad Software). All data are shown as the
mean value  SD of three independent experiments. Statistical
analysis (one-way ANOVA) was carried out with the Statgraphics
plus 5.1. Statistical package (Manugistics). Cisplatin was bought
from Alfa Aesar (Thermo Fisher Scientific Inc.).
Gene expression analysis
The A549 cell line was seeded at a density of 2 105 cells in 60-
mm plates and allowed to grow for 24 hours. Subsequently, cells
were exposed to the IC50 of the tambjamine analogues 1 or 2 for 6
or 16 hours. Total RNA was extracted and purified using
the column-based RNeasy Mini Kit (Qiagen), according to the
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manufacturer's protocol. Total RNA concentration and purity was
checked in a nano spectrophotometer (Implen GmbH) and
integrity was analyzed using an Agilent 2100 Bioanalyzer (Agilent
Technologies). For the reverse transcription, 1 mg of total RNAwas
used for cDNA synthesis using amixture of randomhexamers and
oligo-dT primers and following the RT2 First Strand Kit protocol
(Qiagen). The Human RT2 RNA Quality Control PCR Array
(PAHS-999ZA format A, Qiagen) was used to assess the cDNA
quality and to check for genomic DNA contamination in an ABI
PRISM 7700 Sequence Detection System (Applied Biosystems,
Thermo Fisher Scientific Inc.). For gene expression analysis,
cDNAs of control and treated cells were mixed with RT2 SYBR
ROX mastermix (Qiagen) and dispensed in the RT2 Profiler PCR
Array of Human Cancer Drug Targets (PAHS-507A format E,
Qiagen). After 2-minute centrifugation at 300  g, the array was
placed in an ABI PRISM 7900HT real-time PCR system (Applied
Biosystems, Thermo Fisher Scientific Inc.) and the analysis was
carried out according tomanufacturer's instructions. Dissociation
curves (melting curves) were carefully analyzed using SDS soft-
ware v2.3 and RQ Manager v1.2 (both from Applied Biosystems,
Thermo Fisher Scientific Inc.) to choose only the highly specific
reaction products in the downstream analysis. The threshold cycle
(CT) values obtained were analyzed in Qiagen Data Analysis
Center (Qiagen) to retrieve the fold-regulation values for each
gene. The network of most altered genes upon compounds
treatment was produced in Cytoscape open-source software
(Cytoscape Consortium; ref. 15) with data extracted from Gene
Network Central (GNC-Pro, Qiagen).
Western blot analysis
A549 cellswere seeded in100-mmculture plates (106 cells) and
allowed to grow for 24 hours. Afterward, they were exposed to
compounds1, 2 (IC25, IC50, and IC75 values), or3 (10mmol/L) for
24 hours. Total protein extracts were obtained from cells by the
addition of lysis buffer containing 0.1% SDS, 1% NP-40, 0.5%
sodium deoxycholate, 50 mmol/L sodium fluoride, 40 mmol/L
b-glycerophosphate, 200 mmol/L sodium orthovanadate, 1
mmol/L phenylmethylsulfonyl fluoride, and protease inhibitor
cocktail (Roche Diagnostics) in 1 PBS. Protein concentration
was determined by BCA protein assay (Pierce, Thermo Fisher
Scientific Inc.) using BSA (Pierce, Thermo Fisher Scientific Inc.) as
a standard. For Western blot analysis, 30 mg of protein extracts
werefirst separated by SDS-PAGEand transferred to Immobilon-P
polyvinylidene difluoride (PVDF) membranes (EMD Millipore,
Merck KGaG). Membranes were blocked in either 5% dry milk or
BSA, both diluted in TBS–Tween (50 mmol/L Tris–HCl pH 7.5,
150 mmol/L NaCl, 0.1% Tween-20) for 1 hour and then incu-
bated overnight with primary antibodies, according to the man-
ufacturer's instructions. Antibodies were obtained from the fol-
lowing sources: anti-caspase-3 (catalog no. 9662), anti-cleaved-
caspase-3 (catalog no. 9661), anti-caspase-9 (catalog no. 9502),
anti-PARP1 (catalog no. 9542), anti-Bak (catalog no. 6947), anti-
Bax (catalog no. 2772), anti-Bcl-2 (catalog no. 4223), anti-Mcl-1
(catalog no. 4572), anti-phospho-p38 MAPK (Thr180/Tyr182,
catalog no. 4511), anti-p38 MAPK (catalog no. 9212), and anti-
Survivin (catalog no. 2808) were all obtained from Cell Signaling
Technology Inc.; anti-Actin (I-19, catalog no. sc-1616) from Santa
Cruz Biotechnology Inc and anti-Vinculin (catalog no. V-4505)
from Sigma-Aldrich,Merck KGaA. Antibody bindingwas detected
with goat anti-mouse IgG-HRP (catalog no. sc-2005), goat anti-
rabbit IgG-HRP (catalog no. sc-2004), or donkey anti-goat IgG-
HRP (catalogno. sc-2020), all fromSantaCruzBiotechnology Inc.
and the ECL Detection Kit (Amersham, GE Healthcare). Actin or
vinculin were used as gel loading controls. The results shown are
representative ofWestern blot analysis data obtained from at least
three independent experiments. Images were captured on an
Image Quant LAS 500 (GE Healthcare) and band densitometries
were retrieved using the Image Studio Lite software (v5.0, LI-COR
Biosciences).
Inhibitor assays
Determination of viable cells (A549 cell line) after different
inhibitors treatment was performed using the dual DNA interca-
lating Fluorescent Dyes Kit MUSE Cell Count & Viability Assay
(EMD Millipore, Merck KGaG). In brief, 2  105 cells/well in
DMEM medium were seeded in a six-well plate. After 24 hours,
tambjamine analogues 1 and 2 at higher IC75 value were added,
and incubated for 6 hours in a 5% CO2 cell culture incubator
(Thermo Fisher Scientific Inc.). A pan-caspases inhibitor (Z-VAD-
FMK; BD Bioscience) or a p38 MAPK inhibitor (SB202190; Cell
Signaling Technology Inc.) was added at 20 and 30 mmol/L
respectively, 2 hours before compound 1 or 2 exposure. After-
ward, cells were collected andwere incubated with the Cell Count
& Viability reagent for 5 minutes. Viability of treated cells was
analyzed using the flow cytometry based MUSE Cell Analyzer
(EMD Millipore, Merck KGaA) according to the manufacturer's
protocol. Viability was calculated as a percentage related to
control cells and results shown were obtained from at least three
independent experiments. Statistical analysis (one-way ANOVA)
was carried out with the Statgraphics plus 5.1. Statistical package
(Manugistics).
Evaluation of reactive oxygen species formation
Quantitativemeasurements of reactive oxygen species (ROS) in
A549 cells were performed using the MUSE Oxidative Stress Kit
(EMD Millipore, Merck KGaG), based on dihydroethidium
(DHE), a well-characterized reagent that has extensively been
used to detect reactive oxidative species in cellular populations.
In brief, 2 105 cells/well inDMEMmediumwere seeded in a six-
well plate. Twenty-four hours after seeding, tambjamine analo-
gues 1 and 2 at higher IC75 value were added, and incubated for 6
hours in a 5%CO2 cell culture incubator (ThermoFisher Scientific
Inc.). A positive control, named tert-butyl hydroperoxide (TBHP,
Sigma-Aldrich, Merck KGaA) was used at 2.5mmol/L for 2 hours,
and the nontransporter tambjamine analogue (compound 3) was
used as a negative control at 10 mmol/L for 6 hours. Afterward,
cells were harvested and processed with the Oxidative Stress Kit
according to the manufacturer's protocol. The percentage of ROS-
positive and -negative cells was calculated and results shownwere
obtained from at least three independent experiments. Statistical
analysis (one-way ANOVA) was carried out with the Statgraphics
plus 5.1. Statistical package (Manugistics).
In vivo evaluation of indole-based tambjamine analogues
therapeutic effect
For the purpose of this article, two murine models have been
designed: the subcutaneous and the orthotopic model systems.
Five-week-old female Crl:NU-Foxn1numice strain (Envigo) were
used in this study. All animal studies were approved by the
Autonomic Ethic Committee (Generalitat de Catalunya) under
the protocol 9111. To generate the subcutaneous xenograft mod-
el, mice were subcutaneously implanted with 4.5  106 DMS53
Manuel-Manresa et al.
cells suspended in a 1:1 solution of RPMI1460:Matrigel (BD
Bioscience). For the orthotopic model, subcutaneous xenografts
of DMS53 in exponential growth from three different animals
were aseptically isolated and placed at room temperature in
DMEM supplemented with 10% FBS plus 50 U/mL penicillin
and 50 mg/mL streptomycin and the surgical resection tumors
were implanted in Crl:NU-Foxn1nu mice following previously
reported procedures (16, 17). Briefly, mice were anesthetized
with a continuous flow of 1% to 3% isoflurane/oxygen mixture
(2 L/minutes) and subjected to right thoracotomy. Mice were
situated in left lateral decubitus position and a small transverse
skin incision (around 5–8 mm) was made in the right chest wall.
Chest muscles were separated by a sharp dissection and costal
and intercostal muscles were exposed. An intercostal incision of
2–4 mm on the third or fourth rib on the chest wall was made
and a small tumor piece of 2 to 4 mm3 was introduced into
the chest cavity. The tumor specimen was deposited between
the second and the third lung lobule. Next, the chest wall incision
was closed with surgery staples, and finally chest muscles and
skin were closed. Mice were inspected twice a week, and moni-
tored for the presence of breathing problems.
Mice bearing homogeneous subcutaneous tumors (approxi-
mately 150–200 mm3) were randomly allocated to three treat-
ment groups (n ¼ 7/treatment). For DMS53 orthotopic-derived
model, mice were randomly allocated (n ¼ 6/treatment) and the
treatment started 30 days after tumor implantation. Compounds
1 and 2 were diluted in 7.5% DMSO/0.8% Tween-80. All treat-
ments were intraperitoneally administrated at a dose of 6 mg/kg
in alternating days during 20 days. Tumor growth was recorded
two to three times per week starting from the first day of treatment
(day 0) and tumor volume (in mm3), estimated according to the
formulaV 0.25(ab2)/2, where a is the length or biggest diameter
and b is the width or smallest diameter). After the final dose of the
treatment, animals were sacrificed and tumors were dissected out
and weighed.
Liver and kidney samples were fixed in 4% paraformaldehyde
overnight, embedded in paraffin, and cut into sections (5 mm).
Paraffin-embedded sections were deparaffinized in xylene and
gradually rehydrated for hematoxylin and eosin staining. Stained
liver and kidney sectionswere gradually dehydrated andmounted
for hepatotoxicity and nephrotoxicity examination, respectively.
Results
Indole-based tambjamine analogues are cytotoxic against lung
cancer cells
To measure the inhibitory effect of novel tambjamine analo-
gues (1–11; Supplementary Fig. S1) on tumor cell proliferation,
we have first performed a single-point MTT assay at 10 mmol/L in
four commonly used lung cancer cell lines (A549, DMS53,
SW900, and H460). After 24 hours of treatment, most of the
compounds showed significant cell viability decrease, being
compounds 1 and 2 the most promising anticancer agents (Fig.
1A). Then, IC50 values of the selected compounds were calculated
in the same cell lines as well as in both adenocarcinoma and
squamous patient-derived PCs (Fig. 1B and Supplementary Figs.
S37 and S38). The two selected compounds had similar potency
against all the cell lines in the study, showing IC50 values below10
mmol/L. When compared with cis-diamminedichloroplatinum
(II) (CDDP), commonly known as cisplatin, the standard che-
motherapeutic agent used for lung cancer treatment in the clinic,
the IC50 values of this compound were all much higher than the
ones of compounds 1 and 2. Interestingly, lung cancer patient–
derived PCsweremore sensitive to our compounds, showing IC50
values below5mmol/Lwhereas for cisplatin theywere higher than
45 mmol/L (Fig. 1B). This IC50 value for cisplatin is in accordance
Figure 1.
Effect of indole-based tambjamineanalogues on cell survival.A,Single point screeningof synthetic tambjamine analogues 1 to 11 (10mmol/L) on apanel of lung cancer
cell lines (A549, DMS53, SW900, and H460). B, IC50 values of selected compounds (1 and 2) on lung cancer cell lines and lung cancer patient-derived primary
cultures (PC#8 and PC#13). For comparison purposes, cisplatin (CDDP) was used as the standard clinical chemotherapeutic agent. Viability was measured
using the MTT assay after 24 hours of treatment. Results were obtained from at least three independent experiments, and bar represents the mean  SD.
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with published data (18, 19). Therefore, the selected tambjamine
analogues displayed better cytotoxic activity against a panel of
lung cancer cell lines and PCs than the current clinical standard
treatment.
Indole-based tambjamine analogues alter the expression of
several cellular key genes
To identify gene expression changes at the cellular level, we
have used a profiler array consisting of 84 genes that are known
cancer drug targets. The selected compounds1 and2were tested in
the adenocarcinoma cell line A549 at their respective IC50 values
during two incubation periods (6 and 16 hours, for raw data
please check Supplementary File S1). Both compounds have
produced changes in several genes fromdiverse functional groups
(Table 1). In general, the observed alterations (higher than 1.5-
fold regulation in at least two conditions) weremore evident at 16
hours with a clear tendency to genes downregulation. In total, 26
genes were modulated, in which 20 were downregulated by
compounds1or2 exposure.Downregulated genes included those
related to: apoptosis, cell cycle, growth factors and receptors,
protein kinases, topoisomerases, to name a few. Especially rele-
vant for cell viability were genes related to cell death like the
antiapoptotic B-cell lymphoma 2 (BLC2) and the inhibitor of
apoptosis (IAP) family member BIRC5/Survivin, as well as those
related to cell cycle (e.g., CDK1 and CDK2). The remaining six
genes were upregulated and related to drug metabolism, protein
kinases, transcription factors, cathepsins, and heat shock proteins
(Table 1). Concerning genes that are altered more than three-fold
regulation in at least two conditions, we have obtained CDC25A,
FIGF/VEGFD, IGF1, NFKB1, and PTGS2/Cox-2. Six randomly
selected genes were reconfirmed by another methodology (Sup-
plementary Table S1; Supplementary Fig. S39). Similar results
were obtained using another lung cancer cell line from squamous
carcinoma SW900 (77% gene match; Supplementary Table S2;
raw data are present in Supplementary File S1), suggesting that
they may be implicated in tambjamine mechanism of action.
Interestingly, three genes that were previously altered more than
three-fold in A549 cell line (FIGF, IGF, and NFKB1) were not
altered, IGF andNFKB1or inversely regulated, FIGF, in the SW900
cell line. We further analyzed the altered genes using protein–
protein interaction data and functional data extracted from Gene
Network Central (GNC-Pro, Qiagen). The results showed that
compound-modulated genes formed a highly connected network
(Fig. 2), suggesting that these genes work as a functional module
at the molecular level. The network also showed that NFKB1 and
TP53 are hubs (densely connected nodes), which integrate signals
from the other nodes. Although these genes are hubs in our
system, we did not observe any consistent transcriptional change
in both cell line models.
Indole-based tambjamine analogues induce apoptosis in lung
cancer cells
Because we have obtained alterations in genes related to apo-
ptosis and cell cycle and these processes are deeply involved in cell
viability, we checked if these mechanisms are activated in our
cellular model. We were unable to detect any cell-cycle arrest for
either compounds tested, whereas cisplatin produced the well-
documentedG2–Mphase arrest (Supplementary Fig. S40; ref. 20).
To elucidate if apoptosis is the molecular mechanism of cell
death induced by these compounds, the expression levels of
Table 1. Genes modulated after indole-based tambjamine analogues treatment
1 2
Gene name Protein name 6 h 16 h 6 h 16 h Functional gene grouping
Downregulated
ABCC1 ATP-binding cassette, sub-family C, member 1 1.11 1.61 1.48 2.32 Drug metabolism
AURKA Aurora kinase A 2.53 2.37 2.69 4.13 Protein kinases
AURKB Aurora kinase B 1.96 2.43 2.16 5.03 Protein kinases
BCL2 B-cell CLL/lymphoma 2 2.17 1.10 1.83 1.90 Apoptosis
BIRC5 Baculoviral IAP repeat containing 5, Survivin 2.08 2.37 2.53 4.72 Apoptosis
CDC25A Cell division cycle 25 homolog A 2.30 1.75 3.72 4.11 Cell cycle
CDK1 Cyclin-dependent kinase 1 1.97 2.71 2.41 3.94 Cell cycle
CDK2 Cyclin-dependent kinase 2 1.81 1.73 1.24 3.21 Cell cycle
ERBB3 Receptor tyrosine-protein kinase erbB-3, HER3 2.42 1.35 2.81 2.18 Growth factors and receptors
ESR2 Estrogen receptor 2 1.65 1.20 2.87 1.78 Hormone receptors
FIGF C-fos induced growth factor, VEGFD 2.25 1.65 3.57 3.74 Growth factors and receptors
HDAC8 Histone deacetylase 8 1.87 1.11 1.52 2.01 Histone deacetylases
HSP90AA1 Heat shock protein 90 kDa alpha, member 1 1.84 1.62 1.43 2.47 Heat shock proteins
IGF1 Insulin-like growth factor 1, Somatomedin C 4.89 17.47 3.48 42.18 Growth factors and receptors
NTN3 Netrin 3 1.81 2.11 2.85 1.17 Structural protein
PARP2 Poly (ADP-ribose) polymerase 2 1.29 1.63 1.63 2.20 Poly ADP-ribose polymerases
PDGFRA Platelet-derived growth factor receptor alpha 3.55 1.59 1.10 2.48 Growth factors and receptors
PLK1 Polo-like kinase 1 2.24 2.46 2.36 4.13 Protein kinases
PLK4 Polo-like kinase 4 1.36 2.51 1.20 2.02 Protein kinases
TOP2A Topoisomerase (DNA) II alpha 170 kDa 2.06 2.78 2.09 4.30 Topoisomerases, type II
Upregulated
CTSL1 Cathepsin L1 1.30 1.92 2.03 2.07 Cathepsins
CTSS Cathepsin S 1.24 2.69 1.71 2.08 Cathepsins
HSP90B1 Heat shock protein 90 kDa beta, member 1 2.00 1.95 1.63 1.97 Heat shock proteins
NFKB1 Nuclear factor NF-kappa-B p105 subunit 3.88 1.23 3.14 1.01 Transcription factors
PRKCE Protein kinase C, epsilon 1.52 1.04 2.53 1.95 Protein kinases
PTGS2 Prostaglandin-endoperoxide synthase 2, COX-2 6.46 1.23 19.29 2.90 Drug metabolism
NOTE: TheA549 lung adenocarcinoma cell linewas treatedwith the IC50 values of compounds 1or2and the expression of 84genes related to cancer drug targetswas
analyzed by qRT-PCR (Qiagen RT2 Profiler Array). Fold regulation values of the most altered genes are presented.
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apoptosis-related proteins were analyzed byWestern blot analysis
because a decrease in the anti-apoptotic proteins Bcl-2 and survi-
vin was detected in the gene expression array. The adenocarcino-
ma cell line A549 was treated with compounds 1 or 2 at the IC25,
IC50, and IC75 concentrations for 24 hours. The results showed
that, at higher concentrations, compounds activated the proteol-
ysis of both initiator pro-caspase-9 (CASP9 gene) and executioner
pro-caspase-3 (CASP3 gene; Fig. 3A). Moreover, activation of the
final apoptotic executioner PARPwas also induced. Similar results
were also obtained in the small cell carcinoma cell line DMS53
(Supplementary Fig. S41). In addition, we checked the levels of
the apoptotic complexes Bak/Mcl-1 (BAK/MCL1 genes) and Bax/
Bcl-2 (BAX/BCL2 genes). The pro-apoptotic effectors of the mito-
chondrial pathway (Bak and Bax) showed an increase in their
protein levels after 24hours treatment.On the contrary,Mcl-1 and
Bcl-2 that are prosurvival members of the Bcl-2 family of proteins
presented a decrease on their protein levels after treatment (Fig.
3A–C). The results for Bcl-2 protein expression corroborated the
gene expression decrease previously observed in the profiler array
(Table 1). Also in accordance with those results, downregulation
of the key oncogene BIRC5/Survivin was observed at the protein
level byWestern blot analysis. A549 cells treatedwith compounds
1 or 2 (IC25, IC50, and IC75) during 24 hours showed a dose-
dependent decrease of survivin, indicating that this proteinmight
play an important role on the cell death fate after compounds
exposure (Fig. 3A).
To further investigate the involvement of caspases activation on
compounds-mediated apoptosis, A549 cells were treated 2 hours
with a broad-spectrum caspase inhibitor, Z-VAD-FMK, and then
with compounds 1 or 2 for 6 hours. Cell viability was then
assessed by flow cytometry and results showed that the decrease
in cell viability induced by compounds treatment was significant-
ly reversed by the pan-caspase inhibitor Z-VAD-FMK (Fig. 3D),
corroborating that apoptosis is involved in compounds-induced
cell death.
Cytotoxic effect of compounds is triggered via a ROS-activated
stress kinase pathway
The unbalance of ionic homeostasis produced by tambjamine
analogues (13) could be initiating ROS production. Therefore, we
tested whether compounds 1 and 2 could promote ROS accu-
mulation in cells. Interestingly, after 6 hours treatment with
compounds 1 or 2 (at higher IC75 value), there is a significant
ROS formation compared with the nontreated condition or when
Figure 2.
Indole-based tambjamine analogues effect on cellular signaling pathways. A directed-network of differentially expressed genes after compounds 1 or 2 treatment in
A549 cells was constructed from the RT-PCR array results and data extracted from Gene Network Central (GNC-Pro).
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the nontransporter tambjamine analogue (compound 3) is used
(Fig. 4A). The effect of compounds is similar to the commonly
used ROS stressor TBHP. The p38 MAPK signaling is one of the
stress sensor pathways downstream of ROS formation that plays
an essential role in inflammation, cell differentiation, growth, and
death. Thus, we have investigated by Western blot analysis, the
phosphorylation of p38 MAP kinase after treatment with indole-
based tambjamine analogues 1, 2, or 3 in A549 cells. After 24
hours treatment with compounds 1 or 2 (IC25, IC50, and IC75),
p38MAPK (MAPK14 gene) phosphorylation increased in a dose–
response manner without any alteration in the total protein
expression levels (Fig. 4B). Conversely, compound 3 (nontran-
sporter) had no effect on the p38 MAPK activation. The ROS
inducer TBHP was shown before to also activate the p38 MAPK
pathway (21). To further investigate whether activation of p38
MAPK was related to cell death, A549 cells were pretreated with
the p38 MAPK inhibitor SB202190 (30 mmol/L) for 2 hours
before compounds treatment. A significant reversion of cell death
induced by compounds 1 and 2 was observed upon inhibitor
pretreatment, which indicates that compounds-mediated cell
death is upstream regulated by the p38 MAPK signaling pathway
(Fig. 4C).
Therapeutic effect on in vivo mice models
To corroborate the anticancer activity of the indole-based
tambjamine analogues seen in several lung cancer cell lines and
patient-derived PCs, we evaluated the therapeutic effect of
compounds 1 and 2 in established DMS53 human small cell
lung carcinoma growing subcutaneous and orthotopically in
nude mice models. The DMS53 cell line was selected for their
ability to grow well in the flank (for subcutaneous model) and
in the lung (for orthotopic model) after cell inoculation. Mice
bearing DMS53 xenografts were treated with compounds 1 or 2
(6 mg/kg in saline with 7.5% of DMSO/0.8% Tween-80) or
vehicle control (7.5% of DMSO/0.8% Tween-80) in alternating
days during 20 days. As shown in Fig. 5A and B, compound 2
produced a significant decrease in tumor growth in subcuta-
neous models. Furthermore, treatment with compound 2
Figure 3.
Analysis of the apoptotic pathway after indole-based tambjamine analogues exposure. A, After 24 hours of treatment with the IC25, IC50, and IC75 values of
compounds 1 or 2, the expression of several apoptotic markers was analyzed by Western blot analysis in A549 cell line. B and C, Bcl-2 family protein complexes
(Bak/Mcl-1 and Bax/Bcl-2, respectively) ratios are represented in bar graphs. D, A549 cells were treated with 20 mmol/L of Z-VAD-FMK for 2 hours followed
by compounds 1 or 2 for 6 hours. Cell viability was measured using the flow cytometry–based MUSE Cell Analyzer Kit. Results were obtained from at least three
independent experiments. Bars represent the mean  SD. Statistically significant results are indicated as  , P < 0.05;  , P < 0.01 and  , P < 0.001.
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significantly (P < 0.05) reduced lung cancer tumor progression
in the orthotopic lung model (Fig. 5C). Importantly, as a single
agent the treatment with compounds 1 or 2 did not produce
any obvious toxicity (hepatotoxicity and nephrotoxicity; Fig.
5D), diarrhea, or significant body weight loss (Supplementary
Fig. S42).
Discussion
Chemotherapeutic agents based on natural compounds are a
potent source of anticancer drugs. Tambjamine analogues of
natural compounds tambjamines have already demonstrated a
good pharmacological activity and to have remarkable anticancer
effects (6, 7, 11–13). In this study, we analyzed the cytotoxic effect
and consequent induced cell death and elucidated the molecular
mechanism of action of novel synthesized indole-based tambja-
mine analogues in lung cancer cells. We have observed a signif-
icant cytotoxic effect (less than 10 mmol/L at 24 hours) of the
selected compounds in several lung cancer cell lines. Moreover,
the selected compounds showed IC50 values remarkably lower
than cisplatin, the main chemotherapeutic agent used in the
treatment of lung cancer patients.
Figure 4.
Indole-based tambjamine analogues
induce ROS, causing cellular stress by
p38 MAPK activation. A, A549 cells
were treated with compounds 1, 2, or 3
(negative control) for 6 hours or with
TBHP (positive control) for 2 hours.
ROS formation was measured
using the flow cytometry–based
MUSE Oxidative Stress Kit. B,
Phosphorylation levels of the stress
kinase p38 MAPK were assessed by
Western blot analysis in A549 cells
exposed to the IC25, IC50, and IC75
values of compounds 1, 2, or 3 for 24
hours. C, A549 cells were treated with
30 mmol/L of SB20219 for 2 hours
followed by compounds 1 or 2 for
6 hours. Cell viability was measured
using the flow cytometry–based MUSE
Cell Analyzer Kit. Results were
obtained from at least three
independent experiments. Bars
represent the mean  SD.
Statistically significant results
are indicated as  , P < 0.05;
 , P < 0.01, and  , P < 0.001.
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Wehave recently demonstrated how tambjamine analogues are
able to alter the plasma membrane potential and decrease the
intracellular pH in the A549 lung adenocarcinoma cell line (13).
Changes in the ion homeostasis of the plasma membrane poten-
tial have already been associated with apoptosis-induced cell
death in several cell types (S49, Jurkat, HL60, and thymocytes;
refs. 22, 23). These observations, in addition toour transcriptomic
results and the failure to arrest cell cycle, led us to further
Figure 5.
Therapeutic effect of indole-based tambjamine-analogues in lung cancer in vivomouse models. A, Growth curve of subcutaneous tumor volumes after compound
treatment show significantly differences between compound 2 versus control. B, The weight of subcutaneous tumors compared with control animals is
significantly lower after compound 2 treatment. C, Compound 2 treatment reduce significantly the tumor weight in orthotopic DMS53 mouse xenograft model.
Statistical analysis was performed using the nonparametric tests.  , P < 0.05. D, Representative illustrations of liver and kidney histology using
hematoxylin–eosin staining, at 100 and 400 magnifications (scale bars correspond to 200 and 50 mm, respectively). Histopathologic examination of mice
liver and kidney detected no obvious pathologic changes after compound 1 or 2 treatment.
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investigate the molecular events related to the apoptotic process
after cell treatment with these compounds.
The mitochondrial apoptotic pathway is closely regulated by
the dynamic equilibrium of a group of proteins belonging to the
Bcl-2 family with pro-apoptotic (e.g., Bax and Bak) and anti-
apoptotic (e.g., Bcl-2 and Mcl-1) functions (24–26). The disrup-
tion of this equilibrium leads to the mitochondrial outer mem-
brane permeabilization (MOMP) with the consequent release of
cytochrome-c from the mitochondria and activation of initiator
caspase-9. The initiator caspase-9 then activates the effector cas-
pase-3 that cleaves regulatory and structural molecules (e.g.,
PARP), culminating in the death of the cell (24, 26). In this study,
the activation of the intrinsic mitochondrial pathway and the
cleavage of pro-caspase-9 and pro-caspase-3, as well as their
substrate PARP were observed in lung cancer cells. In addition,
the unbalance of the apoptotic pairs (Bcl-2/Bax and Mcl-1/Bak)
towards the pro-apoptotic proteins unveils the final fate of these
cells (27). In our system, the expression levels of prosurvival
members of the Bcl-2 family (Bcl-2 and Mcl-1) decreased in a
dose-dependent manner and the pro-apoptotic proteins (Bax and
Bak) increased after the treatment. In terms of Bcl-2, this decrease
further corroborates our transcriptomic results and shows that this
alteration is occurring at the gene level. The IAP proteins (IAPs, e.
g., XIAP and survivin) are proteins that maintain the small
leakages of cytochrome-c or small activations of death receptors
controlled by inhibiting the initiator and effector caspases. Survi-
vin is a member of the IAP family that prevents mitochondrial-
dependent apoptosis through the inhibition of caspase-9 and
caspase-3 by direct or indirect binding (24, 28). Interestingly, after
compounds treatmentwehave seen adownregulation of survivin,
at both the transcript and protein levels, which also contributes to
the triggering of the apoptotic cell death. Furthermore, using a
pan-caspase inhibitor, we were able to significantly reverse the
cytotoxic effect of our compounds. These results clearly indicate
that compounds induce cell death through apoptosis by activat-
ing apoptosis-related proteins (caspase-9 and caspase-3) and
decreasing the levels of anti-apoptotic proteins (Bcl-2, Mcl-1, and
survivin).
The ionophoric activity of tambjamine analogues has an
impact on cellular ion homeostasis and intracellular pH levels
(13), thus, it is feasible that their actions will produce a cellular
stress. Several recent works have shown that unbalanced ionic
homeostasis is deeply involved in ROS generation (29–31). In
our hands, treatment with the selected compounds induced a
clear ROS production and this could be mediated by the anion
transport because our previous work has shown that these
compounds also induce cellular acidification (13). Conversely,
the nontransporter compound neither produced pH changes
nor generated ROS.
The MAPKs are crucial signaling players in the integration of
stress signals and their conversion to cellular responses (32). One
major MAPK signaling pathway that is important for detecting
cellular stress, including intracellular acidosis and ROS, is the p38
MAPK cascade (32–34). The p38MAPK-mediated apoptosis leads
to caspase activation (35, 36), and several chemotherapeutic
drugs have been shown to promote this cascade in order to
produce apoptotic cancer cell death (36–42).Moreover, reversion
of the apoptotic-mediated cell death produced by chemothera-
peutic drugs that de-polymerize (nocodazole, vincristine, and
vinblastine) or stabilize (taxol) microtubules was achieved by
using p38 MAPK-specific inhibitors (e.g., SB203580 and
SB202190). Likewise, genotoxic agents (cisplatin and oxaliplatin)
and topoisomerase II inhibitors (doxorubicin) were also able
to activate p38 MAPK route (43, 44). Nowadays, a dual-role of
this route is known with the action as tumor suppressor or
tumor promoter largely depending on the type of cancer and
tumor stage (45). Interestingly, our results have shown a robust
p38 MAPK activation and using the specific p38 MAPK inhib-
itor, SB202190, we were able to significantly restore cell via-
bility. Reversion of cell death using the pan-caspase inhibitor
or the stress kinase inhibitor is very similar, which foresight
that our compounds mediate cell death by apoptosis mainly
through the p38 MAPK route.
Moreover, several transcription factors have been implicated in
the regulation of both anti-apoptotic proteins, survivin, andBcl-2:
Sp1, p53, NF-kB, and STAT3 (38, 46–48). Although Sp1, NF-kB,
and STAT3 are generally implicated in transactivation of Bcl-2 and
survivin genes, p53 was shown to be responsible for transcrip-
tional repression of these genes. In addition, these transcription
factors are all substrates of the p38MAPK signaling pathway (49).
In fact, several articles connect p38 MAPK activation with a
downregulation of survivin and Bcl-2 expressions (39, 40, 50–
53). Nevertheless, caution should be taken because other path-
ways are also involved in the activation/repression of these
transcription factors and so, crosstalkwithother routes is possible.
Further experiments are underway to understand the regulation of
these genes, which have a profound impact in the fate of the cells
by apoptosis. Our study has also shown the therapeutic effect of
our compounds in a preclinical setting using subcutaneous and
orthotopic mousemodels for lung cancer, which indicates a good
potential for pharmaceutical development.
In conclusion, we have shown the cytotoxic effect of novel
indole-based tambjamine analogues towards lung cancer cells in
vitro and in vivo. We have also identified several gene-expression
profile alterations produced by our compounds in lung cancer
cells and have shown that the main molecular route of induced
cell death is apoptosis, whichmight be activated by the p38MAPK
through ROS cellular stress induction. Ultimately, by understand-
ing the mechanism of action through which these natural-based
small molecules mediate their effect in cancer cells will provide a
way to improve future studies of drug efficacy and pharmacody-
namics, as well as establish drug–response biomarkers and syn-
ergistic drug combinations.
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